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ABSTRACT
Numerous small non-coding RNAs have been identified in mammalian cells, includ-
ing microRNAs and piwi-interacting RNAs. The patterns of gene expression within
cells can be altered in response to cellular stress. To examine the effects of cellu-
lar stress on all small RNA types, a number of human cell lines were treated with
Poly(I:C), a mimic of viral infection, and the levels of small RNAs were examined
by next generation sequencing. Surprisingly, we did not find many differentially ex-
pressed microRNAs, but we discovered a new class of small RNAs that were 30-35
nucleotides and showed up-regulation following Poly(I:C) treatment. These slightly
longer small RNAs were derived from many different types of non-coding RNA
and only very few small RNAs were derived directly from messenger RNAs. Small
RNAs derived from various types of RNA were validated by northern blot. Further
sequencing libraries were prepared for Poly(I:C)-treated and untreated MCF7 cells,
as well as Poly(I:C)-treated and untreated SW1353 cells. The human Y5 RNA gene
was chosen as an example of a Poly(I:C)-induced small RNA-producing gene. This
gene was cloned into an expression construct and systematically mutated to alter
the sequence or secondary structure of the resulting Y RNA. These mutant plasmids
were expressed in mouse cells and the effect on small RNA production determined.
These individual mutants together helped to determine a region vital for cleavage,
and that it is the structure rather than the sequence within this region that is impor-
tant. A high-throughput method was also implemented, involving the generation of
large pools of plasmids containing all possible sequences within a particular region
of the RNA gene. These pools were expressed in mouse cells and the mutants that
were expressed and processed into small RNAs were sequenced. These experiments
showed that the formation of the large internal loop determines the internal cleavage
site.
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ABBREVIATIONS
30mer 30-35 nucleotide small RNA
AGO Argonaute
ANG Angiogenin APS Ammonium persuphate
ARG Analytical reagent grade
ATP Adenosine triphosphate
cDNA Complementary DNA
CNBP Cellular nucleic acid binding protein
CRM1 Chromosome region maintenance 1 (also exportin1 or Xpo1)
∆3’ Mutant with 3 nucleotide in 3 tail deleted
∆1S Mutant with one side of the stem deleted
∆2S Mutant with both sides of the stem deleted
∆ACC Mutant with ACC nucleotides deleted
∆Ro Mutant with Ro60 binding site deleted
DGCR8 DiGeorge Syndrome Critical Region 8
DMEM Dulbecco’s modified eagle medium
dsRNA Double-stranded RNA
dsDNA Double-stranded DNA
DTT Dithiothreitol
dNTPs Deoxyribonucleotides
drY D. radiodurans homolog of Y RNA
EBER Epstein-Barr virus-encoded small RNA
EDC 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride
EDTA Ethylenediaminetetraacetic acid
eIF4F Eukaryotic initiation factor 4F complex
eIF4G/A Eukaryotic initation factor 4G/A complex
Endo-siRNA Endogenous small interfering RNA
FAM Fluorescein amidite
FBS Fetal bovine serum
gDNA Genomic DNA
HDAC Histone deacetylase
hnRNP Heterogeneous nuclear ribonucleoprotein particle
hY Human Y RNA
IFIT5 Interferon-induced protein with tetratricopeptide repeats 5
IRES Internal ribosome entry site
IPTG Isopropyl -D-1-thiogalactopyranoside
LB Luria-Bertani
LNA Locked nucleic acid
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lncRNA Long intergenic non-coding RNA
MBq Megabecquerel
MCPIP1 Monocyte chemotactic protein-induced protein
mESCs Mouse embryonic stem cells
MIDAS Metal ion-dependent adhesion site
miRNA MicroRNA
MOV10 Moloney leukaemia virus 10, homolog (mouse)
mRNA Messenger RNA
mRo60 Mouse Ro60
mY Mouse Y RNA
ncRNA Non-coding RNA
NGS Next generation sequencing
nt Nucleotides
OptiMEM OptiMEM I reduced serum media
PAGE Polyacrylamide gel electrophoresis
PASR Promoter-associated small RNA
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PI Propidium iodide
piRNA Piwi-interacting RNA
Piwi P-element induced wimpy testes in Drosophila
PKR Protein kinase RNA-activated
PNK T4 polynucleotide kinase
PNPase Polynucleotide phosphorylase
Poly(I:C) Polyinosinic:polycytidylic acid
Puf60 Poly(U)-binding splicing factor 60 kDa
RISC RNA-induced silencing complex
RNase Ribonuclease
RNASET2 Human orthologue of Rny1p
RNH1 Ribonuclease inhibitor of angiogenin
RNP Ribonucleoprotein particle
Rny1p Ribonuclease in yeast 1
RoBP1 Ro60-binding protein 1
RPA Replication protein A
Rpm Revolutions per minute
RRM RNA recognition motif
rRNA Ribosomal RNA
Rsr Ro-sixty related (D. radiodurans orthologue of Ro60)
RT-PCR Reverse transcriptase PCR
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QC Quality Control
SAP Shrimp alkaline phosphatase
sbRNA Stem bulge RNA
SDS Sodium dodecyl sulfate
siRNA Small interfering RNA
sitRNA Stress-induced tRNA-derived RNA
SLE Systemic lupus erythematosus
sno-miRNA Small nucleolar RNA with microRNA-like activity
snoRNA Small nucleolar RNA
snRNA Small nuclear RNA
sRNA Small RNA
SS Sjo¨grens Syndrome
SSC Sodium chloride - sodium citrate buffer
STS Staurosporine
Sub1S Mutant with one side of the stem substituted
Sub2S Mutant with both sides of the stem substituted
svRNA Small vault RNA
TBE Tris-borate-EDTA
TEMED Tetramethylethylenediamine
tiRNA Transcription initiation RNA
TOP Terminal oligopyrimidine tract
tRNA Transfer RNA
Tsix Antisense RNA transcribed from Xist locus
TTSaRNA Transcription start site-associated RNA
UV Ultra violet
vWFA Von Willebrand factor A-like motif
X-gal 5-Bromo-4-chloro-3-indolyl -D-galactopyranoside
XIAP X-linked inhibitor of apoptosis
XiRNA X-inactivation RNA
Xist X-chromosome inactivation-specific transcript
xRo60 Xenopus sp. Ro60
xY Xenopus sp. Y RNA
YB-1 Y box-binding protein 1
ydRNA Y RNA-derived RNA
ZBP1 Zipcode-binding protein 1
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1 INTRODUCTION
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When the human genome sequence was completed many scientists struggled to
explain how so little of the genome could contain protein-coding genes. From this
point on an examination of the ‘junk’ DNA in the genome began and an expanding
area of science resulting from this is the study of the human ‘transcriptome’. This
transcriptome is made up not only of messenger RNAs (mRNAs), but also of many
different types of non-coding RNA (ncRNA). A number of classes of ncRNA, such
as transfer RNA (tRNA) and ribosomal RNA (rRNA), were discovered over fifty
years ago but other classes are still being discovered. Research into novel types of
ncRNA is progressing at a phenomenal pace, as a result of continuing advancements
in sequencing technologies. Below are detailed some of the more recently discovered
classes of ncRNA identified in mammals.
1.1 Long non-coding RNAs
This class of RNAs consists of all ncRNAs that are longer than 200 nucleotides. The
majority of long ncRNAs (lncRNAs) are thought to be produced by RNA polymerase
II (Guttman et al., 2009). Wang and Chang describe examples where lncRNAs act
as “signals, decoys, guides, and scaffolds” or often combinations of these functions
(Wang and Chang, 2011). These RNAs are sometimes further classified into long
intergenic ncRNAs that are present in the genome between protein-coding genes,
and long intronic ncRNAs (Sharma and Misteli, 2013)
1.2 Small non-coding RNAs
ncRNAs shorter than 200 nucleotides are considered small ncRNAs. They are
grouped based on their biogenesis and function.
1.2.1 MicroRNAs
MicroRNAs (miRNAs) are short RNA species that are around 22 nucleotides in
length in their mature form (Lagos-Quintana et al., 2001; Lau et al., 2001; Lee
and Ambros, 2001). They are expressed endogenously and interact with target
mRNA transcripts to block their expression (Lee et al., 1993). miRNA binding
can either prevent translation (Wightman et al., 1993), or de-stabilize the mRNA
transcript resulting in it being targeted for degradation (Lim et al., 2005). miRNAs
are generally either located within the introns of previously annotated genes (Aravin
et al., 2003; Lagos-Quintana et al., 2003; Lai et al., 2003; Lim et al., 2003) or are
clustered together within regions of the genome that do not contain protein-coding
genes (Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and Ambros, 2001). Some
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miRNAs are expressed in many parts of the organism (Pasquinelli et al., 2000; Lagos-
Quintana et al., 2003), while others are expressed in only one or two tissues (Lee
and Ambros, 2001) As well as having a specific spatial expression pattern, many
miRNAs are also expressed temporally (Reinhart et al., 2000).
1.2.2 Small interfering RNAs
Unlike miRNAs, small interfering RNAs (siRNAs) are produced as a result of pro-
cessing of a long double-stranded RNA (dsRNA) molecule (Hammond et al., 2000;
Zamore et al., 2000). This dsRNA was originally thought to be produced exoge-
nously, entering the cell through viral infection or being transcribed from transpos-
able elements that have inserted into the genome (Hamilton and Baulcombe, 1999;
Ketting et al., 1999; Tabara et al., 1999). Several years after siRNAs were first dis-
covered, a subclass of endogenous siRNAs (endo-siRNAs) was identified (Hamilton
et al., 2002; Ambros et al., 2003; Zilberman et al., 2003). endo-siRNAs are produced
when long dsRNA molecules are cut by the Dicer protein (Bernstein et al., 2001;
Grishok et al., 2001; Ketting et al., 2001). As opposed to its action in miRNA bio-
genesis, Dicer produces endo-siRNAs by moving along the dsRNA and cutting at
various positions (Myers et al., 2003; Provost et al., 2002). endo-siRNAs have been
found in only a few mammalian tissues to date.
1.2.3 Piwi-interacting RNAs
The main function of piwi-interacting RNAs (piRNAs) is their involvement in the
prevention of transposon mobility, preserving the integrity of the genome in germline
cells (Vagin et al., 2006; Brennecke et al., 2007). These RNAs interact with the
Piwi (originally P-element induced wimpy testis in Drosophila) clade of Argonaute
proteins (Grivna et al., 2006; Aravin, 2006; Girard et al., 2006; Lau et al., 2006).
There appears to be a “ping-pong” method of biogenesis, where a primary piRNA
is produced and aids the biogenesis of a secondary piRNA (Brennecke et al., 2007;
Gunawardane et al., 2007). This secondary piRNA is often antisense to target trans-
poson mRNAs and it hybridizes to them, blocking their expression. This biogenesis
is not dependent upon an RNase III enzyme, as miRNAs and siRNAs are (Houwing
et al., 2007; Vagin et al., 2006; Brennecke et al., 2007). piRNAs were initially thought
to only be expressed in the germline, but we now know that they are expressed in
somatic cells (Li et al., 2009; Malone et al., 2009) and in a number of cancers (Cheng
et al., 2011; Cui et al., 2011; Lu et al., 2010).
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1.2.4 Promoter-associated RNAs
The class of promoter-associated RNAs encompasses a number of different groups
of RNAs that have been discovered; including promoter-associated short RNAs
(PASRs), transcription start site-associated RNAs (TSSaRNAs), and transcription
initiation RNAs (tiRNAs). All of these RNAs are produced from highly expressed
genes (Seila et al., 2008; Taft et al., 2009c,a). PASRs are usually capped (Affymetrix
ENCODE Transcriptome Project and Cold Spring Harbor Laboratory ENCODE
Transcriptome Project, 2009), they are between 20 and 200 nucleotides in length,
and their 5’ ends map to the transcription start sites of the genes they regulate
(Kapranov et al., 2007). TSSaRNAs are 20 to 90 nucleotides in length and are
transcribed from the -250 to +50 region of the gene (Seila et al., 2008). The shorter
18nt tiRNAs are produced from position -60 to +120 in relation to the transcription
start site of the gene. RNA polymerase II stalls at a nucleosome at the +1 position,
which results in a backtracking and release of these short transcripts (Taft et al.,
2009c).
1.2.5 X-inactivation RNAs
Prior to and post X-chromosome inactivation, the X-inactivation specific transcript
(Xist) and the Xist antisense transcript (Tsix) RNAs are expressed from both chro-
mosomes, but during X-chromosome inactivation only one RNA is expressed from
each chromosome (Lee et al., 1999). Ogawa et al. have shown that these two RNAs
can form a dsRNA duplex, some of these dsRNAs are less stable than others and
are degraded into shorter RNAs of varying length called X-inactivation RNAs (xiR-
NAs) (Ogawa et al., 2008). xiRNAs are only produced during X-inactivation and
not before or after. These xiRNAs are proposed to repress Xist on the active X, but
their exact mode of action has yet to be confirmed (Ogawa et al., 2008).
1.2.6 Small vault RNAs
Vault RNAs were discovered in the 1980s (Kedersha and Rome, 1986) and later
were linked to drug resistance (Mossink et al., 2003). Vault RNAs associate with a
number of different proteins to form vault particles (Kedersha and Rome, 1986). In
2009 human vault RNAs were found to be processed into at least six different small
vault RNAs (svRNAs), between 23 and 40 nucleotides in size. At least one of these
acts like a miRNA, binding to Argonaute proteins and targeting the mRNA of the
CYP3A4 gene, which produces a protein key in drug metabolism (Persson et al.,
2009). The levels of svRNAs vary between tissue types, but this does not seem to
correlate with the levels of vault proteins in these tissues (Persson et al., 2009).
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1.2.7 Transfer RNA-derived RNAs
Transfer RNAs can be cleaved by a number of different enzymes to produce miRNA-
sized fragments. The RNase Z (ELAC2) enzyme is involved in the removal of the
tRNA 3’ trailer sequence during normal tRNA maturation (Takaku et al., 2003). Lee
et al. detected a number of small tRNA fragments in human cells, some of which
were produced by RNase Z and were derived from these 3’ trailers (Lee et al., 2009).
One of these RNase Z-dependent fragments was found to be essential for proliferation
(Lee et al., 2009). Other groups detected miRNA-sized tRNA fragments that were
Dicer-dependent (Cole et al., 2009; Babiarz et al., 2008).
1.2.8 SnoRNA-derived RNAs
Small nucleolar RNAs (snoRNAs) can be divided into two classes; the box C/D
snoRNAs and the H/ACA snoRNAs, depending upon the sequence motifs they
contain. Both of these classes of snoRNA have been shown to produce miRNA-
like fragments that have gene-silencing activity in human cells (Brameier et al.,
2011), although the H/ACA box snoRNAs more commonly produce microRNAs
(Ender et al., 2008; Taft et al., 2009b). A number of sequences already entered
into miRBase, the miRNA registration database (Griffiths-Jones, 2004), have been
re-classified as sno-miRNAs (Brameier et al., 2011).
1.3 Stress-induced small ncRNAs
Cells within the body are under constant stress from the external environment and
need to respond rapidly to stimuli. They may detect many different threats, such
as viral infection, changes in temperature or changes in oxygen levels. Cells must
decide how to react to these new conditions, and whether to warn surrounding cells
of the threat. Cells alter their metabolism in order to adapt to these changes in
the environment. They may decide to try and repair any damage caused by the
stress, or they may decide that the damage is too great and undergo apoptosis or
necrosis. It is now widely accepted that ncRNAs play an important role in many
cellular processes and this project aims to investigate their role in cellular response
to stress.
Since the commencement of this project a number of groups have published evi-
dence of stress-induced small RNAs derived from longer RNAs, many of which were
seen in our dataset. Here is a summary of this very recent data. Unlike the miRNA-
sized fragments derived from snoRNAs and tRNAs already discussed, these groups
focused on longer small RNAs that were produced in response to stress.
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1.3.1 Transfer RNA ’halves’
Transfer RNAs were first found to be bisected in E. coli cells in the presence of the
plasmid-encoded colicins E5 and D (Ogawa et al., 1999; Tomita et al., 2000). These
longer tRNA-derived fragments were denoted tRNA ‘halves’ after cleavage was found
to occur roughly in the middle of the molecule (Ogawa et al., 1999). The E5 colicin
produces 5’ and 3’ halves derived from tRNATyr, tRNAHis, tRNAAsp and tRNAAsn
and these tRNAs are cleaved in the anticodon loop, between the nucleotides at
positions 34 and 35 (Ogawa et al., 1999). The D colicin targets tRNAArg specifically
and cuts these molecules in a different place, cutting between positions 38 and 39
(Tomita et al., 2000). Both of these colicins are toxic to bacterial cells, as the tRNA
halves produced block translation (Ogawa et al., 1999; Tomita et al., 2000).
The first stress-induced tRNA halves were found in Tetrahymena thermophila
during nutrient starvation (Lee and Collins, 2005). A deficiency in any one of the
ten essential amino acids led to cleavage of tRNAs into fragments of between 30-35
nucleotides in size. A similar reaction was seen when these cells were heat-shocked,
or entered stationary phase of the cell cycle (Lee and Collins, 2005). The fragments
detected were derived from mature tRNAs, the majority of which were nuclear-
encoded rather than mitochondrial (Lee and Collins, 2005). This group also noted
that these fragments were only seen in early responses to starvation and were absent
in later stages.
After tRNA half discovery in T. thermophila, the race was on to identify these
small RNAs in other organisms and three years later they were discovered in single-
celled organisms, such as the fungus Aspergillus fumigatus (Jo¨chl et al., 2008) and
the yeast Sacchromyces cerrevisiae (Thompson et al., 2008), as well as the simple
eukaryote Giardia lamblia (Li et al., 2008). Aspergillus cells produce tRNA halves
as they undergo a sporulation stage of their life cycle, when protein synthesis is
blocked (Jo¨chl et al., 2008). Yeast tRNA halves were detected after a number
of stresses, most significantly after oxidative stress. Interestingly they were not
detected after amino acid starvation (Thompson et al., 2008). Yeast cells appear
to produce tRNA halves derived from the 3’ and the 5’ end of the tRNA at equal
levels and these fragments were sized at 40 nucleotides (Thompson et al., 2008).
These halves were detected for the first time in unstressed cells and were found at
much lower levels than in stressed cells (Thompson et al., 2008). The situation in
G. lamblia cells is more complex, as two classes of tRNA-derived small RNAs have
been detected: tRNA halves and 40 nucleotide fragments named stress-induced
tRNA-derived RNAs (sitRNAs) (Li et al., 2008). SitRNAs were present as these
cells changed from the vegetative state into cysts, whereas tRNA halves were not
detectable under these conditions (Li et al., 2008). Both of these types of tRNA
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fragments were detectable in G. lamblia cells undergoing serum starvation (Li et al.,
2008). SitRNAs are likely a unique adaptation of this early eukaryote in response
to particular stress situations.
In 2008 tRNA halves were also detected in human cells (Kawaji et al., 2008;
Thompson et al., 2008) and plant cells (Thompson et al., 2008). In human cells
tRNA halves were found to be 30-40 nucleotides in length and were induced by
phosphate buffered saline (PBS) treatment and serum starvation (Fu et al., 2009).
Kawaji et al. noticed that the abundance of these fragments did not correlate with
the level of the full length tRNA from which they were derived, or the number
of copies of that tRNA gene present in the genome, suggesting that either certain
tRNAs are targeted for cleavage over others, or certain fragments are more stable
after cleavage than others (Kawaji et al., 2008). The 5’ and 3’ halves produced
from the same tRNA molecule were often present at different levels (Kawaji et al.,
2008). Transfer RNA halves are expressed in many different human tissue types
after stress (Fu et al., 2009) and each tRNA half shows a unique tissue-specific
expression pattern (Kawaji et al., 2008). Figure 1.1 shows the levels of various
tRNA halves present in HepG2 cells after growth in PBS or in DMEM without
serum. Thirty minutes of growth in PBS produced the highest level of 5’ tRNA
halves for all tRNAs, except tRNATyr, which produced no detectable halves (Fu
et al., 2009). Fu et al. suggested that this is because the secondary structure of
tRNATyr is different to other tRNAs, as it is longer (Fu et al., 2009). Based on
their own results and those of Kawaji group, Thompson et al. suggested that the
purpose of tRNA cleavage is unlikely to be to reduce full length tRNAs, as the levels
of full length tRNAs were hardly affected and levels of each cleavage product were
much lower than the corresponding full length tRNA. They hypothesized that the
fragments are likely to play some sort of direct role in blocking translation, although
they found no evidence for this at the time (Thompson et al., 2008).
In 2009 further work by Thomspson et al. uncovered the enzyme responsible for
cleavage in yeast. Rny1p, an endonuclease normally stored in the vacuoles of yeast
cells, is released into the cytosol in cells undergoing stress and is then able to target
the cytoplasmic tRNAs (Thompson and Parker, 2009a). Two groups simultaneously
proved that the enzyme responsible for stress-induced tRNA half production in hu-
man cells is Angiogenin (Yamasaki et al., 2009; Fu et al., 2009). This protein had
previously been identified as a tRNase, but cleavage conditions had not been well
characterised (Saxena et al., 1992). Angiogenin is present in the nucleus, nucleolus
and the cytoplasm of human cells (Moroianu and Riordan, 1994; Tsuji et al., 2005).
Cytoplasmic Angiogenin is held in an inactive form by its binding partner Ribonu-
clease/Angiogenin inhibitor 1 (RNH1) (Shapiro and Vallee, 1987). Under conditions
such as oxidative stress Angiogenin could become active by two mechanisms. Firstly,
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Figure 1.1: The cleavage of tRNAs.
In experiments by Fu et al. (2009), HepG2 cells were treated with PBS or
grown in DMEM without serum. Northern membranes were probed for
the 5’ tRNA half of various tRNAs. Tyr-tRNA halves were not detected
in these experiments. 5.8S rRNA stained with ethidium bromide was
used as a control for RNA loading.
24
the associated RNH1 could be released, allowing cytoplasmic Angiogenin to become
active and cleave tRNAs. Secondly, Angiogenin could be released from the nucleus
or nucleolus and act on tRNAs in the cytoplasm. An inverse relationship between
the levels of RNH1 and Angiogenin suggests that it is mainly cytoplasmic Angio-
genin that is responsible for tRNA cleavage (Yamasaki et al., 2009). Yamasaki et al.
showed that the 5’ halves, when purified from a polyacrylamide gel and transfected
back into cells, blocked translation but the 3’ halves did not. They indicated that
the 5’ halves most likely have a monophosphate at the 5’ end and a 2’, 3’ cyclic
phosphate at the 3’ end (Yamasaki et al., 2009). The 3’ fragments are unlikely to
have a 5’ monophosphate or a 2’, 3’cyclic phosphate at the 3’ end, and are therefore
less likely to be functionally active (Yamasaki et al., 2009). These results should be
viewed objectively however, as it is impossible to rule out that other functional small
RNAs were not purified alongside the 3’ or 5’ tRNA fragments. In their review in
2009, Thompson et al. suggest that the anticodon loop is targeted for cleavage as it
is the most accessible point on the tRNA molecule (Thompson and Parker, 2009b).
It was Ivanov et al. who more fully characterized the role of these tRNA fragments
in translation. They found that only a small proportion of tRNA 5’ halves had this
role and that those that did had 4-5 guanine bases at their 5’ ends (Ivanov et al.,
2011a). These are essential in inhibiting translation as they interact with the initi-
ation factors eIF4G/A and the initiation complex eIF4F, causing dissociation from
mRNAs. Transfer RNA halves likely inhibit translation through an interaction with
Y box-binding protein 1 (YB-1), which has also been shown to have an involvement
in this process (Ivanov et al., 2011a). tRNAAla and tRNACys are most active in this
process and it is mainly uncapped translation initiation that is blocked by these
tRNA halves (Ivanov et al., 2011a).
In summary, the process of tRNA half generation appears to be a conserved re-
sponse to cellular stress, despite the fact that cleavage positions and stress conditions
differ between organisms, these differences are probably the result of a range of nu-
cleases acting on tRNAs (Li et al., 2008). Why tRNA halves are generated from so
many different tRNA types in mammalian cells, when only a small proportion block
translation, requires further investigation. It seems likely that they are involved in
a host of other stress-related processes that have yet to be uncovered.
1.3.2 Ribosomal RNA-derived RNAs
As with tRNAs, ribosomal RNA (rRNA) was found to be cleaved in E. coli af-
ter the expression of a toxin. Colicin E3 is specific for bacterial 16S rRNA and
cleaves towards the 3’ end to give a fragment of 50 nucleotides. This cleavage event
blocks translation at the elongation step in E. coli cells, resulting in cell death. In
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Figure 1.2: The cleavage pattern of 25S ribosomal RNA.
Experiments by Thompson et al. (2008), were conducted in yeast cells
during stationary phase or under oxidative stress conditions after treat-
ment with hydrogen peroxide. Membranes were probed for various tRNA
halves. An arrow marks an sRNA of 50 nt in size, although many other
RNA fragments can be seen on both gels.
Tetrahymena RNase T2 enzymes have been shown to cleave rRNAs during starva-
tions conditions (Andersen and Collins, 2012), but stress-induced rRNA cleavage
in eukaryotic cells is less well defined. Ribosomal RNA cleavage was identified in
yeast cells in response to oxidative stress, but a number of fragments were detected
rather than a fragment of one specific size, as for tRNAs (Thompson et al., 2008).
The investigation of ribosomal RNA fragment production is impaired by the size of
these RNA molecules and the complexity of their secondary structure.
1.4 Origins of the project
In preliminary experiments conducted by Dr. Nicolas, a senior research associate
in the Dalmay group, the MCF7 breast cancer cell line was subjected to a number
of environmental stresses, before being harvested for RNA extraction. Stress condi-
tions included heat shock, cold shock, starvation and Polyinosinic:polycytidylic acid
(Poly[I:C]) treatment. Poly(I:C) is a synthetic double-stranded RNA used to mimic
viral infection (Larson et al., 1969). Libraries were prepared for each sample where
RNAs of 19-33 nucleotides were selected and sequenced using Illumina next gener-
ation sequencing (NGS). The levels of small RNA expression under each condition
were compared to those of a control untreated sample.
Initially, the aim was to identify miRNAs that were differentially expressed be-
tween the stressed and control samples, but a surprisingly small number of miRNAs
displayed altered expression. What was also unexpected was that a large number
of sequences derived from other ncRNAs were increased in the Poly(I:C)-treated
sample when compared with the control. These differences were not seen in cells
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treated with any of the other stress conditions.
In the Poly(I:C) sample 21,837,679 redundant reads were sequenced, 79% of which
could be mapped to the human genome. Filtering of the data identified 490,826
non-redundant, or unique sequences, 33% of which could be mapped to the human
genome. This suggests that the unique sequences mapping to the genome make up
a large percentage of the total reads (since almost 80% of all reads mapped to the
genome) but many unique sequences (67%) did not map to the genome, therefore,
these must have low read numbers (since only 21% of all reads did not map to the
genome).
Figure 1.3: The distribution of sequencing reads.
NGS libraries were prepared from control and Poly(I:C)-treated samples
and this is a graphical representation of the distribution of the sequencing
reads according to size and abundance. Control sample reads are shown
in turquoise and Poly(I:C)-treated sample reads are shown in red.
In a graphical representation of the Illumina NGS data (see Figure 1.3), where
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the number of reads of each sequence is plotted against the read length, the miRNA
fraction can be seen as a peak at around 22 nucleotides. The majority of the ncRNAs
altered in the stressed samples are present in a peak of 31 nucleotides. The 22
nucleotide peak is present in the control and Poly(I:C)-treated samples. The 31
nucleotide peak is present in the control sample, but at substantially lower levels
than in the Poly(I:C)-treated sample.
One of the most highly up-regulated sequences in the Poly(I:C)-treated sample
compared to the control is derived from a human Y RNA. We initially focused
on this sequence, as it was originally annotated as a miRNA, but has since been
removed from miRBase (Griffiths-Jones, 2004). Work by the Dalmay group has
provided much evidence to show that this sequence, as with a number of other Y
RNA-derived sequences, is not generated by the miRNA biogenesis machinery and
is also not incorporated into the RNA-induced silencing complex (Nicolas et al.,
2012).
1.4.1 What are Y RNAs?
Systemic Lupus Erythematosus and Sjo¨gren’s Syndrome are diseases characterized
by the presence of antibodies against a patient’s own antigens (Fennell et al., 1962;
Vazquez, 1963). Widespread targets include DNA, RNA and protein. Early experi-
ments characterizing the nuclear targets of these autoantibodies led to the discovery
of Y RNAs. The term Y RNA was coined to distinguish the cytoplasmic location of
these RNAs from the nuclear U RNAs (Lerner et al., 1981b). Y RNAs are around
100nt in size and are usually found in ribonucleoprotein complexes (RNPs). They
are still generally accepted to be mainly cytoplasmic in location. Y RNAs have been
conserved throughout evolution and have so far been identified in many vertebrates,
as well as bacteria, nematodes and mosquitos (Van Horn et al., 1995; Perreault et al.,
2007; Mosig et al., 2007; Chen et al., 2000). Y RNAs differ in sequence, but have a
conserved secondary structure. In certain regions of these molecules, however, the
sequence is highly conserved, as these regions contain protein binding sites.
Y RNAs were originally identified through their interaction with the autoantigens
Ro60 and La (Lerner et al., 1981b). Each Y RNA can bind to either or both of
these proteins to form an RNP complex (Hendrick et al., 1981). They are believed
to commonly interact with Ro60 and a subset of these Ro RNPs also contain La
(Hendrick et al., 1981; Wolin and Steitz, 1984). Each type of Y RNA in humans can
bind to a subset of Y RNA-binding proteins depending on its conserved secondary
structure, as will be discussed later.
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Figure 1.4: The proposed evolution of the Y RNA genes.
Adapted from Mosig et al. 2007.
1.4.1.1 Y RNA evolution
All Y RNAs are believed to be paralogs, as they are derived from the same ancestral
Y RNA gene, which has been duplicated during evolution (Perreault et al., 2007;
Mosig et al., 2007). Figure 1.4 shows a representation of how these RNAs are
thought to have developed (Mosig et al., 2007). During the evolution of placental, or
eutherian, mammals the Y RNA gene cluster at some point contained four different
Y RNA genes, as they are all present to some degree in each taxonomic group within
this lineage (Mosig et al., 2007). Figure 1.5 displays the structure of the Y RNA
gene cluster in this eutherian ancestor. In genomes that contain Y RNAs, each Y
RNA is thought to be expressed from a single gene (Mosig et al., 2007), except for
in Xenopus, where two versions of Xenopus Y3 (xY3) RNA with a one nucleotide
difference have been identified, suggesting that there may be two active copies of
this gene in the Xenopus genome (O’Brien et al., 1993). Y RNA pseudogenes are
found in many eukaryotes (Perreault et al., 2007; Mosig et al., 2007), but in primates
a large number of psuedogenes have developed (Perreault et al., 2005, 2007). None
of these pseudogenes, either in primates or in other eukaryotes, are thought to be
expressed (Perreault et al., 2005, 2007; Mosig et al., 2007).
Figure 1.5: The proposed structure of the ancestral vertebrate Y RNA gene cluster.
Adapted from Mosig et al. 2007.
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In humans all four Y RNA genes are clustered together on chromosome 7, with
Y1 inverted in orientation compared to the rest (Wolin and Steitz, 1983; Maraia
et al., 1994b). In what is a striking difference between humans and rodents, both
mice and rats only have two active Y RNA genes, which are homologous to hY1 and
hY3 (Hendrick et al., 1981), while in humans all four genes are active. Frogs have
genes for xY3, xY4 and xY5 having lost the homolog of hY1, but gained a paralog
Y RNA called Yα (O’Brien et al., 1993). Dogs and cows also have four different
functional Y RNA genes (Perreault et al., 2007). Zebrafish and nematode worms
were found to have two versions of this family of ncRNAs, so have Y RNAs gained
an important tetrapod-specific function, with more copies developing as tetrapods
have evolved? In C. elegans a large class of RNAs known as stem-bulge, or sbRNAs,
have recently been re-classified as Y RNAs (Boria et al., 2010), providing evidence
of a lower complexity organism with many more potentially functioning Y RNAs
than tetrapods. This family of RNAs may have a vital function which has been
conserved through evolution, or certain family members could have evolved to take
on specialized functions within particular taxonomic groups.
1.4.2 Y RNA secondary structure
All vertebrate Y RNAs have a similar secondary structure. In Figure 1.6 the common
structure has been divided into different regions. Region 1 forms a terminal stem
made up of the 3’ and 5’ ends of the molecule (Wolin and Steitz, 1983). This region
is important for Ro60 protein binding, as will be discussed in greater detail later.
There is some variation in the length of the 3’ tail between different Y RNAs; in
humans Y5 has the longest single-stranded overhang (Kato et al., 1982; Wolin and
Steitz, 1983). An extra uridylate, marked in Figure 1.6 in brackets, is present at
the 3’ end of some Y RNA molecules (Wolin and Steitz, 1983). In region 2 there is
a conserved cytosine bulge and a larger bulge on the opposite stem. A further stem
is formed in region 3. The helix in region 3 has been linked to Y RNA export from
the nucleus (Rutjes et al., 2001), as well as being required for the RNA to function
in DNA replication (Christov et al., 2006), as discussed later. Regions 1 and 3 are
highly conserved between Y RNAs and across species (Pruijn et al., 1997; Teunissen
et al., 2000). In region 2 the two bulges are conserved (Green et al., 1998). In region
4 there is an internal loop and in region 5 there may be one or two stem-loops.
Regions 4 and 5 are less well conserved than regions 1-3 and have been proposed
to be rather dynamic, as “breathing” occurs to allow conformational changes and
potentially enable interactions with proteins or other nucleic acids (van Gelder et al.,
1994; Teunissen et al., 2000). Comparison of the sequences of all identified Y RNAs
suggests that there are five central base pairs that are conserved across all Y RNAs
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Figure 1.6: The secondary structure of a human Y RNA.
This structure can be divided into particular regions according to se-
quence conservation and function. Adapted from van Gelder et al. 1994.
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and these are likely to be essential for a common function of these RNAs (Green
et al., 1998).
The secondary structure of all human Y RNAs has been experimentally deter-
mined by a number of groups using enzymatic digestion and chemical modification.
Comparison of experimentally validated structures with those predicted by folding
algorithms highlighted a few differences. Firstly, in region 2 there is some variation
in the cysosine that bulges out, but it is more often the cytosine at position 9 in the
Ro60-free Y RNA, rather than the predicted cytosine at position 8 that is present
in the bulge (van Gelder et al., 1994). Secondly, the larger bulge in region 2 was
shown to be closer to the terminal end than predictions suggested. In a proportion
of Y RNA molecules these two separate bulges can join to form a small internal loop
(van Gelder et al., 1994). Finally, in region 4 early prediction algorithms produced
two loops, while experimental data indicated that this region is more likely to form
a single large loop. In the larger Y RNAs this large internal loop may form tertiary
structures, although this is unlikely for smaller RNAs such as Y5 (van Gelder et al.,
1994). This loop is likely to have an altered conformation when interacting with
proteins (van Gelder et al., 1994).
1.4.3 Y RNA binding proteins
Figure 1.7: Protein binding sites.
The secondary structure of a human Y RNA with the binding sites for
Ro60 and La displayed. Proteins A-D represent where proteins other
than Ro or La are known to bind.
32
Many of the RNAs within a cell will associate with RNA-binding proteins to form
RNPs. As detailed in Figure 1.7, the Ro60 and La proteins interact with each type
of human Y RNA (Hendrick et al., 1981; Wolin and Steitz, 1983). There have been
some suggestions that the 52 kDa Ro protein may be incorporated into Ro RNPs,
but work by various groups has shown that this is not the case (Kelekar et al., 1994;
Boire et al., 1995; Itoh et al., 1992).
1.4.3.1 Ro60 and misfolded ncRNA binding
The binding of Ro60 to misfolded ncRNAs has been well characterized. There is
increasing evidence to suggest that these Ro60-ncRNA interactions lead to either the
degradation or correct folding of ncRNAs; this supports a quality control function
for Ro60 in many different organisms, including bacteria, mice and humans (Chen
et al., 2003, 2007; Hogg and Collins, 2007). The Ro60 protein is made up of two
domains; a ringed donut-shaped domain made up of α-helical HEAT motifs and a
von Willebrand Factor A (vWFA) domain (Stein et al., 2005). The HEAT motif
helices fold to make the central cavity. The vWFA domain is comprised of a β sheet
and a number of α helices (Stein et al., 2005). Within the β sheet is a metal-ion
dependent adhesion site (MIDAS) motif. This motif may be important for structural
changes to occur within the Ro60 protein (Stein et al., 2005).
In Xenopus oocytes Ro60 (xRo60) interacts with variant pre-5S rRNAs (O’Brien
and Wolin, 1994). These RNAs usually have a 3’ extension as a result of aberrant
RNA polymerase III termination, as well as a number of mutations within the se-
quence of the RNA (O’Brien and Wolin, 1994). The majority of these mutations
have been predicted to result in the destabilisation of existing helices and the for-
mation of an alternative helix (O’Brien and Wolin, 1994; Shi et al., 1996). X-ray
crystallography experiments indicate that the 3’ single-stranded end of misfolded
5S rRNAs binds to the xRo60 basic inner surface, while a helical domain of these
RNAs binds to a basic region on the outer surface of xRo60 (Fuchs et al., 2006).
A 3’ tail of at least 5 nucleotides, along with a particular helical domain within
the RNA, is key for this type of interaction with xRo60 (Fuchs et al., 2006). Altering
the sequence of this helix, or a nearby loop region, appears to have a large effect on
Ro60-binding efficiency, as Ro60 probably binds directly to this region (Fuchs et al.,
2006). xRo60 is thought to have a large flexible misfolded ncRNA-binding surface,
as sequence alterations in the rest of the variant pre-5S rRNA have little effect on
xRo60 binding, as long as the secondary structure remains the same (Fuchs et al.,
2006). In vitro, xRo60 can interact with wild type pre-5S rRNA, but Fuchs et al.
hypothesize that this RNA would be unlikely to be available for binding in vivo and
that xRo60 acts as a scavenger, picking up free misfolded RNA (Fuchs et al., 2006).
Along with variant 5S rRNA, xRo60 can interact with the viral EBER1 RNA, as
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well as Saccharomyces cerevisiae tRNA and U6 snRNA in vitro; all of these ncRNAs
have 3’ tails (Fuchs et al., 2006).
In mouse embryonic stem cells mouse Ro60 interacts with variant U2 snRNAs
(Chen et al., 2003). 68% of these variant RNAs contain at least one sequence
change. Experiments involving injecting mouse variant U2 snRNAs into Xenopus
oocytes revealed that xRo60 interacts with variant pre-U2 and variant processed
U2 snRNA, but does not interact with wild type U2 snRNA (Chen et al., 2003).
Like the Xenopus variant pre-5S rRNA, Ro60-bound variant U2 snRNA appeared to
commonly have two different mutations, resulting in the formation of an alternative
helix in the RNA (Chen et al., 2003). In mouse cells Ro60 only associates with a
small proportion of variant U2 snRNA, likely as a result of only a small proportion
of these RNA molecules forming the required alternative helix (Chen et al., 2003).
It is possible that mouse Ro60 also binds to wild type U2 snRNA at low levels to
aid its folding (Chen et al., 2003). In Xenopus oocytes many 5S rRNAs are present,
including variants. Many of these variants are encoded in the genome of Xenopus
(Peterson et al., 1980). Similarly there are many variant versions of the U2 snRNA
gene encoded in the mouse genome (Mouse Genome Sequencing Consortium, 2002).
The ability of Ro60 to specifically recognize misfolded RNAs in different organisms
is likely to have evolved to protect cells from the presence of high levels of these
RNAs produced from variant genes (Chen et al., 2003).
1.4.3.2 Ro60 and Y RNA binding
Ro60 binds to regions 1 and 2 of each Y RNA (Wolin and Steitz, 1984) and a bulged
cytosine that projects from the stem is important for this interaction (Simons et al.,
1996). Mutation studies and chemical modification experiments give conflicting
evidence as to whether the cytosine at position 8 (C8) or the cytosine at position
9 (C9) is important for Ro60 binding. Bearing in mind that this region can form
either two bulges or a small internal loop, Green et al. hypothesized that either C8 or
C9 could be free in the protein-free Y RNA, depending on its conformation. They
further hypothesize that C9 is either base-paired or directly interacts with Ro60
when Ro60 binds to the Y RNA. This would explain why this nucleotide appears to
be more important for Ro60 interaction than C8 (Green et al., 1998). Work by the
Wolin group using xRo60 and Xenopus Y3 (xY3) RNA indicates that both bulges,
or the alternative small loop structure that they can form, are also required for
Ro60 binding (Green et al., 1998). The sequence of this region is not important,
only the structure (Stein et al., 2005; Green et al., 1998). This group further suggest
that the bulges are essential because they allow the secondary structure of the Y
RNA to be open enough for Ro60 to enter and read the sequence in this region
(Green et al., 1998). X-ray crystallography experiments have shown that Xenopus
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Ro60 undergoes a conformational change when either a misfolded RNA or Y RNA
associates (Stein et al., 2005). As well as Ro60, each Y RNA also undergoes a change
in conformation as a result of this interaction (Green et al., 1998; Stein et al., 2005).
1.4.3.3 La
La associates with many different RNAs including Alu element RNAs, Pre-5S RNAs
and pre-tRNAs (Rinke and Steitz, 1982; Shen and Maniatis, 1982). La also interacts
with viral RNAs including Epstein-Barr virus non-coding RNAs and virus associated
RNAs (Lerner et al., 1981a; Rosa et al., 1981; Lerner et al., 1981b). This protein
usually interacts with RNA precursors, rather than RNAs in their mature form. Its
ability to bind to a run of uridylates at the 3’ end of target RNAs has been well
characterized (Francoeur and Mathews, 1982; Reddy et al., 1983). La binding is
involved in stabilization of nascent RNA polymerase III transcripts (Maraia et al.,
1994a; Yoo and Wolin, 1997). This protein regulates tRNA maturation by binding
to the 3’ end of pre-tRNAs and preventing their degradation by exonucleases (Fan
et al., 1998; Yoo and Wolin, 1997). La is also involved in the correct folding of pre-
tRNAs, enabling further processing to produce mature tRNAs (Fan et al., 1998).
La interaction can allow internal ribosome entry site (IRES)-mediated translation of
viral RNAs (Meerovitch et al., 1993), prevent RNA export from the nucleus (Boelens
et al., 1995) or aid RNA integration into RNPs (Gottlieb and Steitz, 1989a).
The La protein is made up of an N terminal domain known as the La motif
(Sobel and Wolin, 1999), the nearby RNA recognition motif RRM1(Bandziulis et al.,
1989; Query et al., 1989), and a carboxyl (C) terminal domain. The La motif and
RRM1 work in combination to recognise and interact with the oligo(U) 3’ terminal
sequences of target RNAs (Ohndorf et al., 2001). There is also evidence suggesting
that La may bind to 3’ targets by recognising structural motifs at their 5’ ends
(Fan et al., 1998). The C terminal part of La has low sequence conservation among
orthologs (Chambers et al., 1988; Chan et al., 1986). Vertebrate La proteins appear
to have a number of domains within their C terminal ends, including an alternative
RRM domain, RRM2 (Topfer et al., 1993; Jacks et al., 2003). This C terminal region
of La has a certain amount of flexibility, allowing it to interact with a vast array of
coding and non-coding RNAs (Kucera et al., 2011).
La interaction with RNAs that do not contain a run of uridylates at the 3’ terminus
requires a different mechanism of binding involving the La motif and RRM1, com-
bined with the RRM2 domain (Martino et al., 2012). La has been shown to interact
with both primary miRNAs (pri-miRNAs) and precursor-miRNAs (pre-miRNAs)
via this 3’ oligo(U)-independent binding mechanism (Liang et al., 2013). As with
tRNAs, La is thought to protect the vast majority of pre-miRNAs from digestion
by enzymes such as monocyte chemotactic protein-induced protein 1 (MCPIP1), al-
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lowing theses pre-miRNAs to be exported from the nucleus and be passed to Dicer
for processing (Liang et al., 2013). La binds to a minority of pri-miRNAs and is
thought to be incorporated into the Drosha/DGCR8 complex as these pri-miRNAs
are processed (Liang et al., 2013). Mutation studies indicate that a stem-loop struc-
ture is required for 3’ oligo(U)-independent binding to pre-miRNAs and Liang et al.
propose that this might be a more general mechanism for 3’ oligo(U)-independent
La binding (Liang et al., 2013).
The La protein is present in cells at much higher levels than Ro60 (Gottlieb
and Steitz, 1989a) and plays many different roles within each cell. La is mainly
located in the nucleus in the cells of many different organisms (Yoo and Wolin, 1994;
Deng et al., 1981; Simons, 1994), although it also has functions in the cytoplasm
(Meerovitch et al., 1993; Casciola-Rosen et al., 1994a). The human La protein
can be phosphorylated on a Serine residue as position 366, altering its functional
activity (Fan et al., 1997). Phosphorylated La is active in tRNA processing (Itine
et al., 2000), while dephosphorylated La has the ability to stabilize nascent Pol III
transcripts (Fan et al., 1997). This protein leaves the nucleus under environmental
stress conditions, such as apoptosis (Casciola-Rosen et al., 1994a) or viral infection
(Meerovitch et al., 1993). During apoptosis the majority of La is dephosphorylated,
probably by a protein phosphatase 2A-like enzyme (Rutjes et al., 1999a). A small
proportion of La is also cleaved at an Aspartate residue in the C terminus, resulting
in the loss of a nuclear localisation signal and the relocation of La to the cytoplasm
(Rutjes et al., 1999a; Shiroki et al., 1999). During apoptosis La cleavage prevents
its association with, and the subsequent unwinding of, double-stranded RNAs (Xiao
et al., 1994). This leaves these RNAs free to be targeted by protein kinase RNA-
activated (PKR)(Rutjes et al., 1999a). La also has many other apoptosis-specific
functions, such as enabling IRES-mediated translation of the cellular protein X-
linked inhibitor of apoptosis (XIAP) (Holcik and Korneluk, 2000). This protein is
important in cellular response to stress (Deveraux et al., 1997).
1.4.3.4 La and Y RNA binding
Y RNAs are RNA polymerase III transcripts and La binds to the 3’ oligo(U) se-
quences in these transcripts and increases their stability, protecting them from degra-
dation (Gottlieb and Steitz, 1989a,b). As well as the 3’ end, La may also interact
with hY3 and hY5 at other sites. It is currently unknown whether these other sites
contain U-rich sequences (Pruijn et al., 1991). Many functions have been assigned to
the La protein, but as yet none have been found to require Y RNA. So do Y RNAs
work with La to perform a particular function or is this interaction solely important
for Ro RNP biogenesis? Human Y RNAs are unusual in that they stay bound to La
after the termination of transcription, while most other polymerase III transcripts
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dissociate when the La-binding site is removed (Peek et al., 1993; Boire and Craft,
1990). La association is necessary for the binding of a number of other proteins to
Y RNAs, so it may also play a role in the correct folding of Ro RNPs (Fabini et al.,
2000, 2001; Belisova et al., 2005). It is possible that Y RNA binding to La may
block certain functions of La, as La is less active in splicing when bound to hY1
(Belisova et al., 2005). The La protein can undergo a number of modifications and
processing events, so it is possible that Y RNAs interact with a form of La that is
not active in splicing, and play no role in blocking this function. La and Ro have
both been implicated in the quality control of pre-5S rRNA (Shi et al., 1996) and,
as already mentioned, hY5 aids in the recruitment of 5S rRNA to Ro60, so it may
also aid any function of La in this process.
1.4.3.5 Nucleolin
In human cells Nucleolin binds preferentially to Y1 and Y3 (Fouraux et al., 2002;
Langley et al., 2010). There is less conclusive evidence that this protein may bind to
the other human Y RNAs (Fabini et al., 2000, 2001; Fouraux et al., 2002; Langley
et al., 2010). Mutation studies show that Nucleolin interacts with Y RNAs via
region 3, the large internal loop (Fabini et al., 2001; Fouraux et al., 2002). Nucleolin
was named as it was originally isolated from the nucleolus, but is also present in
other areas of the cell (Orrick et al., 1973; Borer et al., 1989). Nucleolin is involved
in DNA repair and replication, chromatin modification and the regulation of rRNA
transcription (Seinsoth et al., 2003; Yang et al., 2009; Angelov et al., 2006; Bouche
et al., 1984). During cellular stress Nucleolin leaves the nucleolus and binds to
Replication protein A (RPA) (Daniely and Borowiec, 2000). RPA is involved in
chromosomal DNA replication, but this function is blocked when it interacts with
Nucleolin (Daniely and Borowiec, 2000; Collins and Kelly, 1991). Perhaps Nucleolin
also binds to Y RNAs during cellular stress. As with RPA, Y RNAs also play a
vital role in chromosomal replication, as discussed later.
1.4.3.6 Calreticulin
Calreticulin (CRT) is another protein that has been associated with Ro RNPs
(Cheng et al., 1996). This protein has been found to bind directly to Ro60 at two
different sites (Staikou et al., 2003). It may also interact with hY RNAs directly
(Cheng et al., 1996). CRT is mainly located in the endoplasmic reticulum, but also
functions at the cell surface and in the nucleus (Opas et al., 1991; Burns et al., 1994;
Dedhar, 1994). It is involved in many cellular processes including the accumulation
of calcium and the regulation of gene expression (Opas et al., 1991; Burns et al.,
1994; Dedhar, 1994). It can also be utilized by viruses for genome replication (Singh
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et al., 1994). CRT causes the release of calcium from mitochondria during apoptosis
(Nakamura et al., 2000). A calcium-dependent modification of CRT causes it to
relocate to stress granules (Decca et al., 2007). It has also been linked to the au-
toantibody recognition of various endogenous antigens and may interact with Ro60
for this purpose (Staikou et al., 2003).
1.4.3.7 Heterogeneous nuclear ribonucleoproteins
In humans heterogeneous nuclear ribonucleoproteins (hnRNP) I and K only interact
with Y1 and Y3 RNA and the ability to bind to Y4 and Y5 has not been demon-
strated (Fabini et al., 2001; Fouraux et al., 2002). Both proteins have been linked
to cellular processes, such as splicing, the regulation of RNA folding (Belisova et al.,
2005) and translation (Ostareck et al., 1997). Like Nucleolin these proteins bind
the large internal loop of hY1 and hY3. hnRNP I and K are unable to bind in the
absence of La (Fabini et al., 2001; Fouraux et al., 2002). HnRNP K is a key player in
cellular response to apoptosis, as it regulates the transcription of XIAP (Xiao et al.,
2013). HnRNP I (also known as polypyrimidine tract binding protein) has recently
been shown to regulate miRNA activity (Engels et al., 2012). It has also been found
to colocalize with human Y RNAs in perinucleolar compartments (discussed later)
(Matera et al., 1995)
1.4.3.8 Ro RNP binding protein I
Ro RNP binding protein I (RoBPI) is also known as Poly-U Binding Splicing Fac-
tor 60 KDa (PUF60). In human cells RoBPI mainly associates with Y5 (Bouf-
fard et al., 2000), but has also been shown to bind human Y1 and Y3 (Hogg and
Collins, 2007). Most of RoBPI is located in the nucleus (Page-McCaw et al., 1999).
RoBPI, in association with the splicing protein p54, is involved in the splicing of
U2 snRNA (Page-McCaw et al., 1999). RoBPI contains a PUMP domain, which
enables protein-protein interactions but may also be important for RNA binding
(Page-McCaw et al., 1999). RoBPI also has two RRM domains, which enable RNA
binding (Page-McCaw et al., 1999).
1.4.3.9 Interferon-induced protein with tetratricopeptide repeats 5
Interferon-induced protein with tetratricopeptide repeats 5 (IFIT5) was found to
interact with only Y5 of the Y RNA family, although it interacts with a number
of other small ncRNAs (Hogg and Collins, 2007). Only this year this protein has
been crystallized and fully characterized (Abbas et al., 2013; Katibah et al., 2013;
Feng et al., 2013). It is able to bind single-stranded A or U rich RNA or double-
stranded AT rich DNA (Feng et al., 2013). Interestingly, like the Y5 RNA, this
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protein is not found in mouse cells, but is found in humans and Xenopus (Feng
et al., 2013). It is thought that the main function of IFIT5 is in cellular response
to viral infection. ITIF5 recognises the 5’ triphosphates in a short 5’ overhang of
single-stranded viral RNAs (Abbas et al., 2013) and has also been shown to bind to
cellular 5’ phosphorylated RNAs, such as tRNAs (Katibah et al., 2013; Hogg and
Collins, 2007).
1.4.3.10 Ribosomal protein L5
Ribosomal protein L5 is another protein that binds to human Y5 RNA specifically.
L5 is involved in shuttling 5S rRNA around the cell (Steitz et al., 1988) and it is
believed to be involved in recruiting variant 5S rRNA to hY5-containing Ro RNPs
(Hogg and Collins, 2007), although in vitro 5S rRNA can interact with hY5 in the
absence of the L5 protein (Hogg and Collins, 2007).
1.4.3.11 Zipcode binding protein I
Zipcode-binding protein I (ZBPI) is located in the cytoplasm under normal condi-
tions, but under conditions such as UV damage, it moves into the nucleus of mouse
cells (Sim et al., 2011). ZBPI interacts with the mouse Y3 (mY3) RNA and is
involved in shuttling the mY3-Ro60 complex out of the nucleus (Sim et al., 2011).
Interaction of this protein with the hY RNAs has yet to be examined, but it is likely
that these RNAs are exported via several nuclear export pathways.
1.4.3.12 Polynucleotide phosphorylase
In Deinococcus radiodurans the polynucleotide phosphorylase (PNPase) enzyme de-
grades structured ncRNAs. It interacts with a Ro60 ortholog known as Ro sixty-
related (Rsr) and bacterial Y RNA and forms a complex to carry out this function
(Chen et al., 2013). The bacterial Y RNA is key for the protein interactions of this
degradation complex (Chen et al., 2013).
1.4.3.13 Other Y RNA-binding proteins
There are many more Y RNA-interacting proteins that have recently been identified
but the function of these associations have not been thoroughly elucidated. MOV10
interacts with Ro60 in an RNA-dependent manner, which is likely to involve Y
RNAs (Sim et al., 2011). YB-1 is also believed to interact with Ro60 in a Y RNA-
dependent manner (Sim et al., 2011), but again further characterization is required.
Also many proteins involved in the initiation of chromosomal RNA replication have
been found to directly bind to Y RNAs (as described later), but the exact role of Y
RNAs in this process is still currently unknown (Zhang et al., 2011a).
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Every human Y RNA was originally thought to stably interact with both Ro60 and
La to form Ro RNPs (Hendrick et al., 1981; Wolin and Steitz, 1984). More recently
it has been suggested that not all Y RNAs take on this form and that they may have
Ro60 and La independent functions (Langley et al., 2010). As discussed above, an
expanding array of proteins appear to bind to Y RNAs in a specific manner, rather
than binding to all with equal efficiency. More and more groups are now proposing
that each Y RNA may be incorporated into a distinct RNP complex to carry out a
particular function (Gendron et al., 2001; Fabini et al., 2001; Fouraux et al., 2002;
Langley et al., 2010). What is still controversial, however, is the idea that Ro60 and
La may not be included in every Y RNP (Langley et al., 2010).
Despite the suggestion that so many specialized Y RNA-containing RNP com-
plexes exist, very few clear functions for these have been identified. Perhaps Y
RNAs simply act as a mechanism for storing proteins within the cell until they
are needed, for example under stress conditions. Y RNAs could recruit proteins so
that a large store is available when released from the Y RNP. Alternatively, these
proteins may have some function that is blocked by Y RNA binding. There are
numerous interactions between Y RNA-binding proteins and other proteins/nucleic
acids in subcellular locations other than the cytoplasm (Cheng et al., 1996; Staikou
et al., 2003; Itine et al., 2000). For example, only the unphosphorylated form CRT
associates with Ro RNPs (Cheng et al., 1996), but its phosphorylated form is known
to be active in viral RNA replication (Singh et al., 1994). Phosphorylated La inter-
acts with Y RNAs, but the phosphate group must be removed before this protein
is active in tRNA maturation (Fan et al., 1998). Y RNA binding may also block
the modification of these proteins, altering their function. Each Y RNA is unlikely
to bind the majority of each of its protein partners, but many of these proteins are
involved in cell stress, so proteins bound to Y RNAs may be stored for this purpose.
1.4.3.14 Y RNP localization
Human Y RNAs, when injected into the nuclei of Xenopus oocytes, are bound in Ro
RNPs and exported in a Ro60-dependent manner (Simons, 1994). The Ro60 binding
site however, is not enough for export, as deletion of region 3 of hY1 blocks export
into the cytoplasm (Rutjes et al., 2001). Rutjes et. al. speculate that a nuclear
factor interacts with the RNA in this region and this factor is essential for nuclear
export of hY1 (Rutjes et al., 2001). Testing of the other human RNAs in Xenopus
oocytes yielded similar results, implicating this pathway in the export of multiple
Ro RNPs. This nuclear factor is likely to be ZBP1, which was found to be involved
in the export of Ro60-mY3 in mouse cells (Sim et al., 2011). ZBP1 associates more
strongly with Ro60 in the nucleus after UV irradiation and this complex is then
exported into the cytoplasm. The mY3-Ro60 complex blocks a Chromosome region
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maintenance 1 protein (CRM1)-independent nuclear export signal in ZBP1, so that
this complex relies on CRM1-dependent export only (Sim et al., 2011). Mouse Y1,
however, was found to be exported via a different pathway in this study (Sim et al.,
2011).
Ro60 is both nuclear and cytoplasmic (Xia et al., 1987; Peek et al., 1993). It
shuttles into and out of the nucleus depending upon environmental conditions. When
mouse Y RNAs are knocked down using siRNAs then Ro60 relocates to the nucleus
(Sim et al., 2009). Sim et al. made various mouse/D. radiodurans fusion proteins
and found that the mouse HEAT repeat domain is required for the stabilization of
mouse Y RNAs and for the accumulation of Ro60 in the nucleus after UV irradiation
(Sim et al., 2009). Mouse Ro60 was also found to relocate to the nucleus after
oxidative stress resulting from hydrogen peroxide treatment (Sim et al., 2009). They
determined that the nuclear localisation signal is likely to reside in helices 1-12 and
that these helices, in the context of a correctly folded Ro60 protein, are required
for stress-dependent relocation of Ro60 (Sim et al., 2009). Interestingly, helices 14
and 16 of mRo60 are required for Y RNA binding, and its interaction with these
RNAs is thought to mask the nuclear localization signal (Sim et al., 2009). Y RNA
association with Ro60 must therefore be altered after UV treatment, possibly in
a similar manner to Rsr-drY RNA when the PNPase enzyme binds (Chen et al.,
2013). It is unclear what proportion of mY RNAs enter the nucleus with mRo60
during UV irradiation (O’Brien et al., 1993; Peek et al., 1993; Chen et al., 2003;
Sim et al., 2009), but it seems likely that their regulation of Ro60 localization is
dependent upon the other proteins present in the complex (Sim et al., 2009)
La is mainly nuclear and contains a nuclear localization signal (Simons, 1994),
but is detectable in the cytoplasm where it is present in Ro RNPs (Peek et al.,
1993; Boire and Craft, 1990). The alterations necessary to allow La to exit the
nucleus are not yet understood. Mutant human Y RNAs lacking the La binding
site are more rapidly exported from the nucleus, suggesting that La is involved in
the nuclear retention of these RNAs (Simons et al., 1996). The study of human Y
RNA export in Xenopus oocytes is complicated by the fact that Y RNAs undergo
processing in these cells, and both xY RNAs and hY RNAs in the cytoplasm of
Xenopus oocytes are not associated with La and are missing their terminal oligo(U)
sequences (O’Brien et al., 1993; Simons et al., 1996). Y RNAs in human cells are
known to be present in the cytoplasm, where they are stably bound to La (Peek et al.,
1993; Boire and Craft, 1990). In certain cell lines, hY1, hY3 and hY5 have also been
detected in discrete nuclear locations known as perinucleolar compartments (PNCs)
(Matera et al., 1995). The function of these PNCs is unknown, but it has been
suggested that they represent sites of RNA polymerase III transcript sequestration
prior to nuclear export or following nuclear import (Matera et al., 1995). This
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subset of Y RNAs is Ro60-independent and may also interact with hnRNP I, which
colocalizes to PNCs (Matera et al., 1995).
1.4.4 Y RNA function
Although there are numerous groups working on this non-coding RNA family, only
two functions have been experimentally validated. The first function is in semi-
conservative DNA replication. The second is in Ro60 quality control.
1.4.4.1 Y RNAs in DNA replication
Before a cell divides, it must duplicate its DNA in order for a copy to enter into each
daughter cell. During semi-conservative DNA replication the DNA strands separate
and each is used as a template to produce a new strand. The new DNA molecules
consist of one strand from the existing DNA and one strand of nascent DNA (Watson
and Crick, 1953; Meselson and Stahl, 1958). Using a cell-free system as a model,
Krude and colleagues evaluated the requirements for chromosomal DNA replication
(Christov et al., 2006). In this cell-free system, the nuclei are removed from cells at
the G1 stage of the cell cycle (Krude et al., 1997). These cells are ready to undergo
replication, but have not yet begun to replicate their DNA. Cytosolic extracts from
replicating cells in S phase of the cell cycle can be added to these nuclei, resulting
in the stimulation of chromosomal replication (Krude et al., 1997). The cytosolic
extracts can be fractionated and different fractions added to the nuclei to determine
which are necessary for replication. Using this method, Y RNAs were found to be
crucial for the replication process (Christov et al., 2006). The exact role of these
RNAs has not yet been determined, but they have recently been found to be essential
for the initiation of replication and are not thought to be necessary for elongation of
the nascent DNA strand (Gardiner et al., 2009; Krude et al., 2009). Human Y RNAs
are recruited to chromatin by their association with protein complexes involved in
DNA replication initiation (Zhang et al., 2011a).
Further studies by the Krude group identified that the human Y RNAs act re-
dundantly in their role during replication, as addition of any one of the hY RNAs
in the absence of any of the others still stimulates semi-conservative DNA replica-
tion (Christov et al., 2006). In fact, the block in replication resulting from targeted
knock-down of a human Y RNA can also be rescued by the addition of any vertebrate
Y RNA, suggesting that their function in replication is conserved across all verte-
brate Y RNAs (Gardiner et al., 2009). Non-vertebrate Y RNAs cannot stimulate
replication in human cells (Gardiner et al., 2009).
As already discussed, certain regions of Y RNAs are more conserved than others.
Analysis of this conservation can give some indication of which regions are present
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in the majority of vertebrate Y RNAs. Mutagenesis studies, combined with this
analysis, were used to narrow the region essential for replication down to a short
duplex within region 3 of each Y RNA (Gardiner et al., 2009). Addition of this
short double-stranded duplex alone is sufficient to stimulate DNA replication in a
human cell depleted of one of the hY RNAs. Intriguingly this duplex must be in an
RNA form, as the addition of the same sequence constructed of DNA did not initiate
replication (Gardiner et al., 2009). In the presence of this conserved duplex alone
DNA replication can occur, but this duplex was found to associate at many locations
on euchromatin and heterochromatin. Full length Y RNAs associate with regions
of the DNA where replication has yet to occur and dissociate on the initiation of
replication at these sites (Zhang et al., 2011a). The RNA region encompassing the
Ro60 binding site, along with the large internal loop of each Y RNA, is required for
specific euchromatin association, but is not sufficient for DNA replication to occur
(Zhang et al., 2011a). A number of regions of the Y RNA must therefore be necessary
for efficient DNA replication in mammalian cells. hY1 and hY3 associate with
euchromatin in the nucleus at distinct, but overlapping sites. hY5 associates with
euchromatin at different sites to hY1 and hY1 was found to cause hY5 dissociation.
This suggests that, although all hY RNAs have a redundant function in chromosomal
RNA replication, certain Y RNAs may do this more efficiently while others have
become specialized for other functions.
The majority of Y RNAs are believed to be in a complex with both Ro60 and
La (Hendrick et al., 1981). Experiments in mouse cells that do not express Ro60
indicate that chromosomal replication can still occur in the absence of Ro60 (Chen
et al., 2003; Xue et al., 2003a). Y RNA mutants lacking La/Ro60 binding sites
can still initiate chromosomal replication, providing further evidence that neither of
these proteins are directly required (Langley et al., 2010). Along with the necessity
of Y RNAs for cellular DNA replication, the Murine Leukaemia Virus incorporates
immature hY RNA transcripts into new virus particles (Garcia et al., 2009), where
they also presumably have a function in viral genome replication (Langley et al.,
2010). Ro60 and La are not present in these particles, further indicating that Y
RNAs have a function independent of either of these two proteins (Garcia et al.,
2009; Langley et al., 2010). Proteins involved in the initiation of DNA replication
are believed to bind only to Ro60/La/ Nucleolin-free Y RNAs (Langley et al., 2010).
Y RNAs may have a level of redundancy in their ability to initiate DNA replication
(Gardiner et al., 2009), but it is possible that, under normal circumstances, hY5
undertakes a unique role in the nucleolus, such as 5S rRNA quality control (Zhang
et al., 2011a). So far, the role of Y RNAs in DNA replication does not appear to
have been validated by any other group. Nonetheless their involvement in semi-
conservative DNA replication is most scrutinized and the most convincing function
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directly involving human Y RNAs to date.
1.4.4.2 Y RNAs in RNPs
The binding of Ro60 homologs to Y RNAs in nematodes and in mice increases
the stability of these RNAs (Labbe´ et al., 2000; Chen et al., 2003). Therefore,
by regulating RNA levels, Ro60 is likely to at least indirectly play a role in the
functioning of Y RNA within the cell.
1.4.4.3 Y RNAs and Ro60 function
Green et al. found that under normal circumstances, Y RNAs compete with mis-
folded ncRNAs for access to Ro60 and have a higher binding affinity for Ro60 than
these ncRNAs (Green et al., 1998). In 2006 partially overlapping binding sites for Y
RNAs and ncRNAs were identified on the Ro60 protein (Fuchs et al., 2006). It there-
fore seems likely that these RNAs are acting as “gatekeepers” for Ro60 function,
allowing access only when necessary (Hogg and Collins, 2007; Chen et al., 2013).
In D. radiodurans, Y RNAs can recruit the exonuclease PNPase to the Rsr RNP
(Wurtmann and Wolin, 2010). Binding of this enzyme to the large internal loop in
region 4 leads the Y RNA to undergo a conformational change in relation to Ro60,
opening up the area around the central cavity of this protein to allow ncRNAs
access. A misfolded ncRNA enters the Ro60 central cavity, where it is then passed
on to PNPase and is targeted for degradation (Wurtmann and Wolin, 2010). When
PNPase interacts with Rsr/drY RNA, its targets are altered as it has greater a
affinity for structured RNAs, but a reduced preference for single stranded RNAs
(Chen et al., 2013). This Rsr-Y RNA-PNPase interaction is conserved in other
bacteria as it is also found in Salmonella typhimurium (Chen et al., 2013). Further
evidence for a recruitment function can be seen in human cells, where hY5 interacts
with misfolded 5S ribosomal RNA through a protein intermediate, the ribosomal
protein L5 (Hogg and Collins, 2007). It seems likely that hY5 is recruiting this
ribosomal RNA to Ro60 for quality control purposes, and that perhaps the other
human Y RNAs have similar interactions with intermediate proteins, as well as with
RNA processing/refolding proteins (Hogg and Collins, 2007). Prior to this work the
community was torn as to whether Y RNAs helped or hindered the binding of Ro
proteins to ncRNAs.
In D. radiodurans cells the Ro60 ortholog Rsr is known to be involved in the
targeting and maturation of 23S rRNA and this processing involves the exonucleases
RNasePH and RNaseII (Chen et al., 2007). The bacterial Y RNA (drY RNA) binds
to Rsr at 30◦C and prevents interaction with 23S rRNA. At higher temperatures Rsr
becomes active, probably by a temperature-dependent drY RNA release mechanism
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(Chen et al., 2007). It is also possible that, as with mammalian Y RNAs, drY
RNA is not released from this Ro ortholog, but undergoes a structural change at
higher temperatures. Bacterial cells lacking the drY RNA can still aid 23S rRNA
maturation (Chen et al., 2007), but this could be an artifact and drY may normally
function as a gatekeeper of Rsr function when present (Hogg and Collins, 2007; Chen
et al., 2013).
D. radiodurans is a bacterium that is resistant to UV-damage. As well as playing
a role in RNA processing, Rsr is also key for this resistance (Chen et al., 2000).
Knocking out Rsr results in bacterial strains that are more sensitive to UV light.
Rsr interacts with a number of small RNAs after UV damage, including drY RNA
(Chen et al., 2000). In D. radiodurans Rsr levels increase after UV irradiation (Chen
et al., 2000), whereas in mouse cells Ro60 levels remain the same, but Ro60 relocates
to the nucleus (Chen et al., 2003). The role of Ro60 orthologs in bacterial or mouse
cells in response to UV remains to be determined. As with mouse Ro60, mouse Y3
also relocates to the nucleus on UV irradiation, suggesting that it is involved in the
UV function of Ro60 in these cells (Chen et al., 2003).
1.4.4.4 Y RNAs in splicing
La and the Cellular nucleic acid binding protein (CNBP) both target the 5’ untrans-
lated region (UTR) of mRNAs that contain 5’ terminal oligopyrimidine sequences
(5’ TOPs) (Pellizzoni et al., 1998). In experiments where binding to the L4 riboso-
mal mRNA was tested, La and CNBP were found to bind to this mRNA mutually
exclusively, despite the fact that they have different binding sites (Pellizzoni et al.,
1998). La binds to 5’ TOP mRNAs via a mechanism that involves both RRMs and
possibly the La motif (Pellizzoni et al., 1998). The interaction of either La or CNBP
requires Ro60 and this interaction is RNA-dependent (Pellizzoni et al., 1998). As
Ro RNPs are known to be stable and can include La, it seems highly likely that
this RNA component is a Y RNA. One caveat with this theory is that binding ex-
periments were conducted using the Xenopus system and xY RNAs dissociate from
Y RNAs in the nucleus under normal circumstances, so the conditions for La inter-
action with 5’ TOP mRNAs must be further investigated. Studies in patients with
decreased levels of CNBP indicate that this protein positively regulates the trans-
lation of 5’ TOP mRNAs (Huichalaf et al., 2009) but the effect of La on 5’ TOP
mRNAs expression has not yet been categorically determined (Crosio et al., 2000;
Zhu et al., 2001). Recent studies of stress-regulated translation of 5’TOP mRNAs
indicate that it is extremely complex and that expression is likely to be cell-type
and tissue specific (Damgaard and Lykke-Andersen, 2011; Ivanov et al., 2011b).
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1.4.4.5 Y RNAs and Apoptosis
In 1999 Rujtes and coworkers discovered that during apoptosis human Y RNAs are
cleaved to produce products of between 22 and 36 nucleotides (Rutjes et al., 1999b).
These fragments are detectable as early as 1.5 hours after treatment and follow a
similar pattern to the cleavage of the U1-70K protein, which is known to undergo
caspase 3-dependent cleavage (Casciola-Rosen et al., 1994b). The hY RNAs appear
to be cleaved in a size dependent manner, with the longer RNAs targeted more
rapidly than the smaller ones (Rutjes et al., 1999b). Further investigation by this
group using various inhibitors of specific caspases determined that this cleavage ap-
pears to be caspase-dependent. When inducing apoptosis using anti-Fas antibodies,
they discovered that all of the caspase inhibitors blocking the death receptor apop-
tosis pathway delayed the accumulation of these Y RNA products (Rutjes et al.,
1999b). The group concluded that, had the mitochondrial apoptosis pathway been
activated, it is likely that fragment production would also be delayed by inhibitors
of this pathway (Rutjes et al., 1999b). Similar cleavage patterns were seen with
different inducers of apoptosis and in a number of human cell lines, as well as one
mouse cell line. Many of the cleavage products were still able to bind to Ro60 and
La (Rutjes et al., 1999b).
1.4.4.6 Y RNAs as microRNAs?
Since the publication of the Rutjes paper in 1999 there has been much speculation as
to the function of these RNA fragments (Rutjes et al., 1999b). Records were created
in miRBase for a number of Y RNA fragments, although a miRNA-like function has
never been proved. Work by our group (Nicolas et al., 2012) indicates that these
fragments are not Dicer-dependent, while the majority of mammalian miRNAs are
Dicer-dependent. Immunoprecipitation experiments did not detect any interaction
with Argonaute 2, suggesting that they do not associate with the RISC complex
(Nicolas et al., 2012). In anion exchange separation experiments these fragments
were detected in protein complexes that were distinct from miRNA-containing pro-
tein complexes (Nicolas et al., 2012). All of these lines of experimentation together
provide strong evidence that these fragments are unlikely to act as miRNAs (Nicolas
et al., 2012).
This PhD project will focus on the validation of other Poly(I:C) induced 30-35
nucleotide ncRNA-derived sRNAs, as well as examining the sequence and structural
requirements for the generation of Y RNA-derived fragments (ydRNAs) from the
hY5 RNA.
46
2 MATERIALS AND METHODS
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2.1 CELL CULTURE
2.1.1 Cell lines and cell culture media
Cell lines were grown in culture incubators at 5% CO2 and at 37
◦C, unless otherwise
stated. Each line was cultured in the appropriate cell culture medium. Cell culture
media and reagents were obtained from Life Technologies, unless otherwise stated.
NIH/3T3, SW 1353, HeLa and MCF7 cell lines were cultured in Dubeccos modi-
fied eagles medium (DMEM) supplemented with 10% (v/v) standard quality filter-
sterilized and heat-inactivated fetal bovine serum (FBS) (GE Healthcare) and 2 mM
L-glutamine.
The DLD-1 cell line was cultured in a 1:1 mixture of DMEM GlutaMAX I and
Hams F12 GlutaMAX I, supplemented with 10% FBS and 2mM L-glutamine. The
DF-1 cell line was cultured in DMEM GlutaMAX I, supplemented with 10% FBS
and 2 mM L- glutamine.
2.1.2 Passaging of cells
When passaging, culture media was removed and cells were briefly washed in Dubec-
cos phosphate buffered saline without calcium or magnesium (DPBS) before 0.25%
(v/v) trypsin-EDTA was added to cover the cells. The cells were incubated at 37◦C
until detached. The trypsin-EDTA was neutralized with an equal volume of the
appropriate culture media. Cells were centrifuged at 250 x g for 4 minutes and the
media removed, before re-suspension in fresh media and transfer to a new flask at
the appropriate dilution.
2.1.3 Seeding of cells
For each cell line the required number of cells were seeded in the appropriate media 1
to 3 days prior to transfection. Cells were always seeded in the absence of antibiotics.
An equal volume of 0.4% tryphan blue (Sigma-Aldrich) was added to the media
containing the cells and a haemocytometer was used to calculate the cell number.
Tryphan blue can only enter dead cells, so any cells stained with tryphan blue were
excluded from the cell count.
2.1.4 Transfection of cells
2.1.4.1 Transient transfection of cells with Lipofectamine2000
Cells were transfected with Lipofectamine2000 (Life Technologies) according to man-
ufacturer’s instructions. Transfection mixes were prepared in OptimMEM I reduced
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serum with GlutaMAX I medium (OptiMEM) and added drop-wise onto the cells.
The OptiMEM was replaced with the appropriate FBS-containing growth medium
4-6 hours after transfection. For DF-1 cells the media was changed 3 hours after
transfection.
5-20 µg of plasmid DNA was added to each T75cm2 flask and Lipofectamine2000
was used at a ratio of 2.5:1, with 25 µL added for every 10 µg of plasmid DNA.
For treatment of cells with Polyinosinic:polycytidylic acid potassium salt [Poly(I:C)]
(Sigma-Aldrich) transfection mixes containing 30 µL of Lipofectamine2000 and 24
µL of Poly(I:C) were prepared for each flask, giving a final concentration of 10
µg/mL. A Lipofectamine2000 control-transfected flask was included in all experi-
ments. Where appropriate, empty vector and untreated control transfections were
also included.
2.1.4.2 Transient transfection of cells with Fugene6
Cells were transfected with Fugene6 (Promega) according to manufacturer’s instruc-
tions. Transfection mixes were prepared in OptiMEM. The media in all flasks was
replaced with the appropriate FBS-containing growth media containing FBS prior to
transfection. Transfection mixes were diluted in the appropriate cell culture medium
immediately prior to transfection.
5-20 µg of plasmid DNA was added to each T75cm2 flask and Fugene6 was used at
a ratio of 3:1, with 15 µL added for every 5 µg of plasmid DNA. A Fugene6 control
transfected flask was included in all experiments. Where appropriate, empty vector
and untreated control transfections were also included.
2.1.5 Stress treatments
2.1.5.1 Hygromycin treatment
Cells were treated with Hygromycin B solution (Melford) at 800 µg/mL diluted in
the appropriate cell culture media. Cells were grown for between 8 hours and 3 days
before harvesting. Hygromycin is an apoptosis inducer.
2.1.5.2 PBS treatment
Cells were treated with DPBS for 30-60 minutes before harvesting.
2.1.5.3 Poly(I:C) treatment
Poly(I:C) stocks were prepared by Dr. Hall at a concentration of 2.5 mg/mL.
Cells were transfected with 10 µg/mL Poly(I:C) unless otherwise stated (see Section
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2.1.4.1 for details of transfection). Cells were grown for 4-8 hours before harvesting.
Poly(I:C) is a viral infection mimetic.
2.1.5.4 Staurosporine treatment
Staurosporine (Cell Signaling Technology) stocks were prepared at a concentration
of 100 µM, Staurosporine was diluted from stocks in the appropriate cell culture
medium. Cells were treated with a final concentration of 1 µM Staurosporine for 4
hours prior to harvesting.
2.1.5.5 Lipofectamine2000 control treatment
Cells were transfected with Lipofectamine2000 in the absence of Poly(I:C) for 4-8
hours before harvesting.
2.1.5.6 Untreated control conditions
Cells were grown in the absence of transfection mixes for 4-8 hours before harvesting.
2.1.6 Flow cytometry of cells treated with Poly(I:C) or
Hygromycin
DLD-1 cells were plated at the appropriate number in 3 wells of a 6 well plate per con-
dition. 24 hours after plating, the cells were treated with Hygromycin at 800 µg/mL
or the media was replaced with fresh media. For Poly(I:C) treatment, cells were
transfected with 10 µg/mL, Lipofectamine2000 mixes alone, or were left untreated
24 hours after plating. 55.5 hours after plating, cells were treated with DPBS. Af-
ter a further 30 minutes, cells for all conditions were harvested by trypsinization,
PBS washed and split into two tubes. For Annexin V/Propidium iodide (PI) flow
cytometry analysis, cells were re-suspended in PBS with 200 mM calcium chloride.
1 µL of Annexin V (Invitrogen) was added and the samples were incubated at room
temperature, in the dark, for 15 minutes. 1 µL of PI (Invitrogen) was added per
tube and samples were loaded onto the Accuri C6 (BD Biosciences) flow cytometry
machine. 2 wells of each treatment were harvested as normal for RNA extraction,
0.5 mL of TRIreagent was added to each well and both wells were combined to give
1 mL of TRIreagent per sample. During the extraction the amount of chloroform
and isopropanol were scaled accordingly. As this was an initial test experiment, only
one replicate of each condition was tested.
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2.2 RNA EXTRACTION
2.2.1 RNA extraction from cell lines for northern blot analysis
Prior to extraction, all pipettes and work surfaces were rinsed with RNaseZAP
(Sigma-Aldrich), wiped over and dried. All solutions except the TRIreagent (Ther-
moFisher Scientific) were sterilized by being passed through a 0.2 µm syringe needle
(Life Technologies).
Each flask was processed individually. Media was completely removed, the flask
placed on ice and TRIreagent was added drop-wise onto the flask surface. The
TRIreagent was pipetted up and down several times and the flask surface was
scraped using a disposable cell scraper (Corning) to ensure complete cell lysis. Where
transfections/treatments resulted in cell lifting, the cell culture media was retained
on harvesting and centrifuged at 250 x g for 4 minutes before media removal and
re-suspension in TRIreagent. Each floating cell fraction was then recombined with
the attached cell fraction. Samples were snap frozen on liquid nitrogen and stored
at -80◦C prior to downstream processing.
Samples were thawed on ice and centrifuged at 12,000 x g at 4◦C for 5 minutes.
Then the supernatant was transferred to a new 2 mL centrifuge tube. Samples were
incubated at room temperature for 5 minutes, prior to the addition of 300 µL of
chloroform (ThermoFisher Scientific). The samples were mixed by vortexing for
20 seconds, before being incubated at room temperature for a further 2 minutes,
followed by centrifugation at 12000 x g for 15 minutes at 4◦C. On ice, the aqueous
phase of each sample was removed and transferred to a tube containing 750 µl
isopropanol (ThermoFisher Scientific). To aid in identification of the RNA pellet,
0.5 µL of glycoblue (Life Technologies) was added to each tube, before mixing by
inversion and incubation at -20◦C overnight, or for at least 2 hours. Samples were
then centrifuged at 12000 x g for 10 minutes at 4◦C and the supernatant removed.
Samples were washed in 1 mL of 80% ethanol twice, before being air dried for 5-10
minutes and re-suspended in Analytical Reagent Grade (ARG) water (ThermoFisher
Scientific).
2.2.2 RNA extraction from cell lines for sequencing libraries
These samples were processed as in Section 2.2.1 but with an extra chloroform wash
step prior to the isopropanol wash. Briefly, 300 µL of chloroform was added to a
fresh tube at room temperature. The aqueous phase was removed and added to
the tube containing chloroform. The samples were vortexed for 20 seconds and
incubated at room temperature for 2 minutes prior to centrifugation at 12,000 x
g for 15 minutes at 4◦C. The aqueous phase was removed and added to the tube
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containing isopropanol.
2.2.3 RNA quality control
The quality of the RNA was examined by agarose gel electrophoresis to confirm
that the ribosomal RNA species were intact and that no degradation had occurred.
Samples were diluted at a ratio of 1:1 in stop mix (95% (v/v) formamide, 5 mM
EDTA, 1.9 mM xylene cyanol, 1.5 mM Bromophenol blue) and denatured by heating
at 70◦C for 2 minutes prior to gel electrophoresis. Samples were run on a 1.5%
(w/v) agarose gel prepared in 0.5 x (v/v) Tris/Borate/EDTA (TBE) buffer (45
mM Tris, 45 mM Boric acid, 1 mM EDTA) and stained with 10 mg/mL ethidium
bromide. Samples were imaged on a transilluminator (UPV) and analyzed using the
Labworks Image Acquisition and Analysis software (UPV). The RNA concentration
and optical density was determined by use of the Nanodrop 8000 spectrophotometer
(ThermoFisher Scientific) and an optical density 260/280 ratio of 1.7 or above was
accepted.
2.3 POLYACRYLAMIDE GEL ELECTROPHORESIS
(PAGE) AND NORTHERN BLOTTING FOR
sRNA
Unless otherwise stated, all reagents and apparatus were obtained from ThermoFisher
Scientific. Prior to use, all pipettes, equipment and work surfaces were rinsed with
RNaseZAP, wiped over and dried.
2.3.1 PAGE sample preparation
The required amount of RNA, 1-10 µg, was diluted in an equal volume of stop mix
(95% (v/v) formamide, 5 mM EDTA, 1.9 mM xylene cyanol, 1.5 mM Bromophenol
blue) and heated to 70◦C for 2 minutes prior to loading.
2.3.2 PAGE separation of small RNA
Total RNA was size separated by gel electrophoresis using the mini PROTEAN III
system (BIORAD). To prepare a 12% denaturing polyacrylamide gel, 6.3 g of urea
was heated in 3 mL of ARG water in a microwave for 20 seconds, or until fully
dissolved. The solution was allowed to cool and then the following were added; 1.5
mL 5 x TBE, 4.5 mL 40% (v/v) 19:1 Acrylamide/Bis solution (BIORAD). ARG
water was added up to a volume of 15 mL and polymerization was induced by
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the addition of 150 µL of 10% Ammonium persufate (APS) and 7.5 µL of tetra-
methyl-ethylenediamine (TEMED). Each gel was rapidly poured between two clean
glass plates, a 1.0 mm 10 well comb was inserted, and left for 30 minutes to fully
polymerize. Gels were run for 1.5 hours at 110 V in 0.5 x TBE. RNA quality and
loading was confirmed by staining with 1 µL of 10 mg/mL ethidium bromide prior
to transfer.
2.3.3 Semi-dry transfer
On the base of the semi-dry transfer apparatus (Scie-Plas) three BLT2 filter papers
(Munktell), pre-soaked in 0.5 x TBE, were placed on top of each other and any air
bubbles were removed. For each gel, a hybond-NX (GE Healthcare) membrane of
the same size was soaked in ARG water and then 0.5 x TBE before being placed on
top of the filter papers. Polyacrylamide gels were removed from the electrophoretic
apparatus and, after ethidium bromide staining, were placed on top of the corre-
sponding membranes. Finally, three 0.5 x TBE-soaked filter papers were placed on
top of each polyacrylamide gel and air bubbles were removed. The top of the semi-
dry apparatus was added and transfer of the RNA from the gel to the membrane
was performed at 350 mA, at 4◦C, for 30 minutes per polyacrylamide gel.
2.3.4 Chemical cross-linking
Chemical cross-linking was used for small RNA northern blotting as it leads to more
effective hybridization than UV crosslinking. 122.5 µL of 12.5 M 1-methylimidazole
was added to 10 mL of ARG water and mixed by inversion. The pH of the solution
was adjusted to 8 by the addition of 6 M hydrochloric acid. 0.373 g of 1-Ethyl-
3-(3-dimethylaminopropyl) carbodiimide (EDC) was dissolved in this solution and
the volume adjusted to 12 mL with ARG water. For each membrane, a filter paper
slightly larger in size was soaked in cross-linking solution and then the membrane
was placed, RNA side up, on top of this. Excess cross-linking solution was removed
and then the filter paper and membrane were wrapped in cling film and incubated
at 60◦C for 1-2 hours.
2.3.5 Northern blotting
After cross-linking, membranes were briefly washed in ARG water before storage at
-20◦C or direct use in northern blotting.
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2.3.5.1 Pre-hybridization and radioactive probe labeling
Prior to incubation with a radiolabeled probe, membranes were placed, RNA side
facing inward, into hybridization tubes containing 10-15 mL of UltraHyb-Oligo hy-
bridization buffer (Ambion) and rotated at 37◦C in a HB-1000 hybridization oven
(UVP) for 1.5 hours. During this time, for each membrane, an oligonucleotide com-
plementary to the small RNA of interest was labeled with the γ−32P from adenosine
5’-γ−32P triphosphate triethylammonium salt (Perkin Elmer). Each reaction had a
final concentration of 10 units of T4 polynucleotide kinase (PNK), 1 x kinase buffer,
0.5 mM oligonucleotide, and 1.1 MBq of γ−32 ATP. Immediately after the addition
of γ−32ATP, the reactions were incubated at 37◦C for 1 hour.
2.3.5.2 Hybridization
After the pre-hybridization and radioactive probe labeling was complete, each probe
reaction was diluted in a small amount of ARG water and transferred to the appro-
priate hybridization tube. Membranes were incubated with radiolabeled probe in a
rotating HB-1000 hybridization oven, at 37◦C, for 16 hours or overnight (see Table
2.3 for details of probes used for northern blot analysis of sRNA expression).
2.3.5.3 Removal of non-specific signal
To remove non-specifically bound radioactivity from the membranes, they were
washed three times in wash solution [0.2 x sodium chloride/sodium citrate, 0.1%
(w/v) sodium dodecyl sulphate (SDS)], at 37◦C for 30 minutes with rotation.
2.3.5.4 Signal detection
On completion of the washes, each membrane was wrapped in cling film and placed
in a radioactive cassette (Fujifilm). A phosporimaging screen (Fujifilm) was placed
in each cassette on top of the membranes and was exposed for between 1 hour and
10 days. Screens were scanned on the Molecular imager FX pro plus (BIORAD) to
visualize the radioactive signal.
2.3.5.5 Signal removal
Once the radioactive signal on the membrane had been detected, this signal was
stripped off the membrane by washing twice in boiling stripping solution (0.1%
SDS, 5 mM EDTA) for 20-30 minutes. Membranes were stored at -20◦C.
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2.4 GENERAL CLONING METHODS
All oligonucleotide primers were synthesized by Sigma-Aldrich and all reagents were
from ThermoFisher Scientific unless otherwise stated.
2.5 DNA EXTRACTION
DNA extractions were carried out according to the DNeasy Blood & Tissue kit
instructions (Qiagen). Human genomic DNA was extracted from HeLa cells by Dr.
Wheeler or Dr. Nicolas.
2.6 DNA SEQUENCING
Plasmid and polymerase chain reaction (PCR) product sequences were determined
by Sanger sequencing either by sending ready reactions to Genome Enterprise Ltd.,
or to Eurofins MWG. For ready reactions 1 µL of DNA was used in a PCR reaction to
give a final volume of 10% (v/v) Half BigDye Terminator reagent, 10% (v/v) BigDye
Terminator reagent, 1 x BigDye Sequencing Buffer and 1 µM of the appropriate
sequencing primer. All sequencing reagents were obtained from Applied Biosystems.
The PCR was run under the following conditions: 96◦C for 2 minutes, followed by
25 cycles of 96◦C for 30 seconds; 50◦C for 15 seconds; and 60◦C for 4 minutes. The
entire reaction was sent to Genome Enterprise Ltd or an aliquot of the reaction
was diluted to the requested concentration and sent to Eurofins MWG. Sequence
analysis was done using BioEdit Sequence Alignment Software (Ibis Biosciences).
2.6.1 Amplification of sequences from genomic DNA
For amplification of sequences from genomic DNA, 100 ng of DNA was added to
a PCR mix with a final concentration of 0.4 mM dNTPs, 0.5 mM of each of the
primers, 1 x Phusion HF buffer and 0.4 units of Phusion High-fidelity DNA Poly-
merase (ThermoFisher Scientific). The PCR was run under the following conditions:
98◦C for 3 minutes, followed by 30 cycles of (98◦C for 1 minute; annealing temper-
ature for 45 seconds; 72◦C for 3 minutes); 72◦C for 10 minutes; 4◦C for ever.
2.6.2 Amplification of sequences from plasmid DNA
For amplification of sequences from plasmid DNA, 5-10 ng of DNA was added to
a PCR mix with a final concentration of 0.4 mM dNTPs, 0.5 mM of each of the
primers, 1 x Phusion HF buffer and 0.4 units of Phusion High-fidelity DNA Poly-
merase (ThermoFisher Scientific). Each reaction had a volume of 20 µL. The PCR
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was run under the following conditions: 98◦C for 3 minutes, followed by 30 cycles
of (98◦C for 1 minute, annealing temperature for 45 seconds, 72◦C for 3 minutes);
72◦C for 10 minutes; 4◦C for ever.
2.6.3 Adenosine tailing
For standard cloning of PCR products (obtained using Phusion PCR) into the
pGEM-T Easy plasmid, 1 µL of GoTaq DNA Polymerase (Promega) was added
to each post-PCR reaction and these were then further incubated at 70◦C for 15-30
minutes, prior to agarose gel electrophoresis.
2.6.4 Restriction digestion
Plasmid DNA was digested for 3-4 hours at 37◦C and reactions were set up accord-
ing to manufacturer’s instructions. All plasmid DNA used for downstream cloning
applications was heated to 65◦C for 20 minutes to inactivate the restriction enzymes.
2.6.5 Agarose gel electrophoresis and DNA recovery
DNA samples were resolved using the appropriate (w/v) concentration of agarose
dissolved in 0.5 x TBE. Either the 100 bp (New England Biolabs) or the 1 kb
(New England Biolabs) double-stranded DNA ladder was run on each gel, depending
upon the size of the product expected. Samples were mixed with 6 x loading dye
(4M Urea, 40% (w/v) sucrose, 120 mM Tris-HCl pH7.5, 30 mM EDTA, 0.25%
(w/v) orange G) before loading. Gels were visualized on a UV transilluminator
and fragments resolving at the appropriate size were cut out using a sterile scalpel.
Gel purification was carried out according to the Zymoclean Gel DNA Recovery kit
instructions (Zymoresearch). Gel slices were dissolved at 55◦C and DNA was eluted
in 6-10 µL of ARG water.
2.6.6 Cloning into pGEM-T Easy
Ligations were performed according to manufacturer’s recommendations (Promega).
50 ng of vector was routinely added to each ligation mix, with the appropriate
amount of ligation fragment for a 1:1 and a 3:1 insert to vector ratio calculated de-
pending on fragment size. The positive and negative ligation reactions recommended
by the manufacturer were performed alongside all pGEM-T Easy transformations.
Ligations were incubated at 4◦C for 16 hours or overnight.
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2.6.7 Transformation into DH5α cells
Unless otherwise stated, a 50 µL tube of home-made DH5α E. coli cells was thawed
on ice for each transformation reaction. 1-2 µL of ligation mix was added to each
tube of cells, mixed by swirling the end of the pipette tip in the liquid, and incu-
bated on ice for 30 minutes. The samples were then placed at 42◦C for 40 seconds
to heat shock the cells and allow the DNA to enter. Samples were incubated on
ice for a further two minutes before being diluted in 450 µL of room temperature
luria broth (LB) (see Appendix 7) and placed in a 37◦C shaker incubator for 1-
1.5 hours. Following this step, cells were mixed by gently inverting and 100-200
µL was spread onto an LB selection plate containing selection antibiotic, 0.5 mM
5-bromo-4-chloro-3- indolyl--D-galactoside (X-GAL) and 80 µg/mL (Isopropyl -D-
1-thiogalactopyranoside) IPTG and incubated at 37◦C overnight.
2.6.8 ‘Home-made’ super-competent DH5α cells
DH5α cells were pelleted from a 5 mL overnight culture in LB without antibiotics.
The pellet was then streaked onto a bacterial M9 plate (Appendix 7) and then
incubated at 37◦C for 48-72 hours. A single colony was streaked onto an LB plate
containing 10 mM MgCl2 as well as an LB plate supplemented with 100 µg/ml
Ampicillin. Plates were incubated at 37◦C overnight. After confirming that there
was no growth on the Ampicillin plate, a single colony from the LB/MgCl2 plate
was transferred to 5 mL pre-warmed TYM liquid culture (see Appendix 7) in a 50
mL centrifuge tube incubated at 37◦C with shaking at 200 rpm overnight. 1 mL of
this culture was then transferred to 100 mL of pre-warmed TYM broth in a 1 L flask
and incubated at 37◦C with shaking at 300 rpm for 1-3 hours, until the O.D.550 =
0.5. The cultures were transferred to 2 x 50 mL centrifuge tubes and spun at 1500
x g at 4◦C for 12 minutes. The pellets were drained and re-suspended in 40 mL of
cold TFB1 (see Appendix 7) solution. The cells were then incubated on ice for 10
minutes. Cells were centrifuged at 1500 x g for 8 minutes and gently re-suspended
in 4 mL of TFB2 (see Appendix 7) before aliquoting and snap freezing on dry ice.
2.6.9 Determining transformation success
Cells containing plasmids with an insert appear white, while cells containing a plas-
mid without an insert appear blue on LB plates containing X-GAL/IPTG. White
colonies were selected and transformation success determined by Sanger sequencing
(see Section 2.6).
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2.6.10 Plasmid DNA purification
Plasmid DNA was routinely purified from bacterial cells using the QIAprep Spin
Miniprep kit (Qiagen) and re-suspended in ARG water. For plasmids used directly
for transfection, plasmid DNA was purified using the HiSpeed Plasmid Midi kit (Qi-
agen) and re-suspended in Water for Injection (Life Technologies), unless otherwise
stated. Plasmid DNA was resolved by agarose gel electrophoresis to check integrity,
while concentration and quality were determined using the Nanodrop 8000.
2.6.11 De-phosphorylation
Plasmids were de-phosphorylated using the appropriate amount of shrimp alkaline
phosphatase (SAP) according to the manufacturer’s instructions (Roche). Plasmid
DNA was incubated with the SAP enzyme for 60 minutes, before deactivation at
65◦C for 20 minutes.
2.6.12 Primer annealing
To anneal two primers together they were mixed in equimolar amounts and added
to a heating block at 95◦C for 10 minutes. The hot block was turned off and allowed
to cool down to room temperature, taking at least two hours. All annealed primer
reactions were verified by agarose gel electrophoresis, to confirm that the majority
of the DNA was resolving through the gel more slowly than either primer alone.
2.6.13 Cloning the human Y5 gene into an expression vector
2.6.13.1 pGEM-T Easy vector structure
The pGEM-T Easy vector system (Promega) is designed as an intermediate vector
that can be amplified at high copy number in bacterial cells. In this project it
was used as a destination vector, as the whole hY5 gene, including promoter and
terminator sequences, was cloned into this plasmid. pGEM-T Easy is a small vector,
designed for bacterial expression, so it should contain no elements that result in
aberrant expression in eukaryotic cells.
The pGEM-T Easy vector is produced in a linear form, with a T overhang at the 3’
end. For maximal ligation success, all fragments cloned into this vector must be 5’ A
tailed prior to ligation. This plasmid provides Ampicillin resistance to bacterial cells
that contain it. The pGEM-T Easy vector also encodes the α-peptide sequence of
the β-galactosidase gene which, when intact, results in blue colonies. When inserts
are successfully cloned the reading frame of this peptide is disrupted, resulting in
white colonies. This plasmid encodes M13 sequences on either side of the multiple
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Figure 2.1: Plasmid map of the circularized version of the pGEM-T Easy plasmid.
Showing the multiple cloning site and in vitro promoter sequences.
Taken from Promega pGEMT-Easy Manual.
cloning site, so the sequence of the insert can be determined by sequencing with
M13 forward and reverse primers.
2.6.13.2 Generating a human Y5 gene expression vector
The human Y5 gene was amplified by PCR from genomic DNA, derived from HeLa
cells, using the standard high-fidelity genomic DNA PCR conditions and an anneal-
ing temperature of 64◦C (See Section 2.6.1). The hY5 wild type forward and reverse
primers were used in this reaction (Table 2.3). The PCR products were A-tailed
and gel purified, before being ligated into the linear pGEM-T Easy plasmid. Ligated
plasmids were transformed into DH5α cells and positive colonies were determined
by restriction digestion using NdeI, for which there is a site within the plasmid and
a site within the fragment, and gel electrophoresis. Out of the colonies that were se-
quenced using the M13 primers, one had the fragment inserted with no mismatches
in the coding region or the sequence 500 bp upstream, so this was chosen as the
expression construct. This plasmid was denoted pWT.
2.6.13.3 Expressing pWT in human, mouse and chicken cells
To determine the expression efficiency of the pWT plasmid in human cells, it was
transfected into MCF7, NIH/3T3 and DF-1 cells. Briefly, cells were plated at the
appropriate cell density in 3 wells of a 6 well plate and, 24-48 hours after plating
cells were transfected with 2 µg of plasmid per well, using the Lipofectamine2000
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transfection reagent. As controls for transfection, flasks were also treated with
transfection mixes containing Lipofectamine2000 alone, or were grown in OptiMEM
in the absence of transfection mixes. 24 hours after transfection, cells were harvested
and total RNA was extracted. 1 µg of total RNA was loaded onto a PAGE gels and
analyzed by northern blot. The full length wild type hY5 RNA was detected using
a hY5-specific radiolabeled oligonucleotide primer.
2.6.14 Generating a human Y5 gene expression vector with
restriction sites
Three primers were designed to insert restriction sites upstream and downstream
of the ends of the hY5 RNA-encoding region. A restriction site for AgeI upstream
of the start site, as well as a restriction site for AfeI downstream of the RNA-
encoding region, was introduced using PCR. The primers were used to amplify
a small fragment (the RNA-encoding region) and a large fragment (the promoter
region) directly from the pWT plasmid. Each fragment was resolved by agarose gel
electrophoresis and gel purified to remove excess primers and salts. The PCR mix
was prepared without the primers and complementary regions within the 3’ ends
of the long and short fragments were annealed and extended for 5 cycles using the
standard high-fidelity plasmid DNA PCR with an annealing temperature of 64◦C
(Figure 2.2). Primers were then added and the PCR continued for a further 25
cycles. The primers used to amplify the small fragment were wild type forward and
overlap reverse and the primers used for the large fragment were overlap forward and
alternative reverse (Table 2.3). Primers used to amplify the annealed and extended
fragments were wild type forward and alternative reverse (see Figure 2.2).
The size of the small fragment was 100 bp and the size of the large fragment
was 2900 bp, making it very difficult to determine the success of the overlap PCR
by gel electrophoresis, as a size shift between the 2900 bp of the large fragment
and the 3000 bp of the successful overlap PCR would be negligible. This PCR was
monitored by the decrease in levels of the free small fragment. The resulting PCR
product was cloned into the linear version of pGEM-T Easy. Overlap clones were
tested by restriction digestion using NcoI and confirmed by sequencing using the
M13 primers. A plasmid with no mismatches within the hY5 RNA-encoding region
and with intact AfeI and AgeI restriction enzyme sites was selected. This plasmid
was denoted pWT-2RE. A plasmid negative according to the IPTG/X-Gal colour
selection was sequenced and confirmed to be a circularized version of the pGEM-T
Easy plasmid, with no insert. This was used as a control for all hY5 transfection
experiments and was denoted empty vector control (pEVC).
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Figure 2.2: Schematic of the overlap PCR method.
Shows the method used to introduce restriction sites on either side of
the RNA-encoding region of the hY5 gene.
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2.6.15 Creating a stuffer plasmid for mutant plasmid generation
Restriction digestion of the pWT-2RE plasmid with AfeI and AgeI gave a wild
type hY5 RNA-encoding fragment, along with a linearized plasmid (pWT-2RE-
promoter). As this fragment was difficult to visualize on a gel and remove, there
was a potential for it to re-ligate into the plasmid. To prevent this and to make it
easier to determine the success of the restriction digest, a stuffer plasmid was created
as an intermediate step in the cloning process. In this stuffer plasmid, the hY5 RNA-
encoding region of the pWT-RE plasmid was removed by restriction digest and then
replaced with an unrelated 1000 bp fragment.
This stuffer fragment was amplified from a plasmid containing an unrelated DNA
sequence using the standard Phusion high-fidelity PCR conditions, an annealing
temperature of 69◦C, and the primers stuffer forward and stuffer reverse (Table
2.3). These primers were designed to introduce an Age1 site or an Afe1 site at
either end of the stuffer fragment. After PCR amplification, the fragment was
resolved by gel electrophoresis and gel purified to removed excess primers and salts.
The fragment was then digested with restriction enzymes AfeI and AgeI to produce
ends complementary to the linearized pWT-2RE-promoter plasmid.
The linear pWT-2RE-promoter plasmid was de-phosphorylated and gel extracted,
to remove as much of the excised 100bp hY5 fragment as possible. The stuffer
fragment was then ligated into the linear pWT-2RE-promoter plasmid according to
the recommendations for pGEM-T Easy plasmids and transformed into DH5α cells.
Positive colonies were selected and sequenced and one plasmid was selected for use
in downstream mutant plasmid generation (pStuffer).
Name Sequence 5’ to 3’
hY5 wild type forward AATACTAGTGAAGATCCATGGAGGTACATC
hY5 wild type reverse GTAAACGTTGTCTACTACTGTTATTAGTGC
hY5 overlap forward AATAACAAGAGACTCACCGGTAACACAGTT
hY5 overlap reverse AACTGTGTTACCGGTGAGTCTCTTGTTATT
hY5 alternative reverse TTATTAGCGCTAAAACAGCAAGCTAGTCAA
Stuffer forward GAAGAGTGTCTCAAGTTCTGCGCCTCC
Stuffer reverse CGTCCTGGCTGTCCTGGATGATCTGT
hY5 sequencing primer GATGAAACAAAGCCGACA
M13 forward CGCCAGGGTTTTCCCAGTCACGAC
M13 reverse TCACACAGGAAACAGCTATGAC
Table 2.2: Primers used for PCR amplification
63
2.6.16 Generating hY5 RNA mutants
The pStuffer plasmid was digested with both AfeI and AgeI, gel extracted and then
de-phosphorylated. Mutant primers were phosphorylated where necessary, annealed
together and ligated into the digested pStuffer plasmid (See Appendix 7 for mutant
primer details).
2.6.16.1 Mutant primer phosphorylation and annealing
350 pmol of each primer in a pair was diluted in 1 x PNK forward reaction buffer,
before heating to 70◦C for 10 minutes. 2 µL of 10 mM ATP and 10 units of T4
PNK were added and incubated at 37◦C for 30 minutes to allow the ends to be
phosphorylated. The PNK was then inactivated by heating to 65◦C for 20 minutes.
For those primers that were phosphorylated in house each of the two primer mixes
were combined in equal volumes. For primers that arrived phosphorylated they
were mixed together in 1 x PNK forward reaction buffer. Mixes were annealed as
in Section 2.6.12
2.6.16.2 Ligation of annealed mutant primers into pStuffer
Double-stranded DNAs were ligated into the pStuffer plasmid at the ratios recom-
mended for pGEM-T Easy. Ligation mixes were incubated at 16◦C overnight, as
recommended for blunt ended ligations. Ligation mixes were transformed into DH5α
cells and plated on LB plates with Ampicillin selection. Positive colonies for each
mutant were sent for Sanger sequencing. For each mutant, one colony was selected
which had both the AfeI and AgeI the restriction sites intact, and no mismatches
within the coding region, or 500 bp upstream.
2.6.17 Expression of the mutant plasmids in human MCF7 and
mouse NIH/3T3 cells
For these experiments the treatments were scaled up to T75cm2 flasks. Briefly,
MCF7 cells were plated 48 hours, and NIH/3T3 cells were plated 24 hours, before
transfection. Cells were transfected with 20 µg of plasmid DNA per flask, or were
treated with either transfection mixes alone, or were untreated. Transfections were
conducted using Lipofectamine2000, unless otherwise stated. Cells were transfected
with mixes containing an unrelated plasmid, pGL3 or the empty vector control pEVC
were included where appropriate. Cells were treated with Poly(I:C), Hygromycin or
Staurosporine as detailed in Section 2.1.5
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2.6.17.1 Removal of the AgeI restriction site and re-introduction of a longer
downstream sequence
On transfecting the pWT-2RE plasmid into a number of different cell types, it
was concluded that the resulting RNA transcripts were on the border of detection
limits by northern blot analysis. Further investigation showed that the lower levels
of transcription were a result of the introduction of the restriction sites. Due to
time constraints, it was not possible to remove both restriction sites from each of
the mutant plasmids, but a further amplification of each of the mutant hY5 RNA
genes with a unique reverse primer removed the AgeI site and extended the 3’
UTR sequence (see Table 2.3 for details of each reverse primer). Transfections in
mouse cells indicated that this dramatically increased the transcription levels from
each of the mutant plasmids. As the levels of the mutant RNAs in the transfected
mouse cells were still lower than the levels of the hY5 RNA produced from the
pWT plasmid, a wild type plasmid with 1 restriction site (pWT-1RE) plasmid was
also created where the 3’ restriction site was removed and a longer 3’ UTR was
re-instated. This plasmid was transfected alongside each mutant plasmid and was
used for direct comparison in all experiments. These mutants were transfected using
the Fugene6 transfection reagent, which is less toxic to cells. The amount of plasmid
transfected ranged from 2.5-10 µg, as Fugene6 had a better transfection efficiency
that Lipofectamine2000.
Name Sequence 5’ to 3’
∆S mutants reverse GTAAACGTTGTCTACTACTGTTATTAGTCAAAACAGCAAGCTAGTCAAGGGGGG
SubS mutants reverse GTAAACGTTGTCTACTACTGTTATTAGTGCAAAACAGCAAGCTAGTCAAGATGGG
∆ ACC mutant GTAAACGTTGTCTACTACTGTTATTAGTGCAAAACAGCAAGCTAGTCAAGCGCTG
∆ 3’ end mutant reverse GTAAACGTTGTCTACTACTGTTATTAGTGCAAAACAAGCTAGTCAAGCGCGGTTG
∆Ro60 mutant GTAAACGTTGTCTACTACTGTTAATTAGTGCAAAACAGCAAGCTCAAGCGCGGTTG
Table 2.3: Unique primers used for mutant correction PCR
2.6.18 High-throughput mutagenesis of the human Y5 RNA
For a more high-throughput method of hY5 mutagenesis, a different method of
mutant generation was used. Long primers (IDT) were synthesised that contained
equal proportions of each of the four bases at each of five positions per primer pool
(Table 2.4). This equates to 1024 different sequences per pool. Three pools were
synthesized and the position of the 5 nucleotides mutated was shifted sequentially
along the hY5 sequence.
Initially, a pool of PCR products was to be generated from each of the three mu-
tant primer pools and these were going to be directly transfected into NIH/3T3 cells
and used to produce mutant RNAs. Due to a high level of primer-dimer adversely
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affecting the success of the PCR, PCRs were initially carried out in the presence of
either the forward or the reverse primer for 10 cycles, before one forward and one re-
verse reaction were combined and amplified for a further 25 cycles. The PCRs were
run as previously described for plasmid DNA PCRs, except for the lower number
of cycles. The annealing temperature was raised to 69◦C, to overcome the primer-
dimer problem. PCR products were purified using the QIAquick PCR purification
kit (Qiagen) and transfected using the same method as for the single-mutant plas-
mids, except that half the amount of PCR product was added, as the PCR product
was half the size of the pWT plasmid. Initial tests suggested that transfection of
PCR products derived from a pGFP plasmid did not produce any detectable sig-
nal. Further northern blot experiments to detect wild type hY5 RNA transcribed
from PCR products derived from pWT were also unsuccessful. For this reason, an
alternative strategy was designed, where the PCR product pools were cloned into
pGEM-T Easy and transfected into NIH/3T3 cells as plasmids.
2.6.18.1 PCR amplification, ligation and transformation
Using the wild type forward primer and either the 1, 2, or 3 reverse primer pools the
hY5 gene was amplified and the degenerate sequences were incorporated, creating
a pool of PCR products from each primer pool. PCR products were created for 3
separate replicates of each of primer pools 1, 2, and 3. PCR products were prepared
as in Section 2.6.18. PCR products were A-tailed, gel extracted and ligated into
the pGEM-T easy vector as already detailed. Transformations were carried out
using super-competent ‘home made’ DH5α cells, or XL2 Blue E. coli cells for pool
3, and the ligations and transformations were optimized for each PCR reaction
to ensure the best efficiency possible. E. coli cells were grown under blue/white
colony selection and it was determined that a minimum of 4850 positive colonies
were required for each replicate to give a 99% chance of selecting each of the 1024
possible sequences at least once. For each replicate of each pool, over 4850 positive
colonies were harvested, for most pools the number was approximately double this.
2.6.18.2 Colony selection, harvesting and plasmid purification
For each pool, 10 positive colonies were selected from one of the replicates and the
presence of an insert was confirmed using colony PCR. To harvest each plate, 3
mL of liquid LB was added and the cells were scraped using a disposable scraper
until no colonies could be seen on the plate. The bacterial cell suspension was then
transferred to a 50 mL centrifuge tube. For each replicate 6-8 plates were combined
into one centrifuge tube. Each centrifuge tube was processed as a separate midi-prep.
Four midi-prep samples were eluted in 1000 µL of water for injection (Invitrogen)
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to maximize plasmid recovery.
2.6.18.3 Ethanol precipitation to concentrate DNA
To concentrate the plasmid DNA, each midi-prep was divided between two 1.5 mL
centrifuge tubes and ethanol precipitated. Briefly, 50 µL of 3 M NaAc was added
(pH 4.8), then 1250 µL of ice cold 100% ethanol was added and samples were placed
in the -20◦C freezer overnight. Samples were spun at 13,000 x rpm for 15 minutes
at 4◦C and the supernatant was removed. Samples were gently washed in 1 mL of
80% ethanol and air dried. For each replicate, all pellets were recombined and re-
suspended in 100 µL of water for injection. Plasmid DNA integrity was determined
by gel electrophoresis, while concentration and purity was determined using the
Nanodrop 8000.
2.6.18.4 Transfection conditions
NIH/3T3 cells were plated at the appropriate number into T75cm2 flasks. Trans-
fection mixes were added to the cells 24 hours after plating. Each replicate plasmid
preparation was transfected into a separate T75cm2 flask, giving 3 biological repli-
cates for each of the 3 pools. Transfection mixes were prepared as for the hY5
mutants, except that 5 µg was used instead of 10 µg (Section 2.6.16.2). 24 hours
after transfection cells were treated with 1 µM STS. Cells were harvested 4 hours
later, and total RNA was extracted.
2.6.18.5 cDNA library preparation for hY5 sRNAs
The RNA was extracted as detailed previously. 2 µg of total RNA was used in each
of the small RNA libraries. Samples were processed according to the ‘HD’ small
RNA library protocol written by Dr. Karim Sorefan, with a few minor adjustments.
Firstly the adapters used were the FAM dye-labeled 3’ ‘HD’ adapter (Dalmay Lab)
and the RA5 5’ RNA adapter (Illumina). The RP1 RNA PCR primer (Illumina)
was replaced with a modified primer containing the RP1 sequence (Sigma), but with
the extra 5 bases of the adapter along with three Cs at the 3’ end. After the first
PCR polyacrylamide gel, a 32 nt and a 24 nt band were separately cut from the gel
and processed. cDNA libraries were prepared for cells treated with each replicate
derived from plasmid pools 1, 2, and 3.
All reagents were from the Truseq small RNA Preparation kit unless otherwise
stated. 2 µg of total RNA was used as the input for the kit. Each reaction was
prepared using half of the volumes recommended in the kit instructions. The 2 µg of
RNA was mixed with 0.5 µL of the FAM dye-labeled 3’ ‘HD’ adapter (10 µM stock)
and the volume was made up to a total of 2 µL with RNase free water. Samples
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were heated at 70◦C for 2 minutes and immediately placed on ice. In a new 0.2
ml tube, 3 µL of ligation mastermix was added. The mastermix was made up of
1.65 µL of T4 RNA Ligase I (New England Bioseciences), 3.3 µL of Ligase I buffer,
1.65 µL of RNase inhibitor and 1.65 µL of 10 mM ATP. Denatured RNA mixes
were rapidly added to these fresh tubes and reactions were incubated at 28◦C for 2
hours. Samples were then run using standard denaturing PAGE for RNA, although
a single-stranded RNA ladder was included for size comparison (Ambion). The gels
were stained with Sybrgold (Invitrogen) and scanned on the FX scanner. Bands
of the appropriate size were cut from each lane, taking care to leave the majority
of the adapter only band behind. A stock of NEB buffer 2 was diluted to 1 x and
used to elute the RNA from the gel. To do this, a 0.2 mL centrifuge tube was
placed inside a 2 mL centrifuge tube. two holes were made in the 0.2 mL centrifuge
tube using a 25G 5/8 inch syringe needle. the gel fragments were placed inside the
0.2 mL centrifuge tube. 300 µL of buffer was added to each lower tube. samples
were spun at maximum speed in a micro-centrifuge for 2 minutes. Samples were
then incubated at 4◦C, with shaking, overnight. Each gel mix was transferred to a
Spin-X 45 µm filter column. Columns were centrifuged for 30 seconds at 600 x g.
The eluate was transferred to a fresh 2 mL centrifuge tube. 30 µL of NaOAc and
975 µL of ice-cold 100% ethanol were added to each tube. Samples were placed in
the -80◦C for 30 minutes and the centrifuged at 20,000 x g for 20 minutes at 4◦C.
Samples were washed in 1 mL of ice-cold 80% ethanol and the dregs of the ethanol
removed. Pellets were then air-dried for 3-4 minutes and re-suspended in 3.5 µL of
RNase-free water.
The samples were transferred to a new 0.2 mL centrifuge tube and 0.5 µL of
Illumina 5’ adapter was added to each tube. Samples were incubated at 70◦C for
2 minutes and immediately placed on ice. The ligation mastermix was prepared as
before and samples were transferred to the tubes containing 3 µL of the mastermix,
before being incubated at 28◦C for 2 hours. On completion of the incubation,
samples were moved to a fresh 0.2 mL centrifuge tube containing 1 µL of RTP RNA
RT primer (Illumina) and incubated at 70◦C for 2 minutes, before immediately
placing on ice. 5.5 µL of RT mastermix was added to each tube. This was prepared
by adding 1.65 µL of 12.5 mM dNTPs, 3.3 µL of 0.1 M DTT, 3.3 µL of RNase
inhibitor and 3.3 µL of Superscript II. Samples were then incubated at 50◦C for 1
hour.
Samples were PCR amplified using standard high fidelity PCR conditions, but
with 0.8 µL of each primer and 2 µL of cDNA in a 20 µL reaction volume. The
alternative RP1 forward primer (Table 2.5) was included in the mastermix and the
Illumina index reverse primer was added separately to each tube. For each replicate,
3 PCR reactions were run for the appropriate number of cycles. On completion of the
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first PCR, samples were run on an 8% non-denaturing polyacrylamide gel and both
the 32 nt and 24 nt bands were cut out and eluted as detailed earlier. Samples from
all 3 PCR products for each replicate were pooled and eluted together. Following
elution, samples were subjected to a second gel extraction to remove contaminating
miRNAs from the 32 nt band and to be sure that all adapter-adapter had been
removed. Samples were sized using the 20bp dsDNA marker (Jena Bioscience). The
full volume of each sample was sent to BaseClear for sequencing using the alternative
sRNA sequencing primer (Table 2.5).
2.6.19 cDNA library preparation of new Poly(I:C)/control sRNA
samples
New control and Poly(I:C) sRNA libraries were prepared as for the high-throughput
hY5 libraries, except that both ‘HD’ adapters were used. Also the Illumina RP1
PCR primer and sequencing primers were used during library preparation. Three
replicates were prepared for each condition and both SW 1353 and MCF7 samples
were treated.
2.6.19.1 cDNA library preparation for full length hY5 RNAs
5 µg of total RNA was DNase treated using the Turbo DNase free kit (Ambion). 500
ng of this RNA was used in an RT-PCR performed according to Superscript II RT kit
instructions (Invitrogen) for using a gene-specific primer, FL library RT (See table
2.6 for primer full length library primer details) . After first-strand cDNA synthesis
a standard high-fidelity PCR was run for 15 cycles, using the FL round 1 forward
and reverse primers and an annealing temperature of 63◦C. This PCR product was
then separated on a 6% PAGE gel, eluted overnight and ethanol precipitated as
previously described. The samples were then diluted 1/100 and used in a second
PCR reaction using the Illumina RP1 forward PCR primer and the appropriate
Illumina index reverse primer. Each sample was PCR amplified for 10 cycles at an
annealing temperature of 60◦C. On completion of the PCR, samples were separated
on a 6% PAGE gel and a band of the correct size excised and purified. cDNA
libraries were prepared for cells treated with each of the three replicate samples for
the three different plasmid preparations 1, 2, and 3.
2.6.19.2 Plasmid bias hY5 library preparation
5 ng of plasmid DNA was used in standard plasmid PCR amplification reactions
using the PB library round 1 forward and reverse primers (See table 2.7 for primer
plasmid bias library primer details). Samples for PCR were run for 15 cycles with
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an annealing temperature of 57.5◦C. Each PCR product was then separated on a
6% PAGE gel, eluted overnight and ethanol precipitated as previously described.
The samples were then diluted 1/500 and used in a second PCR reaction using the
Illumina RP1 forward primer and the appropriate Illumina index reverse primer.
Each sample was PCR amplified for 10 cycles at an annealing temperature of 60◦C.
On completion of the PCR, samples were separated on a 6% PAGE gel and a band of
the correct size excised and purified. DNA libraries were prepared for each replicate
derived from the three different plasmid preparations A, B, and C.
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Name Sequence 5’ to 3’
Alternative RP1 forward AATGATACGGCGACCACCGAGATCTACACGTTCAGAGTTCTACAGTCCGACGATCCCC
Alternative sRNA sequencing primer CTACACGTTCAGAGTTCTACAGTCCGACGATCCCC
Table 2.5: Custom primers used for hY5 mutant sRNA library preparation and se-
quencing
Name Sequence 5’ to 3’
FL library RT AAACAGCAAGCTAGT
FL library round 1 F GTTCAGAGTTCTACAGTCCGACGATCAGTTGGTCCGAGTGTTGTGGGT
FL library round 1 R CCTTGGCACCCGAGAATTCCAAACAGCAAGCTAGTCAAGCG
FL/bias sequencing primer GTCCGAGTGTTGTGGGTTATTGTTAAGTTGATTTAAC
Table 2.6: Custom primers used for hY5 full length library preparation and sequenc-
ing
Name Sequence 5’ to 3’
PB library round 1 F GTTCAGAGTTCTACAGTCCGACGATCTAACACAGTTGGTCCGAGTGTT
PB library round 1 R CCTTGGCACCCGAGAATTCCATTAGTGCAAAACAGCAAGCT
Table 2.7: Custom primers used for hY5 plasmid bias library preparation
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3 GENERATION OF hY5-DERIVED
RNAS IS SECONDARY
STRUCTURE DEPENDENT BUT
SEQUENCE INDEPENDENT
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3.1 INTRODUCTION
Human Y RNAs are between 84 and 112 nucleotides in length and are denoted hY1,
hY3, hY4 and hY5 (Wolin and Steitz, 1983). The RNA originally named hY2 was
later found to be a truncated version of hY1 (Wolin and Steitz, 1983), and so is no
longer considered to be a separate Y RNA. This project focuses on the Y5 RNA,
which appears to have arisen at some point in the tetrapod lineage and has a notably
more divergent sequence in primates than any of the other Y RNAs (Perreault et al.,
2007).
3.1.1 Human Y5 RNA
hY5 RNA is the smallest hY RNA and it arose the most recently during evolution
(Kato et al., 1982; Wolin and Steitz, 1983; Perreault et al., 2007). With a smaller
internal loop than the other hY RNAs (Kato et al., 1982; Wolin and Steitz, 1983)
one might suppose that it has less functionality, but this RNA has taken on some
surprising characteristics. For example, hY5 RNA has a 3’ tail at least 5 nucleotides
longer than the other hY RNAs (Wolin and Steitz, 1983). hY5 is thought to bind to
the La protein more tightly than hY1-4 (Wolin and Steitz, 1983; Boire and Craft,
1990), possibly as a result of this extended tail. Alternatively, La could be interacting
elsewhere on the molecule, as this protein has recently been found to associate
with non uracil-containing sequences within RNAs (Fan et al., 1998), as well as
recognising structures at the 5’ ends of certain RNA molecules (Martino et al., 2012).
Both Ro60 and La are known to undergo modifications under certain conditions, so
it may be that the cytoplasmic hY1-4 and the mainly nuclear hY5 bind to a different
fraction of these proteins (Gendron et al., 2001).
Another interesting characteristic of hY5 is that it uniquely interacts with a num-
ber of proteins that do not bind to the other hY RNAs (Hogg and Collins, 2007).
There are few proteins that bind to only one of the other hY RNAs uniquely, more
often binding to two or more (Fabini et al., 2001; Fouraux et al., 2002). hY5 is the
only hY RNA that has been found to be directly involved in Ro60 QC functions
through its recruitment of the ribosomal protein L5 (Hogg and Collins, 2007). Per-
haps this is a specialized function that this RNA has evolved to perform. Evidence
supporting a specialized and possibly vital function of this hY RNA is that it is
found at the highest concentration of all of the Y RNAs within certain human cell
types (Gendron et al., 2001), despite the fact that hY3 is the most conserved (Far-
ris et al., 1995). All hY RNAs can function in chromosomal replication (Christov
et al., 2006), but perhaps hY1 and hY2 are replication-focused and have limited
alternative functions. One final unique characteristic of the hY5 RNA is that it acts
as an autoantigen and can be targeted by antibodies in patients with SS or SLE
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(Boulanger et al., 1995). Ro60 and La are also autoantigens for these disorders, but
none of the other hY RNAs contain sequences that are recognised by autoantibod-
ies (Boulanger et al., 1995). All of these lines of evidence together suggest that the
hY5 RNA has a specialized function that has evolved separately from the other hY
RNAs.
3.1.2 Preliminary work
As discussed in Chapter 1, Dr. Nicolas (from the Dalmay group) discovered that
Y RNAs are cleaved specifically after treatment with Poly(I:C), a mimic of viral
infection. This chapter will focus on the cleavage of hY5, as the cleavage of the
other Y RNAs has been discussed in work by Dr. Hall (Hall, 2013). Prior to the
start of this PhD project, Dr. Nicolas further characterised the conditions of hY5
cleavage.
Following on from the Poly(I:C) and control NGS libraries discussed in Chapter
1, Dr. Nicolas found that Poly(I:C)-dependent sRNAs were produced from both the
5’ and 3’ ends of the hY5 RNA: these sRNAs will be referred to as Y RNA-derived
RNAs or ydRNAs. Northern blots of total RNA prepared in the same manner as for
the NGS libraries led him to determine that the production of Y5 3’ end ydRNAs
was time-dependent and Poly(I:C) concentration-dependent, with the majority of
the Y5 RNA cleaved after 24 hours (Figure 3.1). A 32 nucleotide ydRNA was
detectable after 1 hour, appearing much earlier than the 24 nucleotide ydRNA,
which was only detectable after 24 hours. Both ydRNAs increased in abundance
at each time point over a period of 72 hours. We cannot say whether these sRNAs
are derived from different Y5 molecules or whether the 24 nucleotide ydRNA is a
processed version of the 32 nucleotide ydRNA, although the latter seems more likely.
Northern blots of the same membranes using a different probe that detects cleavage
products derived from the 5’ end of hY5 identified another 32 nucleotide ydRNA,
but a laddering was seen on the northern blot image, suggesting that this fragment
might be a degradation product rather than a bona fide ydRNA (Figure 3.2).
Dr. Nicolas discovered that, after Poly(I:C) treatment, the hY5 3’ ydRNAs en-
tered apoptotic vesicles (data not shown). This is of interest because both Ro60
and La have been found to enter apoptotic bodies in keratinocytes (Casciola-Rosen
et al., 1994a). Rutjes et. al. showed that hY RNAs are fragmented in apoptotic
cells and that the smaller fragments seem to have lost the La binding site (Rutjes
et al., 1999b). After Poly(I:C) treatment, Dr. Nicolas noted that MCF7 cells clearly
looked like they were undergoing apoptosis, as they could be seen to be rounding
up and undergoing chromatin condensation, although this was not confirmed exper-
imentally.
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Figure 3.1: Poly(I:C) concentration- and treatment time- dependent cleavage of the
hY5 RNA.
(A) Dr. Nicolas examined the effect of treating cells with different con-
centrations of Poly(I:C) on the production of Y5-derived 3’ sRNAs. (B)
Dr. Nicolas investigated the cleavage pattern of human Y5 RNA into
Y5-derived 3’ sRNAs after Poly(I:C) treatment over a period of 72 hours.
Figure 3.2: Poly(I:C) time-dependent cleavage of the hY5 RNA.
Dr. Nicolas examined the effect of Poly(I:C) treatment over a period of
72 hours on hY5 5’ end ydRNA production.
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When human cells detect foreign nucleic acids they mount an immune response.
One of the proteins involved in this response is Protein Kinase RNA-activated (PKR)
(Laurent et al., 1984). PKR detects and associates with dsDNA (Galabru and
Hovanessian, 1985). Using a chemical inhibitor of PKR, Dr. Nicolas found that the
cleavage at the Y5 3’ end was PKR-independent (data not shown). Recognition of
double-stranded RNA within the cell is complex and proteins other than PKR can be
involved, so it is possible that the Y RNA cleavage products detected were dependent
upon apoptosis rather than an immune response, or it could be an immune response
activated by another cellular protein. In 2009 the Wolin group showed that, after
infection with Murine Leukemia Virus, mouse Y RNAs were taken up by newly made
virus particles independently of the Ro60 and La proteins (Garcia et al., 2009). It is
therefore possible that this Y RNA cleavage, which we know occurs when we mimic
viral infection, is to prevent the viral hijacking of cellular RNAs. Y RNAs play a
key role in chromosomal replication in mammalian cells (Christov et al., 2006), but
this virus has no need for DNA replication, so it seems likely that these RNAs are
required by the virus for a different function.
The aim of this chapter was to mutate the sequence of the hY5 gene to pro-
duce mutant versions of the hY5 RNA. These mutants would be used to determine
whether it is the sequence of the RNA that is recognised by proteins involved in
cleavage or whether it is features of the secondary structure that are important.
3.2 RESULTS
3.2.1 Confirming apoptosis induction by Poly(I:C) treatment
The DLD-1 cell line was utilized for assaying apoptosis. DLD-1 cells were grown
under various conditions, including Poly(I:C) treatment, and harvested. At the
point of harvesting, samples were split into two and the first replicate was processed
for flow cytometry, while total RNA was extracted from the second replicate and
used for northern blotting. For flow cytometry experiments, cells were stained with
Annexin V and PI before analysis on the flow cytometer. For each sample, the cells
of interest were manually gated to exclude clumps of cells and cell debris (Figure
3.3). Flow cytometry clearly showed that over 50% the population of Poly(I:C)
treated cells were undergoing apoptosis at the 8 hour time-point, while around 10%
of cells treated with Hygromycin for 8 hours were undergoing apoptosis (Figure 3.4).
For northern blot analysis, the membrane was probed for the hY5 3’ end-specific
ydRNA. This ydRNA was detectable at low levels in the Hygromycin sample and
higher levels in the Poly(I:C)-treated sample (Figure 3.5). The level of this ydRNA
in the PBS-treated sample was similar to that in the control samples, indicating
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Figure 3.5: Detection of hY5 cleavage in DLD-1 cells grown under different condi-
tions.
DLD-1 cells were plated in 6 well plates. After 24 hours they were tran-
siently transfected with Poly(I:C) transfection mixes, Lipofectamine2000
alone, or were treated with PBS, Hygromycin or left untreated. After
the required incubation, cells were harvested and either used for flow
cytometry or for northern blotting. 3 µg of total RNA was separated by
PAGE. The membrane was probed with a hY5 3’ end-specific radiola-
belled probe.
that PBS does not induce cleavage.
3.2.2 Cloning of the wild type hY5 RNA gene into the pGEM-T
Easy plasmid
The hY5 RNA gene, including the RNA Polymerase III promoter and terminator
sequences, was PCR amplified from genomic DNA and then cloned into the pGEM-T
Easy plasmid (Figure /refy5 gene).
Maraia et al. were the first to fully characterize the hY5 RNA gene, and the
sequence features important for trancription of this gene (Maraia et al., 1996). This
gene contains a TATA box at positions -36 to -26 and a proximal sequence element
at positions -64 to -47. Possible octamer sequences are also present at positions
-242 to -234 and -216 to -209. In this paper Maraia noted that, in mouse cells,
when a plasmid containing the hY5 gene was co-transfected with the same amount
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Figure 3.6: Structure of the hY5 gene.
2900 bp upstream of the hY5 RNA encoding region was cloned into the
pGEM-T Easy plasmid. This includes two octamer sequence elements
(-242 to -234 and -216 to -204), a proximal sequence element (-64 to
-47), and a TATA box (-36 to -26). The transcription termination signal
is an oligo dT stretch at the end of the RNA encoded region. 30 bp
downstream of the oligo dT element was included in the sequence cloned.
of a plasmid containing the hY4 gene, despite the fact that hY5 is the most highly
expressed Y RNA in numerous human cells line, hY4 was expressed at notably higher
levels (Maraia et al., 1996). To take into account the possibility that important
sequence elements might have been missed during the characterization of this gene,
a 2.9 kb region upstream of the transcription start site was cloned into pGEM-T
Easy, along with the RNA-encoding region. A 30 bp region downstream of the
termination signal was also included: no important elements had been annotated
beyond this point. This plasmid will be referred to as the pWT plasmid.
Y5 RNA is expressed in humans, but not in chickens or in mice. In order to
confirm that the hY5 RNA can be produced from this plasmid, it was transfected
into the human MCF7 cell line, as well as the mouse NIH/3T3 and the chicken
DF-1 cell lines. These initial transfection experiments were conducted to deter-
mine whether transcription of hY5 from the plasmid would be sufficient to give a
detectable difference between the levels of full length hY5 in untransfected versus
pWT-transfected cells i.e. whether the exogenous hY5 could be distinguished from
endogenous hY5. In transfecting the plasmid into mouse and chicken cells, the aim
was to determine whether any detectable full length hY5 and any cleavage products
could be detected in the transfected cells, which would indicate that the cleavage
machinery is conserved between these organisms and humans.
A secondary aim was to determine the specificity of a northern probe designed
to be hY5 3’ end-specific, which should not hybridize to any of the other human
Y RNAs or any of the mouse/chicken Y RNAs, which are not homologs of hY5.
This probe should detect the full length hY5 RNA, as well as any fragments which
contain the 3’ end derived sequence that Dr. Nicolas identified.
Initial experiments involved transfection with 2 µg of plasmid DNA per well of a 6-
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Figure 3.7: Detection of hY5 in cell lines derived from different organisms.
Human (MCF7), mouse (NIH/3T3) and chicken (DF-1) cells were plated
in 6 well plates. After 24 hours they were transiently transfected with
2 µg of plasmid DNA using the Lipofectamine2000 transfection reagent
(lanes 2, 4, 6) or were left untreated (lanes 1, 3, 5). After a further 24
hours cells were harvested and total RNA was extracted. 1 µg of total
RNA from each sample was used for northern blot analysis. Membranes
were probed with a hY5 3’ end-specific radiolabelled probe.
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well plate. RNA was extracted and separated by denaturing PAGE, before northern
blotting and radioactive probing using a probe specific for the hY5 3’ end ydRNAs
(Figure 3.7). A band corresponding to the full length hY5 RNA was seen in both
the MCF7 untreated and the pWT-transfected cells. This band was noticably more
intense in the transfected cells, indicating strong expression from the plasmid. A
lower band was clearly visible in the transfected cells, whereas a band of this size
was not visible in the untreated cells. This band represents the 32 nucleotide Y5 3’
ydRNA. We know from previous experiments that the 24 nucleotide ydRNA is only
detectable after longer incubations with Poly(I:C). There seemed to be no cross-
hybridization of the hY5 3’ end-specific probe with other hY RNAs in the human
MCF7 cells, which would be present above the full length hY5 band as the other hY
RNAs are longer. The specificity of this probe has since been more closely examined
by Dr. Hall (Hall, 2013).
Transfection of pWT resulted in detectable levels of full length Y5 in both the
chicken and mouse cell lines. Cleavage products were not detectable in these cell
lines. There appeared to be no cross-hybridization of the hY5 3’ end-specific probe
with endogenous Y RNAs in either the mouse or chicken cells: these cells contain Y
RNAs of a different size and only a single full length Y RNA band is visible in these
samples. This band is also present only in the transfected cells, giving us confidence
that it is the hY5 RNA produced from the plasmid.
3.2.3 Expression of hY5 from plasmids in MCF7 cells
The region targeted for mutagenesis was at the 3’ end of the hY5 RNA gene. Mu-
tations would be inserted by replacing a small region of the gene with a mutant
double-stranded DNA. No suitable restriction enzyme sites were available close to
this region in the pWT plasmids, so they were artificially inserted using a series
of PCRs. The pWT plasmid was used as a template to amplify the hY5 gene in
two separate sections, using primers to introduce an AgeI restriction enzyme site
upstream and an AfeI restriction enzyme site downstream of the RNA-encoding
region. Overlap PCR was used to combine these sections and the resulting PCR
product was ligated into the pGEM-T Easy vector to give pWT-2RE (Figure 2.2).
In order to determine the effect of the restriction sites on transcription of the RNA,
the pWT and pWT-2RE plasmids were transfected into human MCF7 cells. As
controls, cells transfected with an empty vector were included in the experiment,
alongside untreated cells and cells grown in the presence of the Lipofectamine2000
transfection reagent alone. As an extra control, MCF7 cells were also transfected
with an unrelated empty vector (pGL3).
The levels of hY5 full length RNA detected in MCF7 cells transfected with the
83
Figure 3.8: Detection of hY5 levels after transfection of MCF7 cells.
MCF7 cells were plated in T75cm2 flasks and 48 hours later were
transiently transfected with 20 µg of plasmid DNA using the Lipofec-
tamine2000 transfection reagent. After a further 24 hours cells were
harvested. 1 µg of total RNA was separated by denaturing PAGE and
probed with the hY5 3’ end-specific probe. As controls, untreated cells
were grown alongside cells treated with Lipofectamine2000 alone, cells
transfected with a pGL3 control plasmid or transfected with an empty
vector. 250 ng of Poly(I:C)-treated MCF7 cell total RNA was loaded in
lane 10.
pWT or pWT 2RE plasmids looked similar, and both had markedly higher levels
of full length hY5 RNA than the controls (Figure 3.8). However, the levels of
cleavage products detected in neither the pWT nor the pWT-2RE transfected lanes
were noticably higher than endogenous hY5 levels (as determined by lanes 1-4),
especially in those cells transfected with control plasmids. 250 ng of a Poly(I:C)-
treated MCF7 total RNA sample was run in lane 10. This control confirms that both
the full length hY5 RNA produced from these plasmids and the resulting cleavage
products migrate at the same size as the endogenous full length RNA and cleavage
products detected after Poly(I:C) treatment, suggesting that the exogenous RNA is
being recognised and processed in the same way as the endogenous RNA.
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3.2.4 Cleavage of exogenous hY5 in DLD-1 cells after Poly(I:C)
treatment
Figure 3.9: Detection of hY5 RNA levels after transfection of DLD-1 cells and
Poly(I:C) treatment.
Cells were plated in T75cm2 flasks and grown for 24 hours before
transient transfection with 20 µg of plasmid DNA using the Lipofec-
tamine2000 transfection reagent. 24 hours after transfection, cells were
treated with 10 µg/ml Poly(I:C) or fresh media was added. After 8
hours of treatment cells were harvested and 10 µg of RNA was used for
northern blot analysis. Samples were probed with the 12 nt hY5 3’ end-
specific LNA probe. As controls, untreated cells were grown alongside
cells treated with Lipofectamine2000 alone or cells transfected with an
empty vector control.
Variability in the levels of endogenous of hY5 has been reported in different tis-
sues (O’Brien and Harley, 1990). Transient transfection experiments were therefore
conducted in a different human cell line, DLD-1, to see whether transcription and
cleavage rates might be more favourable (Figure 3.9). However, very high levels of
endogenous hY5 were evident in DLD-1 cells, making interpretation of cleavage of
exogenous hY5 RNA difficult. In these cells there was a barely detectable increase
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in full length hY5 after transfection. Unlike the previous northern blot, this mem-
brane was probed with a 12 nt locked nucleic acid (LNA) probe specific for hY5.
This probe will be used to detect potential ydRNAs from mutant hY5 RNAs, as
well as wild type ydRNAs. The original hY5-specific probe cannot be used to detect
mutants, as the sequence it maps to overlaps the region targeted for mutagenesis.
Based on these results, we decided to move to expressing hY5 wild type and
mutant plasmids in a system without endogenous hY5, so that the expression of wild
type and mutant hY5 RNA expressed from plasmids could be directly compared and
we could be confident that any conclusion drawn on the effect of the mutation would
not be masked by endogenous hY5.
3.2.5 Analysis of the NIH/3T3 cell lines for use in hY5 mutant
cleavage assays
Initial transient transfection experiments in mouse NIH/3T3 cells highlighted that
there was a difference in transcription efficiency between the pWT and the pWT-
2RE plasmids, with the pWT-2RE-transfected lanes showing much lower levels of full
length hY5 than the pWT-transfected lanes (Figure 3.10). This dramatic difference
was not as clear when these plasmids were expressed in MCF7 cells (See Figure 3.8).
This difference was most likely masked by the endogenous hY5 RNA in human cells,
although it could also be the result of inherent differences between the two organisms.
It was clear that this difference would make detection of mutant RNAs difficult
in NIH/3T3 cells, so the pWT-2RE and the mutant plasmids were corrected by a
second PCR using the hY5 wild type forward primer and a reverse primer designed to
correct the most 3’ restriction enzyme site by returning it to the wild type sequence.
This new wild type plasmid was denoted pWT-1RE. The expression of hY5 from
pWT, pWT-1RE, and pWT-2RE was compared by transfecting them into NIH/3T3
cells (Figure 3.11). Although the levels of full length RNA produced from the
plasmid with one restriction enzyme site was lower than the plasmid with purely
wild type sequence, the levels were vastly improved when compared to the plasmid
with two sites, confirming that both of these restriction enzyme sites have an effect
on the levels of transcription of this gene. Correction of the 5’ restriction enzyme site
would have required numerous overlap PCRs, so to take account of the differences
in expression of hY5 from pWT and pWT-1RE, the levels of mutant hY5 RNA were
compared to the levels of wild type hY5 RNA produced from the pWT-1RE plasmid
in all subsequent experiments.
The levels of ydRNA detected in prior experiments were higher in cells treated
with Lipofectamine2000/empty vector DNA mixes than untreated cells grown only
in OptiMEM, suggesting some toxicity of these mixes to the cells. Fugene6 is a
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Figure 3.10: Detection of hY5 RNA levels from pWT and p2RE plasmids in
NIH/3T3 cells.
Cells were plated in T75cm2 flasks and 24 hours later were transfected
with plasmid DNA using the Lipofectamine2000 transfection reagent.
After a further 24 hours, cells were harvested and 3 µg total RNA was
used for northern blot analysis. Samples were probed with the hY5 3’
end-specific probe.
transfection reagent known to be less toxic to cells than Lipofectamine2000. Com-
parison of the growth of cells treated with Lipofectamine2000 alone and Fugene6
alone also indicated a greater toxicity, as cells grew faster and were more conflu-
ent after treatment with the latter transfection reagent than the former (data not
shown). In lane 6 of Figure 3.12 cells were transfected in the same manner as for lane
2, but with Fugene6 rather than Lipofectamine2000. The higher level of full length
hY5 in the Fugene6-transfected compared to the Lipofectamine2000-transfected lane
shows that Fugene6 gave a higher transfection efficiency in NIH/3T3 cells, as well
as a lower toxicity. For this reason, Fugene6 transfection reagent was used in all
subsequent mutant hY5 transfection experiments.
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Figure 3.11: Detection of RNA expression from pWT, p1RE and p2RE in NIH/3T3
cells.
NIH/3T3 cells were plated in T75cm2 flasks and 24 hours later were
transfected with plasmid DNA using the Lipofectamine2000 transfec-
tion reagent, except for lanes 5 and 6, where the Fugene6 transfection
reagent was used. After a further 24 hours, cells were harvested and
10 µg total RNA was used for northern blot analysis. Samples were
probed with the hY5 3’ end-specific probe.
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3.2.6 Optimization of apoptosis induction and ydRNA detection
in NIH/3T3 cells
Figure 3.12: Detection of hY5 ydRNAs after apoptosis induction.
NIH/3T3 cells were plated in T75cm2 flasks and 24 hours later
were transfected with pWT-1RE using Lipofectamine2000 transfection
reagent. After a further 24 hours, cells were treated with Poly(I:C),
(A) Hygromycin or (B) Staurosporine (STS) for the stated time before
harvesting and northern blotting. Control cells were treated with Lipo-
fectamine2000 alone. Samples were probed with the hY5 3’ end-specific
probe. P(I:C) - Poly(I:C), Hygro - Hygromycin.
ydRNAs were at the limits of detection in unstressed NIH/3T3 cells and these
cells were also much less sensitive to Poly(I:C) than MCF7 cells. Treatment with
Poly(I:C) requires direct transfection into cells and is not ideal for testing the cleav-
age of exogenous hY5 RNA, as it requires a second transfection of cells already trans-
fected with a plasmid. To minimize the transfection toxicity, along with switching
to Fugene6 for transfections, drug-induced apoptosis was also tested. These drugs
could be added directly to the cell culture media, thereby reducing stress from
sources other than the drug itself. Addition of drugs diluted in cell culture media
directly to the flasks should also increase the consistency between samples, as media
from the same drug batch could be added to each flask. Test experiments were con-
ducted using Hygromycin, but again the response to this drug was slow and resulted
only in low levels of detectable hY5 ydRNA after three days of treatment (Figure
3.12 (A)). NIH/3T3 cells have been shown to be very sensitive to Staurosporine
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(STS) treatment with visible signs of apoptosis occurring after just 4 hours (Liu
et al., 2001). Experiments were therefore conducted to mirror these conditions and
a 4 hour treatment with a final concentration of 1 µM of Staurosporine 24 hours
after plasmid transfection gave detectable levels of hY5 ydRNA. Cells could clearly
be seen to be undergoing apoptosis, showing signs of rounding under the microscope.
3.2.7 Analysis of the levels of mutant hY5 RNAs and cleavage
products in NIH/3T3 cells
Sense and antisense primers covering the entire RNA-encoding region of the hY5
RNA gene and containing mutations (specificed later) were annealed to each other
to give blunt and sticky ends complementary to the ends produced when DNA is
digested with the AfeI (blunt) and AgeI (sticky) restriction enzymes. A stuffer
plasmid was created where the 100 bp hY5-encoding region was replaced with a 1
kb unrelated sequence. This plasmid was then digested with AfeI and AgeI and
ligated to the appropriate mutant DNA. To correct for any effects of the second
restriction enzyme site on transcription efficiency, a final PCR amplification step
was carried out to remove the terminal restriction enzyme site and restore the full
30 bp sequence downstream of the termination signal in all of the mutant plasmids.
The PCR products containing the hY5 gene with wild type or mutant sequences were
then re-cloned into new pGEM-T Easy plasmids. All constructs were sequenced at
each stage to confirm that no mismatches had been introduced and to verify their
identity.
3.2.7.1 The deletion mutants
Figure 3.13 shows the predicted secondary structures of the wild type hY5 RNA, the
mutant with one strand deleted (∆1S), and the mutant with both strands deleted
(∆2S). These structures were predicted using the RNAfold default prediction algo-
rithm. (See Appendix 7 for a fuller prediction of the secondary structure of each
mutant using all RNA folding algorithms in RNAfold and in Mfold). The ∆1S mu-
tant was designed so that a sequence on the right-hand side of the stem (contained
in the red boxed region on the wild type prediction) was deleted. This mutation was
predicted to have a dramatic effect on the secondary structure of the resulting RNA
molecule (Figure 3.13 shows that this mutation affects the larger bulge in region 2
and the stem in region 3). With the secondary structure predicted to be so dra-
matically altered, the hypothesis was that this mutant would produce no detectable
cleavage products as it would not be recognised by the cleavage machinery.
The ∆2S mutant was designed so that the sequences on both sides of the stem
within the red boxed region were deleted. According to predictions, this second
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mutation should rescue the first as, although a portion of the RNA molecule has
been deleted, the rest of the structure closely resembles the wild type structure.
Determining whether this mutant was cleaved would provide us with information as
to whether the region targeted for deletion is important for cleavage, or whether it
is dispensable in this process.
The full length ∆1S mutant RNA appeared to be consistently lower than either
the wild type or ∆2S mutant (Figure 3.14). Neither the ∆1S nor ∆2S mutants
produced fragments that were detectable with the 12 nt Y5 3’ end-specific LNA
probe, even when the membrane was exposed for a much longer period of time
(data not shown). For ∆1S it is possible that there was a fragment produced with
the same efficiency as the wild type, but that it was below the levels of detection as
a result of the levels of the ∆1S mutant full length RNA being so much lower than
the levels of the wild type full length RNA. This is less likely to be the case for ∆2S
which, in some of the replicates, was produced at levels comparable to the wild type
but still no fragments were detected.
3.2.7.2 The substitution mutants
Figure 3.15 shows the predicted secondary structures of the wild type, sub1S, and
sub2S mutant RNAs using the default prediction algorithm in RNAfold. Sub1S was
designed so that the sequence on the right-hand side of the stem, here highlighted in
the blue box on the wild type prediction, was substituted for different nucleotides.
The sequence was chosen to deliberately disrupt the secondary structure of the RNA
molecule as much as possible (Figure 3.15 shows that this mutation affects regions
2, 3, and 4, introducing an extra stem loop compared to the wild type prediction).
With the secondary structure predicted to be so dramatically altered, the hypothesis
was that this mutant would produce no detectable cleavage products.
The sub2S mutant was designed so that the sequences on both sides of the stem
in the blue boxed region were substituted for different nucleotides. According to
predictions, this second mutation rescues the first as, although a portion of the
RNA molecule has a different sequence to the wild type, the secondary structure
resembles the wild type RNA. Determining whether this mutant was cleaved would
provide us with information as to whether it is the sequence within this region
or whether it is the secondary structure that is important for cleavage to occur.
The blue region highlighted on the sub1S and sub 2S mutant predictions shows the
nucleotides that replaced those on the wild type prediction.
All repeat transfections of these mutants clearly showed that there was no 32
nt fragment produced from sub1S, but there was from sub2S (Figure 3.16). This
indicates that a change in the structure abrogated cleavage, but where the structure
was the same and the sequence was different, a clear 32 nt apoptosis-dependent
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Figure 3.14: Detection of hY5 deletion mutant cleavage after STS treatment.
NIH/3T3 cells were plated in T75cm2 flasks and 24 hours later were
transfected with plasmid DNA using Fugene6 transfection reagent.
Then 24 hours after transfection, cells were treated with 1 µM Stau-
rosporine for 4 hours before harvesting and 10 µg of total RNA was
used in northern blotting. Samples were probed with a 10 nt hY5 LNA
probe. In experiment 1 cells were transfected with 2.5 µg (top) of plas-
mid DNA, in experiment 2 cells were transfected with 5 µg (middle) of
plasmid DNA, and in experiment 3 cells were transfected with 10 µg
(bottom) of plasmid DNA.
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Figure 3.16: Detection of hY5 substitution mutant cleavage after STS treatment.
NIH/3T3 cells were plated in T75cm2 flasks and 24 hours later were
transfected with 5 µg of plasmid DNA using Fugene6 transfection
reagent. Then 24 hours after transfection, cells were treated with 1 µM
Staurosporine for 4 hours before harvesting. Membranes were probed
with the 12 nt hY5 LNA probe.
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cleavage product was detectable. Interestingly, there was a smaller cleavage product
detectable in the sub2S lane that was not detectable in the wild type lane. This
cleavage product was not apoposis-dependent as it was present at similar levels in
both the unstressed cells and the cells undergoing apoptosis. It is possible that this
cleavage product was also present in the sub1S STS-treated lane, but was too faint
to detect with any level of confidence.
On different northern membranes, a ∆3’ mutant was run alongside sub1S and
sub2S (Figure 3.17). This mutant was missing three nucleotides between the Ro60-
and La-binding sites towards the 3’ end of the molecule. The region where the three
nucleotides were deleted is shown in orange on the predicted structure (Figure 3.18).
The ∆3’ mutant could not be detected using the 12 nt LNA probe, as some of the
nucleotides required for hybridization were deleted in this mutant (data not shown).
The membranes that included this mutant were reprobed with a 10 nt LNA probe
designed further away from the 3’ end of the full length RNA, and therefore not
overlapping the deleted region in ∆3’. The new 10 nt LNA probe detected a similar
band pattern to the 12 nt LNA probe, but this time it also detected a full length
RNA and a cleavage product in the ∆3’ samples. In repeat 1, the full length ∆3’
mutant RNA was present at even higher levels than the full length sub2S mutant,
which explains why an sRNA was present at low levels in the ∆3’ untreated lane,
and an sRNA was present in the ∆3’ STS-treated lane at higher levels than in the
WT STS-treated lane. This ∆3’ ydRNA band was not clearly detectable in the
untreated sample in the other two repeats. This ∆3’ ydRNA was noticeably smaller
than the WT ydRNA, suggesting that the cleavage happened in this mutant at the
same position as in the WT, resulting in a smaller product.
3.2.7.3 Further mutants
Two proteins known to consistently interact with all types of hY RNA are Ro60
and La; interestingly they both interact with the region of the hY5 molecule that
is present in the 5’ and 3’ apoptosis-dependent ydRNAs. The ∆Ro mutant was
designed to further investigate the role of Ro60 in the cleavage of hY5 (Figure 3.18).
The orange line highlights where 4 nt from the right and 3 nt from the left of the
terminal stem were deleted. This mutation includes a deletion of the C bulge.The
secondary structure is not predicted to be dramatically altered by these deletions.
The region deleted is, however, one of the most conserved regions across Y RNAs
and across organisms, as it is the region that interacts with Ro60. Similar mutants
have been made by a number of groups and have been shown to lack the ability
to associate with Ro60. The ∆Ro mutant has no detectable ydRNAs 3.19, even
though the full length mutant is present at only slightly lower levels than the wild
type RNA.
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Figure 3.17: Alternative detection of hY5 substitution mutant cleavage after STS
treatment.
NIH/3T3 cells were plated in T75cm2 flasks and 24 hours later were
transfected with 5 µg of plasmid DNA using Fugene6 transfection
reagent. Then 24 hours after transfection, cells were treated with 1
µM Staurosporine for 4 hours before harvesting. Northern blots were
probed with the 10 nt hY5 LNA probe.
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Figure 3.19: Detection of hY5 further mutants cleavage after STS treatment.
NIH/3T3 cells were plated in T75cm2 flasks and 24 hours later were
transfected with 5 µg of plasmid DNA using Fugene6 transfection
reagent. Then 24 hours after transfection cells were treated with 1 µM
Staurosporine for 4 hours before harvest. Northern blots were probed
with the 12 nt hY5 LNA probe.
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To examine the effect of smaller changes on cleavage, a further mutant was de-
signed (Figure 3.18). In the ∆ACC mutant, 3 nts in the predicted large bulge were
deleted. The regions where the nucleotides were deleted is marked on the struc-
ture prediction in orange. The aim of this mutant was to determine whether this
bulge is necessary for cleavage. The large bulge in experimentally validated Y RNA
structures is thought to be nearer the terminal end than the predicted structure,
but the stem produced by the prediction program when the ACC nucleotides are
deleted has a low predicted free energy of -32.31 kcal/mol, so this deletion is likely
to disrupt any downstream bulge which may be present in the wild type. The Wolin
group propose that this bulge is important for the recognition of this RNA by Ro60
(Green et al., 1998), so this mutant was also designed to be used in immunopre-
cipitation experiments, to determine whether the large bulge really is necessary for
Ro60 binding.
The ∆ACC mutant, like the ∆2S mutant, which was run here as a control, is not
cleaved(Figure 3.19). No ydRNAs are seen in either of these lanes, while a clear
ydRNA band is visible in the wild type lane.
3.3 DISCUSSION
Poly(I:C) has been shown by others to induce apoptosis (Larson et al., 1969), but
has not been tested at the concentrations and incubation times used in the prelim-
inary work and, although the cells look to be undergoing apoptosis when inspected
visually, one of the first aims of this project was to prove that apoptosis was oc-
curring under these conditions. Initial transfection experiments were conducted in
MCF7 and DLD-1 cells, both of which visibly showed signs of undergoing apoptosis
after 8 hours of treatment. Both MCF7 and DLD-1 cells were derived from human
cancers and both have characteristics different from normal human cells. MCF7 has
been documented to lack the Caspase 3 protein (Kirsch et al., 1999), a key effec-
tor protein in one of the major apoptosis pathways. For this reason, the DLD-1
cell line was instead utilized for assaying apoptosis. DLD-1 cells were grown under
various conditions, including Poly(I:C) treatment and treatment with the apoptosis
inducer Hygromycin, and subsequently harvested. Samples were split into two and
processed either for northern blot analysis or for flow cytometry analysis. Flow cy-
tometry samples were further split and stained with Annexin V or PI. On obtaining
the flow cytometry data, each sample was gated to select cells and remove debris.
Phosphatidyl serine residues (PS) are located on the inner surface of the cell mem-
brane in healthy cells. Early in apoptosis these PS residues are translocated to the
outside of the membrane. Annexin-V targets these PS residues and stains them.
PI only enters dead cells and indicates early or late necrosis. The Annexin V/PI
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plots (Figure 3.4) show that 87.4% of cells in the Poly(I:C) treated sample are un-
dergoing apoptosis and 10.9% are healthy, whereas in the Hygromycin treated cells
71.7% of cells are undergoing apoptosis and 13.6% of cells are healthy. Only a small
proportion of cells under either of these two treatment conditions have necrosed.
From the Annexin V/PI plots the location of the majority of cells is different for the
Poly(I:C) and Hygromycin conditions. In the Poly(I:C)-treated sample the majority
of cells are in the centre of the lower right quadrant, while in the Hygromycin-treated
sample a small proportion are in this position, but the majority of the cells in this
quadrant are on the border of the lower left and the lower right quadrants, suggest-
ing an earlier stage of apoptosis. This is reflected in the median FL1-A value (the
position along the X axis, representing the level of Annexin-V staining). In all other
conditions tested, no detectable population of cells was seen undergoing apoptosis
or necrosis (See Appendix 7 for Flow cytometry data table and SSC/FSC gating
plots).
Figure 3.5 shows that the level of 32 nt hY5-derived ydRNA in the Hygromycin
lane is slightly above the levels in the control lanes and that the level of ydRNA
is higher again in the Poly(I:C)-treated sample. This northern blot correlates with
the flow cytometry results and from these data we can deduce that the 32 nt Y5
3’ ydRNA is likely to be apoptosis-induced. Alongside these flow cytometry ex-
periments, Dr. Nicolas also treated MCF7 cells with varying concentrations of Hy-
gromycin. The northern blot image in Figure 3.20 shows that Hygromycin, like
Poly(I:C), induces hY5 cleavage in this cell line, providing further evidence that
this ydRNA is apoptosis-induced. From this we can conclude that the specific Y5-
derived RNAs in our experiments, as with those detected in (Rutjes et al., 1999b),
are apoptosis-dependent rather than viral infection-dependent, especially as we know
that this ydRNA is PKR-independent.
Early optimization experiments in mouse cells highlighted the fact that the wild
type hY5 RNA was still cleaved to produce a 32 nt 3’ ydRNA, despite the fact
that this RNA is not endogenous to this organism. These results indicate that
the cleavage protein or cleavage complex that produced this sRNA is conserved
between mice and humans. This is supported by data from Dr. Hall, which showed
that endogenous mouse Y RNAs were also cleaved after Poly(I:C) treatment (Hall,
2013). Further experiments to quantify the levels of these ydRNAs in treated and
untreated cells found that they were present in untreated human cells, albeit at
much lower levels (Nicolas et al., 2012). So far we have not investigated whether
all cells in a normal untreated population produce ydRNAs at low levels or whether
these RNAs are derived from a small number of cells within the population which are
currently undergoing apoptosis during their natural life-cycle. Fluorescent activated
flow cytometry could be used to answer this question. If a large sample of untreated
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Figure 3.20: Detection of hY5-derived small RNAs after treatment of MCF7 cells
with different apoptosis inducers.
Dr. Nicolas showed that, when MCF7 cells are treated with increasing
concentrations of Hygromycin, there is an increase in the levels of hY5-
derived small RNAs detected by nothern blot analysis. These levels are
comparable to those detected after 8 hours of Poly(I:C) treatment.
human cells was sorted by an early apoptosis marker and then hY5 RNA cleavage
determined in the apoptotic and non-apoptotic populations, then we could compare
the cleavage of hY5 in these populations and determine whether it occurs in non-
apoptotic cels.
The addition of a plasmid encoding hY5 RNA led to an increase in the levels of
hY5-derived cleavage products in human cells (see Figure 3.7), even in the absence
of an apoptosis inducer. This is likely due to the toxic effects of the transfection
agent increasing the levels of apoptosis in these cells compared with untransfected
cells.
In order to create each of the mutants, their sequences were manually altered
and then a combination of Mfold and RNAfold algorithms were used to predict the
resultant structural alterations. Both the deletion and substitution mutants were
designed to alter regions 2 and 3 of the RNA. The Ro60 and La binding sites were
conserved as much as possible when designing these mutants so as not to affect the
stability of the full length RNA and complicate interpretation of the results.
In all three repeat experiments of the deletion mutants, the full length ∆1S mutant
was present at consistently lower levels than either the wild type or the ∆2S mutant.
This could have occurred for a number of reasons. Firstly, the ∆1S RNA could
be transcribed at lower levels than the wild type or the ∆2S mutant RNA. The
human Y RNA genes have been reported to contain elements that regulate their
own transcription and it is possible that one of these was disrupted in this mutant.
The fact that this did not occur for the full length ∆2S mutant, which had even more
sequence deleted, suggests that this was not the case. A second possibility is that the
mutation disrupted the structure of this RNA in such a way that it was recognized
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as misfolded and was more rapidly targeted for degradation than the ∆2S mutant.
Both deletion mutants were designed to maintain the integrity of the Ro60 binding
site and keep the C bulge intact. Green et al. have published data to show that the
large bulge in the wild type structure is also necessary for Ro60 binding and allows
the RNA structure to open up enough to allow Ro60 access (Green et al., 1998).
This requirement for the large bulge has not been verified by other groups. If this
bulge is necessary for Ro60 binding, then it is unlikely that either of these mutants
would bind to Ro60. Y RNAs bind to the outer surface of the Ro60 ring (Stein
et al., 2005), but this protein can also interact with misfolded RNAs (Green et al.,
1998). It is therefore possible that, not only did it no longer recognize these mutants
as Y RNAs, but it was also actively involved in the degradation of ∆1S. Another
possibility is that this mutant RNA interacted with other proteins, resulting in its
degradation.
It is not possible to make conclusions about the targeting of the ∆1S mutant for
cleavage, as the full length levels were so much lower than the levels of full length
wild type RNA. No cleavage products were visible in the ∆1S lane, even after STS
treatment, but it may be that this RNA was fragmented at a similar rate to the
wild type and the cleavage products were not detectable because they were below
the levels of detection. Although the full length ∆2S mutant was present at similar
levels to the full length wild type Y5 RNA, no detectable cleavage products could be
seen. This mutant has a similar secondary structure to the wild type, but is missing
the large bulge in region 2 as well as some of the stem in regions 2 and 3. We can
conclude that region 2 must be necessary for the production of detectable 32 nt 3’
ydRNA.
Along with the binding of Ro60 in this region, the Prujin group has shown that
the binding of a nuclear factor to each Y RNA is required for the export of Ro RNPs
into the cytoplasm (Rutjes et al., 2001). This nuclear factor is probably ZPB1 (Sim
and Wolin, 2011). The exact binding site of this protein has not been identified,
but it requires a 10 nt terminal stem for Y RNA interaction (Sim and Wolin, 2011).
The ∆1S mutant has an altered secondary structure resulting in a shorter terminal
stem, while the ∆2S mutant has a terminal stem one base pair shorter than the wild
type RNA. It is therefore interesting that the ∆1S mutant is less stable than the
∆2S mutant. Simons et. al. discovered that both Ro60 and this nuclear factor must
interact with Y RNAs for them to be relocated into the cytoplasm, but that shorter
mutant Y RNAs can be exported when they contain only one of these proteins
(Simons et al., 1996). Therefore the ∆1S mutant may not be able to efficiently
bind either Ro60 or the nuclear factor, while ∆2S may be able to associate with
the nuclear protein more strongly, and this association is enough for transport into
the cytoplasm. Simons et. al. also hypothesized that degradation occurs in the
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nucleus and that, if Y RNA mutants are successfully transported to the cytoplasm,
they evade degradation (Simons et al., 1996), giving a plausible explanation for
the increased stability of ∆2S over ∆1S. We know that hY5 fragments are found
in apoptotic bodies after apoptosis-induction, but presumably this can only occur
if they can be exported from the nucleus. Only immunoprecipitation and cellular
localisation studies will categorically determine whether this hypothesis is correct,
although the ∆Ro mutant, which is missing the Ro60 binding site, appears to be
as stable, if not more stable, than the wild type RNA, suggesting that stability is
not reliant upon Ro60 binding. Perhaps it is only the stability of mouse-derived Y
RNAs that is reliant upon mRo60 binding and, as these mutants are derived from a
Y RNA which is not naturally produced in these cells, the degradation machinery
that targets Ro60-free mouse Y RNAs may not recognise these mutants.
From Dr. Hall’s experiments in MCF7 cells (Hall, 2013) it is not possible to
make a clear conclusion about the importance of Ro60 in ydRNA production from
hY5 RNA, as siRNA-mediated transient Ro60 knockdown and subsequent Poly(I:C)
treatment in these cells resulted in a reduced level of full length hY5 and therefore
also those ydRNAs derived from it. Using calculations of the ratios of full length
to ydRNA in each lane and comparing the siRNA-treated lanes with control lanes,
Dr. Hall concluded that Ro60 was required for cleavage (Hall, 2013). To further
explore the involvement of this protein, he went on to transiently transfect pWT
into mouse embryonic stem cells (mESCs) that were Ro60 -/- and then induced
apoptosis. Interestingly, the mouse Y RNAs levels were drastically reduced in the
Ro60 -/- cells, while the transfected hY5 levels were actually higher in the Ro60 -/-
cells compared to the Ro60 wild type cells. Comparison of the Poly(I:C) treated
Ro60 wild type and Ro60 -/- cells in these experiments highlighted that Ro60 is
certainly required for cleavage as there were no cleavage products present in the
Ro60 -/- cells. It seems likely that the increase in full length levels of hY5 in the
Ro60 -/- Poly(I:C)-treated cells compared to the Ro60 wild type Poly(I:C)-treated
cells arose because the full length RNA was not processed into ydRNAs in these cells.
It is somewhat puzzling that this exogenous Y RNA is unaffected by Ro60 absence,
while endogenous Y RNAs are degraded. It would be interesting to create a plasmid
containing one of the other hY RNAs and determine whether the same phenomenon
is seen on transfection into mouse cells. Perhaps this is an artifact resulting from
the production of an artificial RNA or perhaps hY5 RNA cannot function correctly
in a cell that does not naturally express it. During their investigations into Ro60
function, the Wolin group designed a number of Ro60 mutants to test its function in
Y RNA binding and ncRNA quality control (Stein et al., 2005). To further confirm
the involvement of this protein in cleavage, a number of these mutants could be
expressed in Ro60 -/- mESCs cells and analysed for cleavage ability.
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Unlike the deletion mutants, none of the nucleotide substitutions in the sub1S
or sub2S mutants adversely affected RNA stability. In fact the full length sub2S
mutant RNA was present at consistently higher levels than either the wild type
or the sub1S mutant RNA. The sub1S mutant, like the deletion mutants, did not
produce detectable 32 nt 3’ ydRNAs on apoptosis induction. Some sub2S molecules
however, appeared to be processed in a similar manner to the wild type, resulting
in a 32 nt ydRNA which was undetectable in the untreated lane and was present
at similar levels to the wild type-derived 32 nt ydRNA in the STS-treated lane.
What was unexpected was that this mutant RNA also appeared to be processed in
a novel manner to yield an apoptosis-independent ydRNA, as shown by the <32
nucleotide band which was detectable at similar levels in the untreated and STS-
treated sub2S lane. It is conceivable that this <32nt small RNA was produced in
the cells transfected with the wild type hY5 plasmid but was not at detectable levels
as a result of the lower level of full length wild type hY5, but this seems unlikely as
this ydRNA was not detected in any previous experiments and was not present in
the wild type lane of this experiment, even if the exposure was increased (data not
shown). It is possible that the full length sub2S RNA has been altered in such a way
that it was recognised as a primary microRNA, although this also seems unlikely
as the mutant RNA is not predicted to form the expected stem-loop structure of a
primary microRNA. However, this ydRNA is likely to be produced by a different
enzyme to the one we are investigating, as it is produced under different conditions.
The sub2S mutant was designed so that the ACC bulge was maintained and
the sequences on either side were substituted; Ro60 binding should therefore not
be affected. The fact that neither of the deletion mutants nor the sub1S mutant
produce cleavage products, while the Sub2S mutant does, suggests that it is the
secondary structure rather than the nucleotide sequence, within the region targeted
for mutation that is important for cleavage. As the 12 nt LNA probe did not
detect the full length ∆3’ end mutant RNA or any cleavage products, the three
nucleotides deleted in this mutant must be essential for the hybridization of this
probe. These nucleotides must therefore be present in all of the substitution mutant
ydRNAs detected with the 12 nt LNA probe, in order for this probe to hybridize
and produce a signal.
As the large bulge in region 2 is thought to be vital for Ro60 binding (Green et al.,
1998), a mutant (∆ACC) was designed where the ACC in the predicted bulge was
deleted. When this mutant was compared to the wild type no cleavage products were
detected. This is likely because Ro60 binding is crucial for cleavage to occur and
this mutation prevents this interaction. In experiments to validate the secondary
structure of Y RNAs, the large bulge was found to be nearer the terminal end of
the molecule than predicted here (van Gelder et al., 1994). We therefore cannot
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with complete confidence conclude that this mutation removes the large bulge, but
the striking effect of deleting these nucleotides suggests this to be the case. This
conclusion is supported by data from Dr. Hall, where the cleavage products are
absent when Ro60 is targeted for siRNA-knockdown (Hall, 2013). It is also possible
that another protein, such as the nuclear protein already mentioned, cannot interact
with the ∆ACC mutant, resulting in a lack of cleavage products. Either way we can
conclude that these three nucleotides are essential for cleavage.
The ∆3’ mutant could not be detected using the 12 nt LNA probe. The northern
blots that included this mutant were re-probed with a 10 nt LNA probe designed
further away from the 3’ end of the full length RNA, which therefore did not overlap
the deleted region. The new 10 nt LNA probe appeared to detect a similar band
pattern to the 12 nt LNA probe, although it was less sensitive. This time, however, it
also detected a full length RNA and a cleavage product in the ∆3’ STS-treated lane.
The <32 nt apoptosis-independent band was not visible using this probe, while it
was clearly visible when the same membranes are probed with the 12 nt LNA probe
(data not shown). As this probe is shorter than the previous LNA probe, this may
be due to a lower sensitivity under the same hybridization conditions, or this small
RNA may not be picked up by the new probe as it is missing nucleotides required for
hybridization. The 10 nt LNA probe was designed against a sequence which is more
conserved between Y RNAs than the sequence targeted by the 12 nt LNA probe,
which explains why there are a number of bands visible above the full length hY5
RNA band; these are mouse Y RNAs. As there are no small RNA bands present in
any of the control lanes, we can be sure that all ydRNAs detected on these northerns
are Y5 RNA-derived. The full length ∆3’ mutant RNA is present at even higher
levels than the full length sub2S mutant, which explains why a ydRNA is present at
low levels in the ∆3’ untreated lane, and a ydRNA is present in the ∆3’ STS-treated
lane at higher levels than in the wild type STS-treated lane. This mutant ydRNA
is noticeably smaller than the wild type 32 nt ydRNA and this could be for two
possible reasons. Firstly, the enzymes involved in cleavage could cut the RNA at a
particular site and therefore a 3 nt deletion close to the end of the RNA resulted in
a shorter product. The second possibility is that proteins were protecting the RNA
and, despite the fact that three nucleotides were missing between where Ro60 and
La bind, the rest of the RNA was protected in the same way and the RNA was still
cut at the same position. Immunoprecipitation experiments are required to be sure
that both Ro60 and La still interact with this mutant and to determine whether it
is shorter because protein binding has been lost.
There are two possible hypotheses to explain how apoptosis-dependent Y RNA
cleavage occurs. In the first hypothesis, RNA binding proteins interact with each Y
RNA in regions 1, 2 and 3 and protect the RNA from degradation. An endonuclease
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nicks the RNA somewhere at an internal nucleotide, and then exonucleases degrade
the regions of the RNA that are not protected, including the 3’ part of the RNA.
These proteins include, but are not exclusively, Ro60 and La. The smaller hY5 3’
ydRNA is likely to result from the release of La from the 32 nt ydRNA, as this lower
band is up-regulated when La is targeted for siRNA-knockdown (Hall, 2013). Nu-
merous groups have used RNase protection assays and electromobility shift assays
to determine the regions bound by Ro60, and these regions do not fully encom-
pass the RNA sequences present in the detected apoptosis-dependent ydRNAs (van
Gelder et al., 1994; Teunissen et al., 2000). It is possible that Ro60 interacts with
these RNAs differently in vivo compared to in vitro and this could explain these
discrepancies, but it seems more likely that other proteins are involved. These other
proteins may bind to Y RNAs directly, or they may protect Y RNAs by interacting
with Ro60. These questions could be answered by conducting RNA immunopre-
cipitation experiments and determining the proteins present in complexes with Y
RNAs, both in untreated cells and in apoptosis-induced cells. If the protein pro-
tection theory is correct, then this raises another possible senario to explain the
accumulation of cleavage products. The cleavage rate may be unaltered between
apoptotic and untreated cells, but more proteins may bind to Y RNAs during apop-
tosis than under normal circumstances. The ydRNAs may therefore accumulate as
more are protected from exnouclease digestion than under normal circumstances.
In the second hypothesis a cleavage complex binds to the Y RNA and this complex
includes an endonuclease. This endonuclease cuts the RNA in a particular position
to produce a cleavage fragment. The fragment is stable, while the rest of the RNA is
targeted for degradation. Perhaps the fragment is rapidly incorporated into a func-
tional protein complex and is therefore protected from further degradation. Data
obtained by Dr. Hall support the second hypothesis, as the hY5 3’ end fragment
is present at three times higher levels than the hY5 5’ end fragment (unpublished
data). If both fragments exist as they are protected from degradation by Y RNA
binding proteins, then it seems unlikely that one fragment would be present at levels
so much higher than the other. Mapping of the predominant 3’ and 5’ fragments
onto the hY5 RNA secondary structure also indicates that these fragments are un-
likely to be the result of Y RNA binding protein protection, as the cleavage positions
of these two fragments are on very different regions of the RNA. It seems likely that
the RNA secondary structure would be partially unwound after the initial cut, and
this is how the cleavage sites occur at such different locations on each of these hY5
ends. It is unlikely that these cleavages could occur without some reorganisation of
the proteins that are bound.
Follow up experiments to these inital studies must involve Ro60 binding assays
in order to more closely determine the role of Ro60 in these cleavage events. When
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these binding assays are analyzed it will be important to take into account that Ro60
has two binding surfaces for RNAs. In X-ray crystallography experiments Y RNAs
were found to bind on the outer surface of this protein (Stein et al., 2005), but Y
RNA fragments were also found to bind inside the Ro60 ring. A positive result in a
Ro60 binding assay does not therefore tell us where these mutant RNAs and mutant
RNA fragments are binding and how they are being recognised. It is possible that
the 3’ end fragment is more abundant than the 5’ fragment as it interacts with Ro60
inside the ring, while the 5’ end is released. So far, whether any of the 3’ and 5’
fragments remain bound to each other has not been investigated.
Figure 3.21: Secondary structure of human Y RNAs determined by a combination
of prediction and experimental validation.
Reproduced from Teunissen et al. 2000.
Initial NGS experiments comparing untreated MCF7 cells to cells treated with
Poly(I:C) for 8 hours, showed that after this treatment all hY RNAs were cleaved to
produce 3’ and 5’ fragments. Findings by Rutjes et al. in 1999 corroborate our NGS
data, as they found that all hY RNAs were processed to give cleavage products after
the induction of apoptosis. We have shown that, after 8 hours of Poly(I:C) treat-
ment, DLD-1 cells were undergoing apoptosis, and that the hY5 RNA was cleaved.
From our initial sequencing data in MCF7 cells, we determined that the predomi-
nant sizes of the hY5 fragments were 32 and 24 nt and the fragment sizes of the other
Y RNAs were 18-32 nucleotides (Hall, 2013). The method Rutjes et. al. used for
examining Y RNA fragments was high resolution PAGE whereupon fragments that
108
differ by 1 nt in size can be separated (Rutjes et al., 1999b). Their method involved
probing for all of the hY RNAs at once and used four oligonucleotides antisense
to the entire length of each of the hY RNAs as probes, so each gel represents all
fragments for each of the four hY RNAs combined (Rutjes et al., 1999b). Dr. Hall’s
data determined that a number of the hY RNAs produce fragments predominantly
of a size between 30-32nt and 27nt (Hall, 2013), although like hY5 it is possible
that these are further processed into smaller fragments that are less abundant or
are present at higher levels during different treatment conditions. Comparison of
his data with that of Rutjes suggests that the larger band they see on their sizing
gels was made up mainly of the 5’ fragments of hY1, hY3 and hY5, which were all
around 31-32nt (Rutjes et al., 1999b). We have reached the same conclusion, but
due to the length of the sequence reads in the initial NGS dataset and the adapter
removal method, we cannot be sure of the accuracy of this sizing and are awaiting
sequencing data with longer reads to confirm this (See Chapter 5).
RNA immunoprecipitation experiments carried out by this group support our data
as, without sequence information and solely going on size, they determined that the
longer fragments bind to both Ro60 and La and that the shorter fragments do not
bind to La (Rutjes et al., 1999b). They suggest that this might be because the
shorter fragments have lost the terminal uracils (Rutjes et al., 1999b). This theory
is supported by our hY5 data, as the 32 nt fragment contains the La binding site, but
the shorter fragment that is produced later does not. In the other hY RNAs the run
of Us recognised by La is closer to the end than in hY5, which makes it more likely
that a mixed population of 3’ fragments exist that do or do not contain the terminal
uracils and therefore some can and some cannot bind to La. La siRNA experiments
conducted by Dr. Hall, as previously discussed, resulted in an increase in the ratio
of the 24 nt ydRNA compared to the 32 nt ydRNA (Hall, 2013), suggesting that the
shorter one is derived from the larger one after La protein release.
One discrepancy between our data and that of Rutjes is that they found that a
31nt fragment did not interact with La (Rutjes et al., 1999b). It is possible that
this fragment had lost enough of the La binding site that it could no longer stably
interact with La. This fragment is unlikely to be derived from hY5, as a hY5-derived
31 nt fragment would still contain three uracils at the 3’ end. It is possible that the
31 nt fragment they investigated was the predominant hY5 RNA 5’ fragment and
it did not bind to La as it was no longer bound to its complementary 3’ fragment.
More experiments need to be done to examine the protein binding of each of these
fragments individually to determine whether they are likely to be functional.
Figure 3.21 shows the secondary structures of human Y RNAs deduced by com-
bining secondary structure predictions and experimental data. When designing
the deletion and substitution mutants tested here, the lower or terminal stem was
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maintained where possible (this terminal stem is shown at the top of the secondary
structures predicted by both RNAfold and Mfold, as the structure has been inverted
by the prediction program). The sequence of the larger bulge does not seem to be
conserved, but the bulge itself is present in the majority of mammalian Y RNAs,
suggesting that it is required for the function of these Y RNAs (Maraia et al., 1996).
Determining whether the deletion mutants, along with sub1S and ∆ACC, bind to
Ro60 in immunoprecipitation experiments should provide more evidence as to the
importance of this bulge in Ro60 binding, and therefore potentially strengthen our
conclusion that Ro60 is essential for apoptosis-induced cleavage of this RNA.
When considering the presence or absence of cleavage products from the mutants
compared to the wild type we must bear in mind that there may be other nucleases
involved. We know that these hY5 ydRNAs are present at low levels in untreated
cells, but that their levels are dramatically up-regulated after Poly(I:C) induction.
We cannot assume that this increase in levels is the result of the increased targeting
of the full length Y RNAs by a processing enzyme. It is also equally feasible that,
in untreated cells, these small RNAs are produced and are then immediately tar-
geted and rapidly degraded by an exonuclease. If this scenario is correct, then this
exonuclease could be down-regulated or re-distributed during apoptosis, resulting in
the accumulation of these ydRNAs. It does however, seem far more likely that the
majority of the mutants tested are not cleaved because of a block in Ro60 binding,
rather than ydRNAs being produced and degraded by a different nuclease to that
which processes the wild type RNA.
So far we have intensely speculated on what is required for the processing of Y
RNAs, hY5 in particular. We have discussed numerous possible models for how
cleavage occurs, but we have not discussed the possible reasons for this cleavage.
Y RNAs interact with many proteins in human cells, both blocking and assisting
with the interaction of these proteins with RNAs and with other proteins. These Y
RNA-protein interactions can alter function and/or localisation within the cell. As a
defining function for these Y RNAs alone has not been identified, their potential roles
during apoptosis appear endless. Work by our group indicates that these ydRNAs do
not act as microRNAs as they do not associate with any of the microRNA processing
machinery or the RISC complex (Nicolas et al., 2012), but further analysis of the
function of these ydRNAs has been hampered by the fact that we cannot separate
them from the full length RNAs they are derived from. Another group of small
RNA researchers has potentially found a way of artificially processing full length Y
RNAs to leave only the ydRNAs (Meister et al. unpublished data), if this is the
case then this should aid the investigation of the function of these fragments.
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4 HIGH-THROUGHPUT hY5 RNA
MUTAGENESIS
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4.1 INTRODUCTION
In the last chapter a number of different hY5 mutant plasmids were generated and
tested. The expression of each mutant RNA provided different information on the
requirements for cleavage to produce ydRNAs. Although each mutant was infor-
mative, the process of designing, synthesizing and testing the mutants was lengthy
and this limits the usefulness of this method. Northern blotting is a low-throughput
method that can take several weeks to produce results and only provides information
on a few mutants at a time. NGS is a technique that can be utilized to examine
millions of sRNAs at a time and has the potential to be much more informative than
northern blotting.
Figure 4.1: Schematic diagram of an individual pool of mutant oligonucleotides.
Oligonucleotide primers were synthesized by IDT and incorporated into
each mutant plasmid pool.
4.1.1 Methodology
A high-throughput method of mutant generation was designed where a five-nucleotide
region of the hY5 RNA was mutated. Instead of testing a few mutants at a time,
pools were prepared that contained every possible nucleotide combination at each
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of these five positions (Figure 4.1). Three different pools of mutants were produced.
Between one pool and the next, the position of the mutated nucleotides was moved
sequentially along the DNA molecule (Figure 4.2). This was achieved by the syn-
thesis of long primers containing degenerate nucleotides at each of the five positions.
The degenerate nucleotides were hand-mixed by the company undertaking the syn-
thesis. This ensured, as accurately as possible, that each different nucleotide would
be present at each of the five positions 25% of the time. Each pool was repre-
sented by three different biological replicates, prepared separately right from the
PCR stage.
The primer mixes were used as reverse primers and were combined with the hY5
wild type forward primer to PCR amplify the hY5 region, including promoter and
terminator sequences (Figure 4.2). Initially, the PCR products were purified and
transfected directly into mouse NIH/3T3 cells, but no hY5 RNA could be detected
in these cells. Using an alternative method, the PCR products were ligated into
the pGEM-T Easy plasmid and transformed into bacteria. If all four possible nu-
cleotides were present in each of the five positions in each pool, this would give 1024
unique plasmid sequences per pool. Dr. Irina Mohorianu (a statistician linked to
the Dalmay laboratory) calculated that, in order for each of the 1024 sequences to
be represented within a pool at a probability of 99%, after transformation we would
need more than 4850 positive bacterial colonies to be harvested per pool. The num-
ber of LB agar plates prepared for each replicate ensured that over this number of
positive colonies were harvested, often the number of colonies harvested was close to
double the number required. The plasmids were then purified and transfected into
NIH/3T3 cells according to the conditions used for single mutant plasmid transfec-
tion. The cells were treated with STS for 4 hours prior to harvesting to increase the
rate of Y RNA cleavage. Upon harvesting, total RNA was extracted and used to
create a number of different types of library (Figure 4.3).
A novel method of generating cDNA libraries from sRNAs for NGS has been
developed, in the Dalmay laboratory, by Dr. Karim Sorefan (Sorefan et al., 2012).
This method has the advantage over the current Illumina method, as it overcomes
the inherent preference of the ligase enzyme for particular adapter-RNA-adapter
sequences (Sorefan et al., 2012). If the abundance of different sequences in a library
are to be accurately compared to each other, overcoming this preference is vital. This
novel sequencing method, here referred to as the ’HD’ method, was integral in the
sRNA libraries prepared in this chapter. sRNA libraries were prepared to determine
which of the full length mutant hY5 sequences expressed in mutant cells underwent
apoptosis-dependent cleavage to produce ydRNAs. In the low-level mutagenesis
experiments in Chapter 3, the full length mutant RNAs were not always expressed
at the same levels as the wild type full length hY5 RNA (see Figures 3.16 & 3.14).
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Full length ∆1S was consistently lower in concentration than the wild type full
length hY5, even in different experiments using different plasmid preparations. It
seems likely that the mutation within the ∆1S plasmid sequence adversely affected
levels of the full length ∆1S RNA, resulting in a lower rate of transcription or a lower
stability after transcription. For the mutant pools, if a mutant sequence was not
detected in the sRNA population, this could be as a result of a lack of cleavage, but it
may also be explained by low levels of the full-length RNA that mutant ydRNA was
derived from. Creating full-length RNA libraries from the same total RNA samples
used for the sRNA libraries should enable us to account for any differences in the
concentrations of each full-length mutant RNA, providing a potential explanation
for some of the sRNA sequences differentially expressed when compared to the wild
type sequence. For this reason, total RNA was also used to prepare libraries where
the full length hY5 mutants were amplified.
By transfecting cells with PCR products, the levels of one mutant construct being
higher than the other would have been minimized. As this method of RNA expres-
sion was unsuccessful, cloning of the PCR products into plasmids and transfection of
the resulting plasmids was the only option. Due to the efficiency of ligation and the
differences in the grown of the bacterial cells transformed with the resulting positive
plasmids, inherent increases in certain sequences would be introduced during the
cloning process. To take into account these differences and correct for them, a small
amount of each plasmid pool was retained and plasmid bias libraries were prepared
from these samples. This would enable us to determine which mutant sequences
were over- or under-represented in the plasmid pools.
4.1.2 Library preparation
Briefly, 2 µg of total RNA was used in 3’ ‘HD’ adapter ligations (Sorefan et al.,
2012) (Figure 4.4). These samples were separated using denaturing PAGE and the
region containing the 30mers, including the ydRNAs, was excised and purified. The
resulting samples were then ligated to the 5’ Illumina small RNA adapter and used as
a template for cDNA synthesis. cDNA was then amplified using PCR and separated
by PAGE. The 30mer inset-containing region was excised and purified from the gel.
The same sized band was gel purified for a second time to eliminate adapter-adapter
sequences, and sent to BaseClear for sequencing.
STS treatment, while enhancing the rate of Y RNA cleavage, also increases the
cleavage rates of many other ncRNA, if this occurred during these experiments it
would dilute the hY5 mutant sequences in the NGS dataset. To overcome this
problem, an enrichment was included in the PCR amplification stage of the library
preparation. The 5’ end of the wild type ydRNA of interest contains 5 C residues.
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Figure 4.2: Schematic diagram detailing the initial PCR of the hY5 sequence.
The wild type hY5 forward primer and the pool of reverse primers were
used in the amplification.
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The positions of the mutated nucleotides in each of the three different pools were
chosen so that the four 5’-most Cs were kept intact. To increase the amplification
of the ydRNAs, the Illumina RP1 forward primer, used at the PCR stage, was
extended to include five extra nucleotides of the 5’ adapter sequence and the 3 Cs
from the 5’ end of the ydRNAs. The amplification of other sequences with 3 Cs at
the 5’ end of a similar size was expected, and also necessary to introduce enough
heterogeneity into the samples for the products to spread adequately across the glass
plate during sequencing.
For full length library preparation, the total RNA sample was DNase-treated
to remove contaminating DNA (Figure 4.4). An RNA-specific primer was used
to reverse-transcribe only hY5-related sequences. These cDNAs were then PCR
amplified using the FL round 1 primers, which were designed only to target the full
length sequences and not any Y5 degradation products. In this first round PCR some
of the sequences required for NGS were added to both ends of the cDNA. Products
of the correct size were gel extracted and, in a final round of PCR, the standard
Illumina Truseq sRNA kit primers were used to add the rest of the sequences required
for NGS onto the ends of each of the products. The samples were then gel extracted
for a final time.
As for the full length libraries, plasmid bias library preparation entailed two
rounds of PCR amplification to add sequences required for NGS sequencing to the
PCR products. Custom primers were used for the first round PCR and the primers
from the Illumina Truseq sRNA kit were used for the second round PCR. Samples
were gel extracted between PCRs and following the final PCR reaction to purify
and concentrate the products.
4.1.3 Aims
The first aim of this chapter was to see if the ‘HD’ NGS technique could be utilized
to generate a more high-throughput method of hY5 mutant generation and analy-
sis. The second and ultimate aim being to gain more information on hY5 cleavage
requirements. Our hypothesis is that the wild type RNA has the optimal level of
cleavage and that the mutants where no cleavage occurs have sequences which more
dramatically alter the structure of the RNA within a region important for the bind-
ing of proteins or nucleic acids important in the cleavage process. It will only be a
combined analysis of all of the mutants together that will allow us to narrow down
the region important for cleavage and to give us some indication of RNA structure
or particular sequence motifs which may be important for this cleavage to occur.
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4.2 Results
For amplification of the hY5 sequence to produce the plasmid pools, the PCR was
initially tested on a truncated version of the pWT plasmid, which was missing the
last 30 nucleotides of the hY5 RNA-encoding region and the downstream regulatory
sequence. Unfortunately, using this truncated version of the hY5 plasmid in the
PCR amplification did not produce PCR products at the concentration required for
ligation, presumably as a result of limited annealing of the primer to this truncated
plasmid. For this reason the pWT plasmid was used as a PCR template.
For each plasmid pool, three replicates were prepared and the appropriate number
of plates were used to produce at least 4850 different white colonies of transformed
DH5α or XL2 Blue E. Coli cells for each replicate. Instead of selecting positive
colonies from each bacterial plate, the positive colonies on each plate were counted
and all colonies on a plate were harvested together, including the negative colonies.
A number of plates were pooled together to produce each replicate. Several plates
were processed in one midiprep reaction, before concentrating by ethanol precipi-
tation, further pooling of samples, and transfection into NIH/3T3 cells. 50 ng of
each plasmid pool was set aside and used to assess plasmid bias. For each different
plasmid pool, 5 µg of each replicate plasmid sample was transfected into a different
T75cm2 flask. The amount of plasmid transfected was reduced in relation to the
single mutagenesis experiments as the plasmid pools appeared to have a higher level
of toxicity to the cells than when a single plasmid alone was transfected, possibly
as a result of the mixture of plasmids present within each pool.
24 hours after transfection, cells were treated with STS for 4 hours and harvested
in TRIreagent. After RNA extraction each of the samples was split into two tubes
and the RNA in one of the tubes was DNase treated to remove contaminating DNA.
3 µg of this RNA was used for northern blot analysis, to gauge the success of the
transfections and to determine the level of the full length Y5 mutants and ydR-
NAs in each sample, compared to controls of known concentration. RNA from the
cells transfected with the first replicate of each pool was analyzed (Figure 4.5). All
plasmid pool samples showed clear expression of full length Y RNA and ydRNA
products. The sample from the first replicate of pool 3 had the highest expression
levels of full length Y5 RNA. Interestingly, the sizes of the ydRNAs produced from
each of the different pools appears to vary, with pool 1 producing the longest ydR-
NAs. The ydRNAs from samples transfected with pools 2 and 3 may also be slightly
different in size, with pool 3 producing slightly shorter ydRNAs than pool 2.
All of the full length RNAs are as abundant, if not more abundant, than the
weakest control oligonucleotide, which was at 5 femtomoles per well. As 3 µg of
total RNA from each of the plasmid pool-transfected samples was loaded into each
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well, the full length plasmids are present at approximately 1.67 femtomoles per µg,
which is over 1 million molecules per µg.
Figure 4.5: Mutant pool expression in NIH/3T3 pools.
(A) 3 µg of total RNA prepared from cells transfected with the first
replicate of each of the mutant plasmid pools was used for northern blot
analysis. In lanes 5-9 the ∆2S R oligo was loaded at different concentra-
tions, to act as a control for size and concentration. The membrane was
probed with the 12 nt hY5-specific LNA probe, which should detect all
mutant Y5 RNAs.
The first tube of each total RNA sample was used for full length library prepara-
tion. PCR amplification was achieved by two rounds of PCR and PAGE purification
(Figure 4.4). A clear band of the correct size was seen after each PCR reaction and
was intense enough to be easily cut from the gel and precipitated (see Figure 4.6).
After the final gel extraction, one tenth of the volume of each sample was quantified
by PAGE and all were deemed to be of high enough concentration to be sequenced
by NGS.
The second tubes were used to prepare sRNA libraries. Samples were ligated
to a 3’ and then a 5’ adapter, before cDNA synthesis and PCR amplification. A
clear band was visible on the gel, below the 100 nucleotide marker. This band
corresponds to the 30-35 nucleotide sRNAs known to be present after Poly(I:C)
treatment [Figure 4.7 (A)]. A band was also visible at 24 nucleotides, as was a band
lower down on the gel, which is most likely made up of adapter-adapter sequences.
The 30mer band was cut from the gel and purified according to the Illumina protocol.
A second gel purification showed a stronger 32 nucleotide product and weaker 24
nucleotide product [Figure 4.7 (B)]. It also showed that the adapter-adapter products
were dramatically reduced in these samples compared to those after the first gel
extraction. In a final test, and to enable calculation of the approximate volume of
each sample to pool with the other sRNA library samples, a third PAGE gel was run
containing one tenth of the total volume of sample [Figure 4.7 (C)]. On completing
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Figure 4.6: cDNA library preparation of full length hY5 mutant RNAs.
Libraries were prepared as in [Figure 4.4 (A)]. (A) Gel separation af-
ter first round PCR amplification (B) Gel separation after second round
PCR amplification (C) Final size confirmation gel prior to sample pro-
cessing. FL - full length.
this analysis, the sRNA library samples were deemed to be of high enough quality
and quantity to be analyzed using the Illumina truseq NGS method.
Plasmid bias sample libraries were prepared using 50 ng of each replicate plasmid
pool. Samples were separated using PAGE after each round of PCR and a final
PAGE gel was used to confirm that they were the correct size and concentration for
sequencing (Figure 4.8). A strong band of the correct size was seen on all of the
PAGE gels and the samples were deemed suitable for NGS. Due to a complication
of the requirements for heterogenity in sequencing samples, there was a delay in the
sequencing of the plasmid bias and full length control libraries, so these have not
yet been analyzed.
4.2.1 sRNA library results
The ‘HD’ adapter sequence was removed from the 3’ end of each sequence read
by removing the 8 nucleotide standard adapter sequence and the preceeding by
4 degenerate nucleotides. Correlation and MA plots were used to compare the 3
replicate samples transfected with each plasmid pool (Figures 4.9, 4.10, & 4.11)
and the outlier replicate was removed from each analysis. Figure 4.12 shows the
correlation plots comparing the two remaining replicates for each mutant pool. The
sequences from the remaining replicates were mapped to the mouse genome and to
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Figure 4.7: cDNA library preparation of mutant ydRNAs.
Libraries were prepared as in [Figure 4.4 (B)]. (A) Gel separation after
enrichment PCR amplification (B) Gel separation after first gel extrac-
tion (C) Final size confirmation gel prior to sample processing.
Figure 4.8: Plasmid bias library preparation of mutant plasmid replicates.
50 ng of plasmid DNA was amplified in two rounds of PCR and gel ex-
traction. A) Gel separation after first round PCR amplification (B) Gel
separation after second round PCR amplification (C) Final size confir-
mation gel prior to sample processing. PB - plasmid bias.
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a set of hY5 mutant reference sequences. These mutant reference sequences were
created by removing the region targeted for mutagenesis from the wild type hY5
sequence, and replacing it with all of the possible mutations within that region. A
set of reference sequences was created for each separate mutant pool.
Figure 4.9: Correlation and MA plots for plasmid pool 1 replicates.
These plots show that the third replicate is the least similar of the
three, so this replicate was removed from the analysis (Plots prepared
by Matthew Beckers).
Table 4.1 details the redundant reads of each replicate mapping to the mouse
genome and those mapping to the reference hY5 sequence set. Table 4.2 shows the
non-redundant reads of each replicate mapping to the mouse genome and to the hY5
sequences. 12-25% of the reads map to the mouse genome and between 3-6% map
to hY5. The removed replicates are MP1 R3, MP2 R1, and MP3 R2. Tables 4.1
and 4.2 show that these replicates are the least similar to the other two replicates
for that library.
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Figure 4.10: Correlation and MA plots for plasmid pool 2 replicates.
These plots show that the first replicate is the least similar of the three,
so this replicate was removed from the analysis (Plots prepared by
Matthew Beckers).
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Figure 4.11: Correlation and MA plots for plasmid pool 3 replicates.
These plots show that the second replicate is the least similar of the
three, so this replicate was removed from the analysis (Plots prepared
by Matthew Beckers).
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Figure 4.12: Correlation plots of included replicates.
Each of the two replicates for each library was compared against the
other to determine similarity (Plots prepared by Matthew Beckers).
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MP and rep Total Reads hY5 % hY5 Mouse genome % Mouse genome
MP1 R1 2823676 43169 1.53 1629839 57.72
MP1 R2 3002246 52761 1.76 1764092 58.76
MP1 R3 2182559 32941 1.51 1289863 59.1
MP2 R1 4884128 73091 1.5 2936298 60.12
MP2 R2 2525008 84626 3.35 1513646 59.95
MP2 R3 24444252 83252 3.41 1380416 56.48
MP3 R1 1367354 108133 7.91 749813 54.84
MP3 R2 3546754 398831 11.24 1782200 50.25
MP3 R3 1061010 65785 6.2 575316 54.22
Table 4.1: Redundant reads mapping to hY5 and the mouse genome.
This table summarizes the redundant reads of each replicate (R) and each
mutant pool (MP) mapping to the mouse genome and mapping to the
hY5 mutant reference sequences (Data provided by Matthew Beckers).
MP and rep Total Reads hY5 % hY5 Mouse genome % Mouse genome
MP1 R1 78087 2702 3.46 19768 25.32
MP1 R2 77896 2655 3.41 20021 25.7
MP1 R3 60648 2103 3.47 15149 24.98
MP2 R1 57217 1450 2.53 10271 17.95
MP2 R2 50032 2294 4.59 10230 20.45
MP2 R3 39765 1738 4.37 7025 17.67
MP3 R1 31809 2036 6.4 4997 15.71
MP3 R2 54325 2824 5.2 6996 12.88
MP3 R3 28082 1698 6.05 4754 16.93
Table 4.2: Non-redundant reads mapping to hY5 and the mouse genome.
This table summarizes the non-redundant reads of each replicate (R) and
each mutant pool (MP) mapping to the mouse genome and mapping to
the hY5 mutant reference sequences (Data provided by Matthew Beckers).
126
Figure 4.13 shows both the size and abundance of the reads mapping to the mouse
genome. Notably there is a peak at 19 nucleotides, along with the peak of around
31 nucleotides. This suggests that mouse cells may also have an abundant 30mer
class of sRNAs after apoptosis treatment. On investigation of the mouse-derived 19
nucleotide sequences present in this dataset, this peak was found to comprise mainly
of two highly abundant sequences mapping to three places in the genome. Both
sequences map to microRNAs, one of which is encoded in two different locations in
the genome. The significance of these sequences in dataset is currently unclear.
It is surprising that such a high 19 nucleotide peak would be present in the data,
as only a region of approximately 32 nucleotides was cut from the gel during library
preparation. These sequences are likely to have a much higher read count in the
total RNA samples than that seen in this dataset, where the majority of sRNAs of
this size have been removed. Mapping of the 19 nucleotide reads to both of these
miRNAs shows that the boundaries of the sequencing reads are distinct and are the
same in all of the libraries (Figure 4.14).
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Figure 4.13: Length and abundance of redundant reads mapping to the mouse
genome.
The different colors represent the different plasmid pools (Graph pre-
pared by Matthew Beckers).
Figure 4.15 displays the hY5 mapping reads in the dataset. The graph shows
that the size of the mutant pool 1 sRNA reads is mainly 32 nucleotides, but that for
mutant pools 2 and 3 the sRNAs are mainly 30/31 nucleotides. It should be noted
that the reads displayed are those as a direct result of sequencing, so the actual
ydRNAs are likely to be 3 nucleotides longer than the reads displayed here.
As well as examining the ydRNAs by size, they were also plotted by start position
(Figure 4.16). The distribution of peaks for mutant pools 2 and 3 is quite different
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Figure 4.14: Mapping the two highly abundant miRNAs to the mouse genome.
miR-99b accounted for 72.1% of the 19mer reads, while miR-125b ac-
counted for 25.5% of the 19mer reads. (Graph prepared by Matthew
Beckers).
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Figure 4.15: The length and abundance of redundant reads mapping to hY5.
Reads were mapped to the hY5 mutant reference sequences. The dif-
ferent colors represent the different plasmid pools (Graph prepared by
Matthew Beckers).
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to the distribution for pool 1. For pools 2 and 3 the vast majority of sequences start
at two discrete positions, with very little variation. This suggests that the majority
of the cleavages to produce the reads detected from these pools occur between T49
and C50 or C50 and C51. This mirrors the main cleavage point seen in endogenous
hY5 after Poly(I:C) treatment of human MCF7 cells, which occurs between C50 and
C51. In the mutant pool 1 sRNA libraries, the start point of the sequencing reads is
less well defined, with the majority of the reads spread over 3 positions. The highest
peak is at position C51, which indicates that the majority of the cleavage events
occurs between C48 and T49.
Rank Rep 1 Rep 2
1 ACCGC ACGTC
2 ACGTC CACAC
3 ACTTC ACCGC
4 CCACG ATGGC
5 ATGGC ACACC
6 CACAC ACTGC
Mutant pool 1
Rank Rep 1 Rep 2
1 CCGTT ACGTC
2 ATCGT CCGTC
3 TCGTC CCGTT
4 ACGTC CTGTC
5 ACTCT ACTCT
6 CCGTC CGTTG
Mutant pool 2
Rank Rep 1 Rep 2
1 GTTTG CGTCG
2 TGTAG GTTTG
3 GATTG GTTCG
4 TGTCG TGTAG
5 CGTTG TGTCG
6 GTTCG GTTAG
Mutant pool 3
Table 4.3: Mutations sorted by abundance for each retained replicate (Rep).
The mutant ydRNA sequences were ranked in order of abundance for both repli-
cates from each mutant pool. Table 4.3 displays the top 6 reads mapping to each
replicate of a mutant pool, while Table 4.4 displays the top 6 reads mapping to
both replicates combined. These tables show that the most abundant ydRNAs were
detected at high levels in this dataset, highlighting the power of this technique when
combined with NGS. When the top reads for each mutant pool are closely examined
and the probabilities predicted and displayed in sequence logos, a preference for
certain nucleotides can be seen at each position. This preference does not seem to
correlate with the nucleotide present at that position in the wild type hY5 sequence.
In the second mutant pool samples there is less of a preference at the first nucleotide,
but for the rest of the sequence there is a preference for CGTC (Figure 4.17), while
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in the third mutant pool samples there is a strong preference for (Figure 4.18) the
sequence CTTTG. For mutant pool 1 the sequence reads were divided by start posi-
tion and abundance plots and sequence logos were generated (Figures 4.21 to 4.26).
These plots show that there is a different pattern of cleavage depending upon the
mutant sequences present at each position (this will be explained in further detail
later).
Mutation Rep 1 Rep 2 Total
ACGTC 699 700 1399
ACCGC 700 698 1398
CACAC 695 699 1394
ATGGC 696 697 1393
ACTGC 692 695 1387
ACCTC 693 691 1384
Mutant pool 1
Mutation Rep 1 Rep 2 Total
CCGTT 700 698 1398
ACGTC 697 700 1397
CCGTC 695 699 1394
ACTCT 696 696 1392
CTGTC 691 697 1388
CGATC 693 691 1384
Mutant pool 2
Mutation Rep 1 Rep 2 Total
GTTTG 550 549 1099
TGTAG 549 547 1096
GTTCG 545 548 1093
TGTCG 547 546 1093
GATTG 548 544 1092
CGTCG 539 550 1089
Mutant pool 3
Table 4.4: Ranked abundant mutations for each pool.
The most abundant mutations for each pool after the rankings for each
replicate have been combined.
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Figure 4.16: The abundance and start position of all of the ydRNAs mapping to Y5.
The mean count at each position for each plasmid pool is displayed. The
different colors represent the different plasmid pools (Graph prepared
by Matthew Beckers).
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Figure 4.17: Sequence logos for mutant pool 2.
The sequence logos showing the probability of finding each nucleotide
at each position within the mutation site for pool 2. This was calcu-
lated for each read start position using all of the abundant sequence
reads, after both replicates had been combined (generated by Matthew
Beckers).
1 2 3 4 5
Position
0
0.2
0.4
0.6
0.8
1
Pr
ob
ab
ilit
y
Mutant pool 3 start position 53
1 2 3 4 5
Position
0
0.2
0.4
0.6
0.8
1
Pr
ob
ab
ilit
y
Mutant pool 3 start position 54
Figure 4.18: Sequence logos for mutant pool 3.
The sequence logos showing the probability of finding each nucleotide
at each position within the mutation site for pool 3. This was calcu-
lated for each read start position using all of the abundant sequence
reads, after both replicates had been combined (generated by Matthew
Beckers).
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Figure 4.21: The ordered abundance of the mutant pool 1 ydRNAs starting at C52
(Graph prepared by Matthew Beckers).
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Figure 4.22: The ordered abundance of the mutant pool 1 ydRNAs starting at C53
(Graph prepared by Matthew Beckers).
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Figure 4.23: The ordered abundance of the mutant pool 1 ydRNAs starting at C54
(Graph prepared by Matthew Beckers).
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Figure 4.24: Sequence logos for mutant pool 1.
The sequence logos showing the probability of finding each nucleotide at
each position within the mutation site for pool 1. This was calculated
for read start position C52 all of the abundant sequence reads, after
both replicates had been combined (generated by Matthew Beckers).
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Figure 4.25: Sequence logos for mutant pool 1.
The sequence logos showing the probability of finding each nucleotide
at each position within the mutation site for pool 1. This was calcu-
lated for read start position C53 using all of the abundant sequence
reads, after both replicates had been combined (generated by Matthew
Beckers).
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Figure 4.26: Sequence logos for mutant pool 1.
The sequence logos showing the probability of finding each nucleotide at
each position within the mutation site for pool 1. This was calculated
for read start position C54 using all of the abundant sequence reads
(generated by Matthew Beckers).
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4.3 Discussion
Analysis of hY5 mutant full length and ydRNA levels in the NIH/3T3 cells trans-
fected with each of the mutant pools showed detectable levels of both in all samples
(Figure 4.5). With approximately a million full length Y5 mutant molecules per µg
of total RNA, assuming that the ydRNAs are present at approximately ten times
lower levels, each of the different ydRNA mutants would be expected to be present at
an average of 975 copies per µg, giving a good chance of detection by next generation
sequencing with an enrichment for 5’ CCC sequences.
Figure 4.29: ydRNA generation is Ro60-dependent.
Wild type (wt) and Ro60−/− mouse embryonic stem cells (mES) were
transfected with a wild type hY5 expressing plasmid (labeled here pY5)
and treated with Poly(I:C) [P(I:C)]. Figure reproduced from Dr. Hall’s
thesis (Hall, 2013).
Surprisingly, there appears to be a size difference between the ydRNAs produced
from each of the mutant pools. The mutant pool 1 ydRNAs appear resolved more
slowly than those of the other two pools. It is also possible that the ydRNAs from
mutant pool 2 resolved slightly more slowly than those of mutant pool 3, but this
is less clear in this figure (Figure 4.5). The interpretation of any size difference is
complicated by the position of the samples on the gel, as this size difference could
be the result of smiling of the gel, where the samples at the edge of the gel resolve
more slowly than those closer to the middle. This does not seem to be the case for
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this gel, as the oligonucleotides loaded in the lanes on the right of the gel are all
present at the same position. It is not possible to tell whether there is also a size
difference between full length RNAs produced from these mutant pools, as RNAs of
84-86 nucleotides would be unlikely to separate on a gel of this percentage. From
the single mutant analysis in Chapter 3, it seems unlikely that any of the mutations
made here would have had an effect on the size of the full length RNA, as none of
the mutated regions are close to either end of the RNA so would not have affected
transcription. The potential size difference in full length Y5 or ydRNA lengths
between the mutant pools will be discussed further, during the interpretation of the
NGS data.
A preliminary analysis of the sRNA data has been conducted, but the full length
and plasmid bias datasets are required for any final conclusions to be made. These
libraries are currently being sequenced. After removal of the outlier replicate for
each mutant pool sample set, all reads were mapped to the mouse genome and to a
set of hY5 mutant reference sequences. The presence of many mouse genome-derived
30mers (as seen by the peak in Figure 4.13) in the NGS data is unsurprising, as it
was necessary to include non-hY5-derived sequences in order to introduce enough
heterogeneity for the samples to be processed by NGS. The presence of the 19
nucleotide peak is more unexpected, however, as the majority of sequences of this
size were removed from the samples in two rounds of gel extraction. This indicates
that the two microRNA sequences present in this peak, miR-99b and miR-125b-1,
were very highly abundant in these samples. The sequence reads mapping to these
miRNAs were 19 nucleotides in length, but taking into account the enrichment
PCR, these sRNAs are more likely to be 21-22 nucleotides in length, meaning that
these reads likely represent the full length miRNAs. Mir-99b contains the sequence
CAC upstream of the sequencing reads (MiRBase), suggesting that the A may have
looped out during the enrichment PCR. Mir-125b-1 contains CC upstream of the
region sequenced, suggesting that the enrichment PCR works inefficiently to amplify
both of these sequences and that they may be underrepresented here. There is
evidence in the literature that both of these miRNAs play a role in cellular response
to apoptosis. miR-99b regulates the expression of the mTOR protein (Sun et al.,
2011). miR-125b has an opposing function to miR-99, as it inhibits apoptosis (Yang
et al., 2013).
It is generally accepted that two different methods of detection are required to
confirm that a sRNA is produced under a certain condition. Often these two meth-
ods do not entirely correlate and sometimes a clear conclusion is difficult. These
discrepancies may be down to differences in sample processing, but work by the
Dalmay group has recently begun to unravel a bias inherent to protocols utilizing
RNA ligases, such as most NGS technologies. Indeed the same bias may be present
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in all methods which utilize a ligation step. Dr. Sorefan found that the ligase en-
zymes commonly used in the preparation of cDNA libraries for NGS have a bias
for ligating together RNAs that can anneal to each other in such a way that the
ligation point falls within a loop close to the base of the stem (Sorefan et al., 2012).
As the adapters used in these techniques are set sequences provided in the kit, the
ligases RNAs that are capable of interacting with these adapters to form preferred
structures.
For this reason it is important to bear in mind that, although the fold change and
general trends seen for abundant RNAs under different test conditions are usually
correct, a direct comparison of the number of reads for one RNA with the number
of reads for another is likely to be inaccurate. For example, if an RNA is favored by
the ligase then it may be present in the data set at very high levels, but in reality it
is present in the cell at below average expression levels. To overcome this problem,
‘HD’ adapters were designed to reduce the ligation bias (See Sorefan et al. 2012
for details). The use of these ‘HD’ adapters will be important when interpreting
the results of this chapter. Due to the necessity of the enrichment PCR, it was not
possible to use the 5’ ‘HD’ adapter, but use of the 3’ ‘HD’ adapter alone should have
dramatically reduced the ligation bias.
The high-throughput method of mutagenesis has several advantages over the orig-
inal method. Firstly, each of the 1024 different plasmids should enter the cells with
the same efficiency, as they will have been transfected under the same conditions.
This was a drawback of the low-throughput method, as different plasmid concentra-
tions and transfection efficiencies could not be accounted for. Differences in concen-
tration between each of the mutant plasmids prior to transfection can be normalized
using the plasmid bias library dataset, when it is available.
It is possible that some of the mutated hY5 RNAs will either not be transcribed
correctly or may misfold in such a way that they are rapidly targeted for degrada-
tion, by complexes such as the exosome, and will not be represent in the full length
hY5 libraries dataset. This means that differences in the levels of full length mutant
RNAs identified in the NGS data are likely to be a result of differences in the ex-
pression and processing of the RNA within the cells, rather than differences in the
levels of mutant plasmids. Mutation of particular regions of hY5, and then subse-
quent examination of the effect on cleavage, was useful for determining a region of
the RNA that is important in the interaction with the protein or proteins involved
in the cleavage, but this method is limited by the time consuming design and gen-
eration of each mutant. The high-throughput method also has the advantage that
no assumptions are made on the structure that the mutants might form, although
secondary structure prediction programs can be used to hypothesize on the effect of
abundant or absent mutant sequences on the secondary structure.
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On examining only the sequence reads in the sRNA libraries that map to the 3’
end of the hY5 RNA and contain the full mutant region, the NGS data confirms
what was seen on the northern blot membrane, as the reads for mutant pool 1 are
1-2 nucleotides longer than those seen for mutant pools 2 and 3 (Figure 4.15). The
length of these reads does not take into account the Cs included in the PCR and
sequencing primers, so the true ydRNA lengths are likely to be 33-35 nucleotides
in length. At the 3’ end of the hY5 RNA there is a run of Us, and there is known
length variation here. The sizes of the mutant pools 2 and 3 derived ydRNAs are
therefore likely to be the same as the wild type ydRNAs. Initial analysis of the
Poly(I:C)/control libraries prepared in MCF7 and SW1353 cells indicates that the
true length of endogenous ydRNAs is 33-34 nucleotides (data not shown). These
libraries were sequenced with reads of a length up to 50 nucleotides, so the sizing
of the sRNAs is likely to be more accurate than the original libraries, which had a
read length of 36 nucleotides.
When examining the start position of the sRNA reads from the different mutant
pools (Figure 4.16), again a clear difference can be seen between the pools. It appears
that pools 2 and 3 are very similar, with the majority of sequence reads starting at
one of two distinct positions, C53 or C54. More reads start at position C54 than C53
for both of these pools. From this data we can assume that the cleavage positions
for these mutant pools are most often either between T49 and C50 or between C50
and C51. This mirrors the wild type cleavage position, which is most often between
C50 and C51, but can also occur between T49 and C50. For ydRNAs produced
from both of these cleavage positions, the enrichment PCR would be expected to
work very efficiently, as both of these cleavage events would produce ydRNAs with
3 C residues at their 5’ ends.
An alternative method of analyzing the data was to sort all of the reads from
each replicate of each library in order of abundance (displayed in Table 4.1). These
mutant sequences were then ranked by the order they appeared in the list and the
data was further sorted by combining the ranks of the two remaining replicates
in each library (Table 4.2). When examining the top 6 mutations for each of the
3 mutant pools, what was unexpected was that the wild type sequence does not
seem to be present in any of the hits. This suggests that the sequence requirements
for Y RNA cleavage are not rigid and selection of mutant RNAs by the cleavage
machinery is more likely to be dictated by the secondary structure of each of the
mutants than the sequence. To examine this more closely, the sequences of the full
length mutants producing the top 10 mutant hits for each of the three pools were
entered into RNAfold and their secondary structures were predicted. Figures 4.19
and 4.20 show the predicted secondary structures for the top three mutant sequences
for mutant pools 2 and 3, the structures of the most abundant mutants in pool 1
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will be discussed later. What is noted in all of these secondary structures is that
there is a 5 base pair stem above the large internal loop. On closer examination of
each of the structures, the cleavage position is most often 2 nucleotides away from
this stem, falling within the large internal loop. Our hypothesis is that the cleavage
machinery binds the 5 base pair stem, possibly recruited by Ro60, and cleaves the
stem between the second and third unpaired nucleotide. What seems likely, from
these secondary structures, is that a 5 base pair stem, followed by a large internal
loop, is required by the cleavage machinery because the most abundant motifs all
maintain that stem.
Another surprising finding from these secondary structure predictions is that there
is much variation at the top of the molecule, towards the 5’ and 3’ ends. In human
cells, the Ro60 and La proteins are required for the stability of Y RNAs. This
does not appear to be the case for hY5 RNAs expressed in mouse cells as, although
the Ro60 binding site mutant tested in Chapter 3 is not cleaved, it appears to be
as stable as the wild type hY5 RNA. This was confirmed when the wild type hY5
plasmid was transfected into Ro60 null mouse embryonic stem cells [See Figure 4.29,
(Hall, 2013)]. In this experiment, the hY5 RNA looks to be stable in mouse cells
regardless of whether mRo60 is expressed. Two different scenarios could explain
this. In the first scenario, the mRo60 gene could have diverged from the human
Ro60 gene in such a way that it can no longer recognize and directly bind to the
hY5 RNA. In the second scenario only Y RNAs expressed from genes within the
genome may be bound by Ro60, and the plasmid-encoded Y RNAs are expressed
in such a way that they can no longer be recognized by mRo60. Perhaps they
are localized to a different area of the cell than endogenous mY RNAs. Further
experiments would need to be conducted to determine which theory is correct. In
order for either scenario to be true, the hY5 must be bound by other proteins within
the cell and therefore be protected from degradation in some other way.
What is evident from Dr. Hall’s work is that mRo60 is required for plasmid-
encoded Y5 RNA cleavage, regardless of whether or not it can directly bind to this
RNA (Hall, 2013). In the mouse Y5 transfected wild type cells a clear ydRNA
product is seen, whereas in the Ro60 null cells no ydRNA product is seen, despite
the fact that the full length hY5 is present at higher levels than in the wild type
mouse cells. The levels of full length hY5 RNA most likely higher in the mutant
cells because none of these RNAs are targeted for cleavage.
Initial interpretation of the secondary structures of full length RNAs producing
abundant ydRNAs in the data from pools 2 and 3, in particular from pool 3 where
the mutation is located close to the Ro60-binding site, suggested that this binding
site was disrupted in many of the mutants and that they were unlikely to still bind
to Ro60. The bulged C seen on the left of the terminal stem (at the top of the
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diagram) in the wild type structure is required for Ro60-binding, but it has been
suggested that this region can form a small internal loop instead of a bulged C and
either of these forms can bind to Ro60. This opening of the stem is thought to be
necessary to allow Ro60 access to the backbone for binding. Further examination
of the predominant mutant sequences for pools 2 and 3 suggests that the region
around the C bulge may form an internal loop, which may still allow Ro60 entry.
The GCTTG sequence to the right of the bulged C on the wild type structure is the
region targeted for mutagenesis in pool 3. Matthew Beckers generated sequence logos
to show the probability of finding each nucleotide at each of the mutant positions
in the most abundant mutant sequences. The logo for mutant pool 3 shows that
very few Gs are present at positions 3 and 4 (Figure 4.17). In mutants where Gs
are present at either of these two positions, these Gs may be able bind to the C
involved in the bulge. If Ro60 truly is required for cleavage, these mutants may be
underrepresented here as they do not produce ydRNAs. What is also interesting is
that the nucleotide at position 5 appears to be almost exclusively a G. Perhaps this
nucleotide stabilizes the terminal stem and is required to maintain the structure for
Ro60 binding. The diversity of sequences present in the sRNA library derived from
mutant pool 3 was unexpected, as this mutation is so close to the Ro60-binding site.
The role of Ro60 in Y RNA stability and cleavage warrants further investigation.
Mutant pool 1 has a very different start position pattern than pools 2 and 3
(Figure 4.16). Rather than having two distinct start sites, the majority of the
detected sequence reads are spread across three different positions. For pools 2 and
3 the second position of the two is more common than the first, while this is not
seen for mutant pool 1, where the majority of the reads start at the first position
of the three. It is harder to predict the most common cleavage position for mutant
pool 1, due to its close proximity to the edge of the run of Cs in the full length
Y5 RNA. It seems likely that it falls either between C48 and T49, or T49 and
C50. Figure 4.30 shows the possible ydRNAs and the way they might expected to
be amplified by the enrichment PCR. If T49 is the first nucleotide present in the
ydRNA, then it would be removed during the enrichment PCR, as either the A49 of
the cDNA or a C of the alternative RP1 primer would be likely to loop out during
the amplification. As the mutation site for mutant pool 1 is closer to the 5’ end of
the ydRNA, it was hypothesized that this mutant would be the most likely to affect
the position of cleavage. What was unexpected was how much longer the ydRNA
population produced from this pool would be compared to the other mutant pools
and to the wild type. The fact that any reads which do not contain 2 or 3 5’ Cs will
not be detected is a limitation of this method. Although it is possible that there
are abundant mutant ydRNAs that were present in the samples transfected with
mutant pool 1 that have been missed in this analysis, it is important to highlight
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that those that will be further investigated from this analysis are abundant and are
informative in the investigation of the requirements for cleavage. This limitation
does not apply to mutant pools 2 and 3, as the predominant cleavage position for
these libraries is suitably positioned so that it falls within the run of Cs and should
be efficiently detected in the enrichment PCR.
In order to examine the variation in cleavage positions in the full length RNAs
from pool 1 compared with pools 2 and 3, which only have two distinct cleavage
sites, the full length mutant RNA sequences from pool 1 were divided by read start
site. Those mutant sequences producing sequencing reads starting at positions C52,
C53 and C54 were selected and separately plotted according to abundance. Figures
4.22 and 4.23 show sequences that resemble the wild type sequence at the mutation
site. In figure 4.23, the most abundant sequence at the mutation site, CCACA, is
actually the wild type sequence. A nucleotides are rare in the first two positions
of the mutation of reads starting at this position. In Figure 4.22, the sequences
are more variable, but again the wild type sequence can be seen amongst the most
abundant sequences (it is the 5th most abundant read). The sequence logo for the
pool 1 reads starting at position 54 shows that there is a clear preference for the
wild type sequence (Figure 4.26). The logo for the reads starting at position 53
shows that there is a slightly weaker, but still a clear preference for the wild type
sequence.
The ordered abundance plot for the pool 1 mutant reads starting at position 52 is
very different to the other two plots for pool 1. In this plot there is a high probability
of getting an A nucleotide at the first position of the mutation site, even though this
is not present in the wild type sequence. The wild type sequence at the mutation site
is not abundant in these reads as the logo for sequence reads at this start position
shows that there is a preference against the wild type sequence.
To explain the reason for the distribution of mutant sequences across the start
sites of the reads, the full length sequences of the three most abundant reads for each
start sites were entered into RNAfold and the secondary structures predicted. Figure
4.27 shows the secondary structures of the full length RNAs with reads starting at
C52 and C53. Although these are only predictions, and the true secondary structure
of these mutant RNAs may vary, a clear pattern is visible when compared to the
wild type structure. Bearing in mind that the predominant cleavage position in
the wild type hY5 RNA in human cells is between C50 and C51, according to the
structure prediction this is between the second and third unpaired nucleotide in
the loop. In all three mutant RNAs at the top of the figure the internal loop has
shifted along the RNA molecule and, although the sequence of the loop is altered,
the cleavage occurs at the same position in the loop. This cleavage position is
between C48 and T49, resulting in ydRNAs that are 2 nucleotides longer than the
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wild type, with sequence reads starting at position C52. Apart from the middle
structure prediction, the most abundant read sequences at position C53 also follow
this pattern. This time the position of the internal loop is shifted in such a way
that the nucleotides within the stem are one position away from where they are
in the wild type. The resulting sequencing reads are 1 nucleotide longer than the
wild type sequence. For the most abundant reads in mutant pool 1 with the same
predominant cleavage position as the wild type RNA (Figure 4.28) the position of
the nucleotides within the internal loop is the same as for the wild type structure
prediction. This fits with the hypothesis that cleavage occurs two nucleotides into
the internal loop of the hY5 RNA structure, regardless of which nucleotide is present
at that position. As a size difference in the predominant sequences produced from
the three mutant pools was also indicated by the northern blot membrane, this size
difference is the result of the area targeted for mutation, rather than any selection
resulting from the enrichment PCR.
4.4 Further work
To determine the most common cleavage positions of each of the plasmid pools,
the top 5 and bottom 5 reads will be validated by creating single mutants and
testing their expression, as well as their cleavage pattern, by northern blotting.
Higher resolution PAGE will be used to size the cleavage products as accurately as
possible and size marker differing in length by 1 nucleotide will be run alongside
the mutants. These validation mutants will be prepared in a similar manner to the
high-throughput mutants, using reverse primers containing specific mutants, rather
than by hybridizing primers together and cloning them into pGEM-T Easy. This
is important to follow the methods of high-throughput mutagenesis as closely as
possible.
On generation of these mutants, it would also be interesting to examine their abil-
ity to interact with both human and mouse Ro60. This could be done by immuno-
precipitating the Ro60 protein from either mouse or human cells and determining if
the transfected mutant RNA is bound. As a control, co-immunoprecipitation of the
endogenous human or mouse Y RNAs with Ro60 should also be examined. Deter-
mining the ability of mRo60 to bind to the wild type hY5 and a substantial number
of mutant sequences would go some way towards determining Ro60 involvement in
cleavage. If Ro60 is not detectably bound to the mutants, then it must play a role
in cleavage by being recruited by other proteins or RNAs that interact with the hY5
molecule.
Another immunoprecipitation experiment that would be interesting would be to
clone a number of mutants containing nucleotides other than G at position 5 of the
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mutation region in mutant pool 3. This G was enriched in the mutant sequences
that were cleaved, so it would provide information on the role of this G nucleotide
in Ro60 binding.
To determine whether the difference in endogenous hY5 cleavage and cleavage of
exogenously expressed hY5 in mouse cells is the result of expression from a plasmid
or a difference between the human and mouse Ro60 protein, a hY5 mutant producing
an abundant ydRNA in the NGS data could be tested in human cells. The mutant
would need to be chosen carefully so that it would be unlikely to affect Ro60 binding,
but be different enough in sequence so that a mutant-specific probe could be designed
that did not cross-hybridize with the endogenous wild type hY5 sequence. shRNAs
designed against the human Ro60 protein could be transfected in combination with
the mutant plasmid and, if the difference in stability of the full length hY5 RNA
is a result of a difference between the mouse and human Ro60 protein, then the
mutant hY5 should not be stable in the absence of Ro60. If, however, this difference
in stability is the result of inherent differences in expression from genomic DNA
versus expression from a plasmid, the mutant RNA levels should be unaffected by
the absence of the Ro60 protein. This mutant RNA would also need to be expressed
in human cells in the absence of the Ro60-targeting shRNA, to confirm that it is
highly expressed when the human Ro60 protein is present.
Once the full length and plasmid bias datasets are obtained, the sRNA library
data will need to be normalized and will need to be re-examined in comparison to
the expression levels of the full length RNA. Those full length mutant RNAs that
are present at very high levels, but do not appear to produce and cleavage products
should also be validated by northern blotting, as these could be equally important
in providing information as to the requirements for hY5 cleavage.
Aside from examining the specific cleavage pattern of hY5 during apoptosis, this
high-throughput method could be utilized to examine cleavage of many of the other
30mer RNAs identified in this project, as well as those that may be identified in the
new Poly(I:C)/control data when it is available. For apoptosis-treated cells a similar
enrichment method would be required in order to be able to detect these sequences,
especially as the majority of the other 30mers appear to be less abundant than
ydRNAs. This method could also potentially be used to examine cleavage patterns
of other ncRNAs. The volume of information provided by a method such as this
could be extremely powerful in more accurately characterizing the processing of
many RNAs or, indeed, the activity of proteins targeting these RNAs.
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5 POLY(I:C)-, AND POSSIBLY
APOPTOSIS-, DEPENDENT
30MER sRNA PRODUCTION
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5.1 INTRODUCTION
In 1941, Beadle and Tatum published the “one gene, one enzyme” hypothesis, sug-
gesting that each human gene encodes one protein with a particular function (Beadle
and Tatum, 1941). This theory was an over-simplification and has been repeatedly
challenged since its conception. For example, protein-coding genes within the human
genome can encode different isoforms of proteins, which are produced by alterna-
tive splicing events following transcription (DeNoto et al., 1981). The “one gene,
one enzyme” hypothesis (Beadle and Tatum, 1941) was further challenged by the
discovery that protein-coding genes can also contain alternative initiation and ter-
mination sites, potentially producing yet more protein isoforms (Early et al., 1980;
Hagenbu¨chle et al., 1981). In recent years, a re-evaluation of protein-coding gene
expression has highlighted further levels of complexity in the form of ncRNAs pro-
duced from the start and end sites of these genes (Kapranov et al., 2007).
Although less than 3% of the human genome encodes proteins, the majority of
it is transcribed (Hangauer et al., 2013). ncRNAs that are produced at very low
levels are likely to be by-products of transcription, but many ncRNAs present at
higher levels, which were missed by previous methods of sequencing, have recently
come into focus (Hangauer et al., 2013). Rapid cellular adaptation means that even
poorly conserved RNAs may have new but important functions (Pang et al., 2006).
The majority of ncRNAs within mammalian cells are processed and modified.
For example, stress-induced small RNAs derived from tRNAs are generated by pro-
cessing enzymes acting on mature tRNAs, rather than targeting precursor tRNAs
(Fu et al., 2009). Investigation into the generation of sRNAs from other ncRNAs is
ongoing.
5.1.1 RNA processing
RNAs can be targeted by ribonucleases during their biogenesis, as the majority of
RNAs are processed from precursor RNAs. RNAs can also be cleaved as part of a
cellular quality control process. If they are recognized as mutant or misfolded, they
must be prevented from entering the translation machinery. Finally, RNAs come to
the end of their life and must be degraded; this process also involves ribonucleases.
There are RNA-targeting enzymes that have endonucleolytic activity, cutting
within the RNA, or exonucleolytic activity, degrading the RNA from the ends.
Exonucleases can digest RNA from either the 5’ or the 3’ end. Many nucleases,
however, have more than one of these functions; some may have one activity on
one RNA target and a different activity on another RNA target. In mammalian
cells, RNA degradation pathways are often overlapping. For example, Angiogenin is
mainly responsible for tRNA half production in human cells during stress (Yamasaki
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et al., 2009; Fu et al., 2009), but work by Thompson et al. showed that the human
RNASET2 enzyme could cleave yeast tRNA to produce these fragments, suggesting
that some redundancy between these two enzymes is likely to occur in human cells
(Thompson and Parker, 2009a).
In mammalian cells RNA degradation is extremely complex, with many enzymes
capable of degrading RNA, as well as cofactors that unwind the RNA secondary
structures or aid recruitment of the degradation machinery to the RNAs. The
eukaryotic exosome complex can either act as an endoribonuclease (Lebreton et al.,
2008; Schaeffer et al., 2009) or an exoribonuclease, degrading RNA from the 3’
end (Mitchell et al., 1997). An example of an exoribonuclease known to digest
RNAs from the 5’ end after cap removal is Xrn1 (Houseley and Tollervey, 2009).
In eukaryotic cells, a number of helicases work in combination with the exosome
to aid its activity. A protein complex known as the TRAMP complex adds a run
of As to the end of RNAs that require degradation and this enables access for
the exosome (Vanˇa´cˇova´ et al., 2005). Recognition of an RNA with a poly(A) tail
depends upon its cellular localization; the addition of a poly(A) tail to RNAs present
in the cytoplasm generally results in increased stability (Decker and Parker, 1993)
while in the nucleus poly(A)-tailed RNA is degraded (Das et al., 2003). Terminal
poly(U) stretches may also act as targets for degrading enzyme complexes in the
nucleus (Mullen and Marzluff, 2008). RNA degradation is extremely rapid, as the
presence of unwanted RNA within the cell can have deleterious consequences on
gene expression. As we know from miRNAs and siRNAs, even very small fragments
can have very dramatic effects on the overall expression patterns of mammalian
cells (Lee et al., 1993).Along with blocking translation, ncRNAs can bind to DNA
molecules within the cell and regulate DNA repair (Pothof et al., 2009). For these
reasons, the decay of unnecessary RNAs within each cell is vital and time is of the
essence.
5.1.2 Virus response in mammalian cells
When viruses infect host cells, dsRNA is often formed during viral genome repli-
cation. This dsRNA is recognized by the host cell as foreign and the cell mounts
an immune response. Poly(I:C) is a synthetic mimic of viral dsRNA and is used
to stimulate an innate immune response (Larson et al., 1969). A variety of recep-
tor proteins are present within, and on the surface of cells to detect the presence
of viral dsRNA. Upon virus detection, cells can induce mechanisms to block viral
genome replication, or they can undergo apoptosis to prevent the spread of new
viral particles. Dendritic cells produce cytokines in response to viral dsRNA (Cella
et al., 1999), alerting surrounding cells to the threat and inducing an inflammatory
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response. Using in vitro systems, Poly(I:C) treatment can stimulate differentiation
or apoptosis, depending upon the cell line used and the concentration and duration
of treatment (Tomida et al., 1980; Flikke et al., 1970).
In our dataset the 30-35 nucleotide sRNAs derived from human Y RNAs, in par-
ticular hY5, were induced after Poly(I:C) treatment. Rutjes et al. found that human
Y RNAs were cleaved in an apoptosis-dependent manner (Rutjes et al., 1999b). It
seems likely that, at least for Y RNAs, the sRNAs detected after Poly(I:C) treatment
are a more general consequence of apoptosis, rather than a virus-specific response
(see Chapter 3 for further discussion). Dr. Nicolas visualized Poly(I:C)-treated cells
under the microscope and noted signs of apoptosis, such as cell-rounding and enu-
cleation. Whether or not these conditions caused apoptosis had not been tested
experimentally. The first aim of this chapter was to measure the levels of apoptotsis
in Poly(I:C)-treated samples, and in control cells, to determine whether Poly(I:C)
treatment caused apoptosis in the cell line tested. Stress-induced fragments from
tRNAs and snoRNAs are abundant in the literature, but at the start of this project
no-one had examined virus or apoptosis induction of tRNA or snoRNA cleavage.
The second aim of this chapter was to more closely analyze sRNAs differentially
expressed between Poly(I:C) and control treatments and validate a number of these
by northern blotting. Four potential sRNAs were chosen for validation, based on
their differential expression between the two conditions, the pattern of small RNAs
mapping to the gene, and the type of RNA gene they mapped to. In addition, a
number of these novel sRNAs were further investigated to determine whether they
were induced by other apoptotic stimulants.
5.2 RESULTS
Apart from snoRNA and mitochondrial tRNA-derived 31 nucleotide fragments, sR-
NAs of this size were generally up-regulated after Poly(I:C) treatment (Figure 5.1).
This resulted in a higher overall read number of sRNAs 31 nucleotides in length in
the Poly(I:C)-treated sample than in the control sample (Figure 1.3 in Chapter 1).
The levels of 31 nucleotide Y RNA-derived sRNAs were notably increased in the
Poly(I:C)-treated sample compared to the control (Figure 5.1). Certain sequences
derived from Y RNAs have previously been miss-annotated as microRNAs. In this
dataset, these Y RNA-derived sequences account for the majority of the up-regulated
sequences annotated as miRNAs. Very few bona fide miRNA sequences were higher
in the Poly(I:C)-treated sample than the control.
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Figure 5.1: The annotation and abundance of 31 nucleotide reads in control vs.
Poly(I:C)-treated MCF7 cells.
Reads from Poly(I:C)-treated cells (shown in red) and untreated control
cells (shown in turquoise) were normalized and grouped according to
annotation type and plotted by read count (produced by Dr. Pais).
Count displayed in reads per million.
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5.2.1 Validation of 30mers
In order to conduct a direct comparison of sRNA levels between Poly(I:C)-treated
and untreated samples, a number of sRNAs were selected for validation by northern
blotting (see Appendix VI for details). To choose sRNAs to validate, the full length
RNAs from which they were derived were examined. All sequenced hits derived
from each full length RNA were mapped and the read counts were compared. Only
those sRNAs that represented distinct reads were further investigated. Where a
large number of staggered reads were found, indicating a generally high level of
degradation across the RNA rather than specific cleavage, these sRNAs were ignored.
As not all of the sRNAs were found to be exactly 31 nucleotides in size, denaturing
PAGE gels were run containing DNA oligos of 30 and 35 nucleotides in length, and
were used to approximately size the detected sRNAs. These sRNAs will be referred
to as 30mers, as this novel class of sRNAs is 30-35 nucleotides in size.
5.2.1.1 Small cajal body RNA 2-derived sRNAs
Three sRNA sequences derived from small cajal body RNA 2 (scaRNA2) were de-
tected in the next generation sequencing data (Figure 5.2). All three sequences had
a higher number of reads in the Poly(I:C)-treated sample than in the control sam-
ple. Two of these sequences, which have a 1 nucleotide difference in length, were
mapped to a C box at the 5’ end of the U2-61 domain of this scaRNA [see Figure 5.3
(B)]. These two sequences are likely to correspond to the same sRNA, which will be
referred to the C box scaRNA2-derived 30mer. The second most abundant sRNA
derived from this scaRNA mapped to a D box closer to the 3’ end of the transcript;
this will be referred to as the D box scaRNA2-derived 30mer.
Figure 5.3 shows that both of the scaRNA2-derived sRNAs, detected on the mem-
branes in (A) and (B), fall between the two size markers and are therefore between
30-35 nucleotides in size. These membranes also confirm that both of these sRNAs
are dramatically up-regulated after Poly(I:C) treatment. The intermediate length
scaRNA band, which is expected to be 82 nucleotides in size, resolved above the 100
nucleotide marker band.
In order to determine whether the C box 30mer sRNA derived from scaRNA2 is a
response specific to Poly(I:C), or whether it is induced as a general consequence of
apoptosis, MCF7 cells undergoing varying lengths of treatment with Hygromyin were
compared with cells undergoing 4 or 8 hours Poly(I:C) treatment, untreated cells,
and Lipofectamine-treated cells (see Figure 5.4). An sRNA band is visible in the
sample treated with Poly(I:C) for 4 hours and a band of a higher intensity is visible
after 8 hours. No sRNA band is visible after any of the Hygromycin treatments, or
in any of the control lanes, suggesting that Hygromycin did not induce scaRNA2
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Figure 5.2: The most abundant reads mapping to the scaRNA2 gene.
Reads were mapped according to size and position from the start of the
gene (produced by Dr. Pais). The colour of each dot indicates the size
of each sequence detected and the size of each dot represents the number
of counts (logged) of each sequence.
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Figure 5.4: Detection of the scaRNA2-derived C box 30mer in MCF7 cells grown
under various conditions.
Cells were plated in T75cm2 flasks. After 48 hours they were treated
with inducers of apoptosis or media was replaced with no treatment.
After the appropriate length of time cells were harvested, total RNA
was extracted and 10 µg was used for northern blotting. Membranes
were probed with a scaRNA2 C box 30mer-specific radiolabeled probe.
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cleavage, at least under these treatment conditions.
5.2.1.2 Small nucleolar RNA C/D Box 7-derived sRNAs
A number of small nucleolar RNA C/D Box 7 (SNORD7)-derived sRNAs were also
dramatically up-regulated after Poly(I:C) treatment in the NGS data. Figure 5.5
displays the location and the abundance of the reads mapping to this snoRNA in
the Poly(I:C)-treated sample. The three SNORD7 30mer sequences with the highest
read number in the Poly(I:C)-treated sample mapped to the 5’ end of this RNA. The
two smaller sequences are derived from the same region of SNORD7 as the larger
sequnce, so they are likely to represent one sRNA, with a slight variation in length.
This region contains the C box (see Figure 5.6).
A probe was designed to detect all three of these sequences and was hybridized
to a membrane containing control and Poly(I:C)-treated MCF7 samples. Figure
5.6 shows that in the Poly(I:C)-treated sample lane what looks to be a doublet
band is visible, probably made up of RNAs varying by at least two nucleotides.
All of these SNORD7-derived small RNAs fall between the two size markers, so are
bona fide 30mers. They are not detectable in the control lanes, confirming that
they are Poly(I:C)-induced 30mers. The upper band on the blot is the mature
SNORD7 RNA. This RNA should be 94 nucleotides in size, but resolved above the
100 nucleotide ssRNA ladder. This is likely to be a result of the ladder being a pure
RNA solution, while the total RNA samples were extracted from cells.
5.2.1.3 Zinc finger MYM-type 2-derived sRNAs
Unlike the other validated sRNAs, a sequence derived from the exon of an mRNA
was selected for validation. This sequence mapped to the Zinc finger MYM-type 2
(ZMYM2) mRNA. It was one of the very few 30mer sequences to be down-regulated
after Poly(I:C) treatment according to the NGS data. The sRNA detected is derived
from exon 4 of the gene (see Figure 5.7), an exon that is present in 4 of the 5
protein-coding isoforms of ZMYM2. On northern blotting with a ZMYM2 30mer-
specific probe (Figure 5.8), an sRNA is present at relatively low levels in both the
control and poly(I:C)-treated lanes, although it looks slightly more abundant in the
control samples when compared to the Poly(I:C)-treated samples. No full length
ZMYM2 RNA is visible on this membrane, as it was too long to run into a gel of
this percentage.
5.2.1.4 tRNA half validation
As seen by many other groups, tRNA halves were abundant in our NGS dataset.
Since they were not novel, they were not the focus of this project, but a number of
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Figure 5.5: The most abundant reads mapping to the SNORD7 gene.
Reads were mapped according to size and position from the start of the
gene (produced by Dr. Pais). The size of the dots represents the number
of reads in the Poly(I:C)-treated sample
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Figure 5.6: Detection of SNORD7-derived sRNAs in MCF7 Poly(I:C)-treated and
control cells.
Cells were plated in T75cm2 flasks. After 48 hours they were treated
with Poly(I:C), Lipofectamine alone, or media was replaced with fresh
DMEM. After 8 hours cells were harvested, total RNA was extracted
and 10 µg was used for northern blot analysis. Membranes were probed
with (A) a SNORD7 C box 30mer-specific radiolabeled probe. (B) The
30mer SNORD7-derived sRNA encompasses the C box region of the full
length SNORD7 RNA.
160
F
ig
u
re
5.
7:
T
h
e
m
os
t
ab
u
n
d
an
t
re
ad
s
m
ap
p
in
g
to
th
e
Z
M
Y
M
2
ge
n
e.
(A
)
R
ea
d
s
w
er
e
m
ap
p
ed
ac
co
rd
in
g
to
si
ze
an
d
p
os
it
io
n
fr
om
th
e
st
ar
t
of
th
e
ge
n
e
(p
ro
d
u
ce
d
b
y
D
r.
P
ai
s)
.
T
h
e
co
lo
u
r
of
th
e
d
ot
s
re
p
re
se
n
ts
th
e
si
ze
of
th
e
se
q
u
en
ce
s
d
er
iv
ed
fr
om
th
es
e
ge
n
e
an
d
th
e
si
ze
of
th
e
d
ot
s
re
p
re
se
n
ts
th
e
re
ad
co
u
n
t
(l
og
ge
d
)
of
ea
ch
se
q
u
en
ce
.
(B
)
T
h
e
p
os
it
io
n
of
th
e
m
os
t
ab
u
n
d
an
t
sR
N
A
re
ad
w
it
h
in
th
e
Z
M
Y
M
2
ge
n
e.
T
h
is
30
m
er
m
ap
s
to
ex
on
4,
w
h
ic
h
is
p
re
se
n
t
in
th
e
m
a
jo
ri
ty
of
th
e
p
ro
te
in
-c
o
d
in
g
is
of
or
m
s
of
th
is
m
R
N
A
.
161
Figure 5.8: Detection of a ZMYM2-derived sRNA in MCF7 Poly(I:C)-treated and
control cells.
Cells were plated in T75cm2 flasks. After 48 hours they were treated
with Poly(I:C), Lipofectamine alone, or media was replaced with fresh
DMEM. After 8 hours cells were harvested, total RNA was extracted
and 10 µg was used for northern blot analysis. Membranes were probed
with a ZMYM2 30mer-specific radiolabeled probe.
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halves were validated by northern blotting to determine the accuracy of the NGS
data. Northern blot analysis, unlike NGS, is unable to distinguish between tRNA-
derived sequences with one or two nucleotide differences, as northern probes can
bind to target RNAs with a number of mismatches. This is particularly problematic
for those RNAs of very high abundance, such as tRNAs. Northern blotting, how-
ever, gives a more accurate read out of the difference in levels of an sRNA between
experimental conditions, as there is no sequence bias in probe hybridization.
Although not the most differentially expressed tRNA halves in the NGS dataset,
Ala-tRNAAGC and Cys-tRNAGCA were chosen for validation as they have been
shown to inhibit translation initiation (Emara et al., 2010; Ivanov et al., 2011a).
The Ala-tRNAAGC 5’ tRNA half was up-regulated 4.8 fold in the Poly(I:C)-treated
sample compared to the control sample, according to the NGS data. The mem-
brane probed for this tRNA half confirms the NGS data as a clear band of 30-35
nucleotides is seen in the Poly(I:C)-treated but not the control lanes. A single band
of the expected size is present higher up the gel, corresponding to the full length
tRNA. No other bands are seen, suggesting that this probe is likely to be specific
for this tRNA isoacceptor type.
The 5’ Cys-tRNAGCA half was chosen for validation as it was present at low levels
in both the Poly(I:C)-treated and the control NGS data, although there was still
a slight increase in the Poly(I:C)-treated sample compared to the control sample.
Despite the low level of reads from this tRNA half in the NGS data, the membrane
probed for this tRNA-derived 30mer showed dramatic differential expression between
the two conditions. The sRNA is of the correct size and its production appears to be
Poly(I:C)-induced. A single band, corresponding to the full length Cys-tRNAGCA is
visible at the top of the membrane and no cross-hybridization is evident.
A probe was also designed against a Leu-tRNA-derived sequence that was highly
up-regulated in the Poly(I:C)-treated sample. When membrane was hybridized with
this probe, an sRNA was detected, but it resolved above the 35 nucleotide size
marker and is probably around 40 nucleotides in size. Interestingly, although this
sRNA is not a 30mer, it is Poly(I:C)-induced. It should be noted that a double-band
is visible at the top of the membrane, indicating that the probe cross-hybridized with
another full length tRNA, as well as Leu-tRNAAAG.
In order to compare tRNA cleavage under different conditions, MCF7 cells were
treated with various stresses, RNA was extracted and used for northern blotting, and
the membrane was probed with a Met-tRNA 30mer-specific probe. The probe used
in northern experiments in this project was the same as that used by Thompson et
al., it was also derived from the same sequence as the probe used by Fu et al. except
that it was slightly shorter and was shifted along the tRNA by one nucleotide at the
3’ end (Fu et al., 2009; Thompson and Parker, 2009a). This probe is specific to the 5’
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Figure 5.9: Detection of Ala-tRNAAGC and Cys-tRNAGCA-derived sRNAs in MCF7
Poly(I:C)-treated and control cells.
Cells were plated in T75cm2 flasks. After 48 hours they were treated
with Poly(I:C), Lipofectamine alone, or media was replaced with fresh
DMEM. After 8 hours cells were harvested, total RNA was extracted
and 10 µg was used for northern blotting. Membranes were probed with
(A) an Ala-tRNAAGC or (B) a Cys-tRNAGCA 30mer-specific radiolabeled
probe.
Met-tRNA half. Unlike the other 30mers tested in this chapter, Met-tRNA is clearly
cleaved after both Hygromycin and Poly(I:C) treatment, although the presence of
Poly(I:C) in the cell clearly results in greater cleavage levels than Hygromycin under
treatments conditions used here. No function for this Met-tRNA-derived sRNA has
yet been shown.
5.2.2 Northern blot analysis of apoptosis in DLD-1 cells
DLD-1 colorectal adenocarcinoma cells were grown under various stress conditions
before harvesting. After harvesting, cells were split into two and one half was used
for flow cytometry, while the other half was used for northern blot analysis (See
Chapter 3 for flow cytometry results and Appendix 7 for data table). RNA was ex-
tracted and 3 µg of each sample was used for northern blot analysis. The membrane
was hybridized with the hY5-specific probe as a control (Figure 5.12). Using this
probe, a high level of 30mer ydRNA is seen in the Poly(I:C)-treated sample and a
lower level is visible in the Hygromycin-treated sample, although still higher than
the levels in the control cells. The cells grown in PBS for 30 minutes have levels of
30mer ydRNA similar to the control cells. Another tRNA fragment that was consid-
erably differentially expressed between the two conditions tested in the NGS data
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Figure 5.10: Detection of Leu-tRNAAAG-derived sRNAs in MCF7 Poly(I:C)-treated
and control cells.
Cells were plated in T75cm2 flasks. After 48 hours they were treated
with Poly(I:C), Lipofectamine alone, or media was replaced with fresh
DMEM. After 8 hours cells were harvested, total RNA was extracted
and 10 µg was used for northern blotting. Membranes were probed
with a Leu-tRNAAAG 30mer-specific radiolabeled probe.
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Figure 5.11: Detection of Met-tRNA-derived sRNAs in MCF7 stress-treated cells.
Cells were plated in T75cm2 flasks. After 48 hours they were treated
with Poly(I:C), Hygromycin, or media was replaced with fresh DMEM.
After 8 hours cells were harvested, total RNA was extracted and 10 µg
was used for northern blot analysis. Membranes were probed with a
tRNAMet-specific radiolabeled probe.
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was the Gln-tRNATTG 5’ tRNA half. When the same membrane was hybridized
with a Gln-tRNATTG 30mer-specific probe, a strong 30mer band is visible in the
Poly(I:C)-treated lane, confirming the results seen in the NGS data. A 30mer band
is not present in any of the other lanes, including the Hygromycin-treated lane. It
should be noted that less total RNA was used for this membrane compared with the
membranes used for validation of the other NGS tRNA-derived 30mer sequences.
Figure 5.12: Detection of Gln-tRNATGG-derived sRNAs in DLD-1 stress-treated
cells.
Cells were plated in T75cm2 flasks. After 24 hours cells were treated
with 800 mg/mL of Hygromycin or media was replaced. After a further
24 hours cells were treated with Poly(I:C) or Lipofectamine alone, left
in Hygromycin-containing media, or media was replaced. 20 minutes
prior to harvest, media was removed from one of the flasks and replaced
with DPBS. Cells were harvested 56 hours after plating, total RNA was
extracted and 3 µg was used for northern blotting. The membrane was
probed with (A) a Gln-tRNATTG-specific radiolabeled probe or (B) a
hY5-specific radiolabeled probe.
5.2.3 Generation of further cDNA libraries of sRNAs following
Poly(I:C) or control treatment
At the initiation of this project, NGS experiments were very expensive. Over the
past few years the cost of running these samples has reduced and, in order to publish
NGS data, a number of biological or technical replicates are now required. To
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overcome this problem, cDNA libraries of sRNAs were prepared from two different
cell lines, after growth in the presence or absence of Poly(I:C) for 8 hours prior to
harvesting. Three biological replicates were prepared for each condition. During
the library preparation process, ‘HD’ adapters were ligated to the ends of the small
RNAs and these were then converted to cDNA (Sorefan et al., 2012). cDNA samples
were separated on polyacrylamide gels and the region containing the 30mers was cut
out of the gel for each sample (Figures 5.13 and 5.14). The miRNA band was cut
out separately. 30mer samples were subjected to a second gel extraction, to ensure
that any adapter-adapter and miRNA sequences had been removed, and then sent
for NGS analysis.
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Figure 5.13: cDNA library preparation of sRNAs from (A) untreated and (B)
Poly(I:C)-treated MCF7 cells.
Cells were plated in T75cm2 flasks. After 48 hours they were treated
with Poly(I:C), or media was replaced with fresh DMEM. After 8 hours
cells were harvested, total RNA was extracted and 2 µg was used for
library preparation. 3 PCR reactions were prepared for each sample,
each run for a different number of cycles. The upper band correspond-
ing to the 30mers was cut from this gel for all three replicates and
combined, before a second gel extraction to ensure the removal of both
the adapter-adapter (lower band) and the miRNA band (middle band).
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Figure 5.14: Small RNA library preparation of (A) untreated and (B) Poly(I:C)-
treated SW1353 cells.
Cells were plated in T75cm2 flasks. After 24 hours they were treated
with Poly(I:C), or media was replaced with fresh DMEM. After 8 hours
cells were harvested, total RNA was extracted and 2 µg was used for
library preparation. 3 PCR reactions were prepared for each sample,
each run for a different number of cycles. The upper band corresponding
to the 30mers was cut from this gel for all three replicates and combined,
before a second gel extraction to ensure the removal of both the adapter-
adapter (lower band) and the miRNA band (middle band).
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5.3 DISCUSSION
The majority of sRNAs derived from ncRNA were up-regulated after Poly(I:C)
treatment in the NGS data (Figure 5.1). Most of the Poly(I:C)-induced 30mers were
probably derived from the ncRNAs directly, as they were sense in relation to the
gene. Annotation of the data showed that many of the up-regulated sequences were
derived from tRNAs and rRNAs. In fact, on closer inspection, a large proportion
of the sequences annotated as hits in introns or exons of protein coding genes also
mapped to poorly annotated rRNA genes, tRNA genes, or pseudogenes derived from
these ncRNA genes.
5.3.1 snoRNAs
C/D box snoRNAs are often given an alternative name beginning with mg, for
methylation guide RNA. The rest of the name indicates the target RNA and nu-
cleotide position that is methylated. C/D box snoRNAs are usually involved in the
methylation of rRNAs or small nuclear RNAs (Kiss-Laszlo et al., 1996; Nicoloso
et al., 1996). C/D box snoRNAs contain C and D box motifs, which are close to
each other as the RNA forms a step-loop structure (Tyc and Steitz, 1989). C’ and
D’ boxes are less well conserved forms of C/D boxes and are usually found more in-
ternally on the RNA molecule (Tycowski et al., 1996). A region of the RNA slightly
upstream of the D box, known as the antisense element, is involved in base-pairing
with the target RNA and is highly complementary to this target (Kiss-Laszlo et al.,
1996; Nicoloso et al., 1996).
Although two C/D box snoRNAs were chosen for validation, it should be noted
that H/ACA box snoRNA-derived 30mers were also present in the NGS dataset. Us-
ing a large number of publicly available small RNA NGS datasets, Taft et al. showed
that animal H/ACA box snoRNAs are generally cleaved into sRNAs of 20-24 nu-
cleotides in size (Figure 5.15) (Taft et al., 2009b). Certain microRNA-size fragments
have also been shown to be derived from snoRNAs (Ender et al., 2008). In fact,
many miRNAs in MiRBase have subsequently been located to H/ACA snoRNA
genes (Scott et al., 2009; Brameier et al., 2011). C/D box snoRNAs are cleaved into
two distinct size classes of 17-19 nucleotides and greater than 27 nucleotides (Taft
et al., 2009b). In many animals, C/D box snoRNA-derived sRNAs are more abun-
dant than H/ACA box snoRNA-derived sRNAs (Taft et al., 2009b). As a general
rule, these fragments also appear to be derived from different regions of the snoRNAs
(Figure 5.16) (Taft et al., 2009b). The majority of C/D box snoRNA fragments are
produced in a Dicer-independent manner and were therefore not thought to act as
miRNAs (Babiarz et al., 2008; Taft et al., 2009b), but a number of microRNA-like
C/D box snoRNA-derived fragments have recently been identified, indicating that
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this type of snoRNA can also alter gene expression (Brameier et al., 2011). With
a less uniform structure than the full length C/D box snoRNA, C/D box snoRNA-
derived sRNAs have been shown to bind to different mRNA transcripts than the
parent snoRNA (Scott et al., 2012). The HBII-180C C/D box snoRNA has C and D
boxes and targets 28S rRNA, but also contains an M box, which is complementary
to an intron of the FGFR3 gene (Scott et al., 2012). Cleavage of this HBII-180C
gives a fragment that contains the M box and is inversely correlated to the levels
of a short isoform of FGFR3 in a number of cell lines, suggesting that this frag-
ment regulates splicing of this mRNA (Scott et al., 2012). Transient transfection of
cells with reporter plasmids containing the intronic region of FGRF3 confirmed this
function (Scott et al., 2012).
5.3.1.1 scaRNA2
scaRNA2 (mgU2-25/61) targeting of U2 snRNA at positions G25 and C61 results in
2’-O-methylation at these positions. Figure 5.4 shows the positions of the box motifs
on the secondary structure of scaRNA2, along with the regions of complementarity
with U2 snRNA. scaRNA2 is unusual, as it is one of the few snoRNAs that is
transcribed independently by RNA polymerase II (Gerard et al., 2010; Tycowski
et al., 2004), and is encoded in an intergenic region of the human genome (Gerard
et al., 2010). scaRNA2 has a snoRNA domain containing a C and a D box (the
3’ mgU2-61 domain) and a snoRNA-like domain containing a C’ and a D’ box
and a C and D box (the 5’ mgU2-25 domain) (Tycowski et al., 2004). The U2-
61 domain is present as a cleavage product of the full length scaRNA2 and is a
homolog of the mouse MBII-382 RNA (Tycowski et al., 2004). Tycowski et al. found
that the mgU2-25 domain is highly conserved among vertebrates (Tycowski et al.,
2004). The full length scaRNA2 was localized to the nucleoplasm, which fits with its
presence in cajal bodies, the site where the U2 snRNA is 2’-O-methylated (Tycowski
et al., 2004). The mgU2-61 domain was found in the nucleolus (Tycowski et al.,
2004). Whether this domain alone is responsible for U2 snRNA C61 methylation,
or whether this role is carried out by the full length scaRNA2 has not yet been
determined. The mgU2-25 domain has not been detected on its own by northern
blot and is not believed to be stable in the absence of the mgU2-61 domain (Tycowski
et al., 2004). This was not investigated here as all probes were specific to the mgU2-
61 domain.
Two sRNAs were found to be highly differentially expressed in the NGS data. The
5’ 30mer scaRNA2 sequence encompasses the C box of domain mgU2-61 (denoted
C box scaRNA2-derived 30mer), while the 31mer sequence includes the D box motif
(denoted D box scaRNA2-derived 30mer). The C box 30mer starts at the same
position as the start of the mgU2-61 domain and includes most of the U2 snRNA
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complementary region, so it may still interact with the U2 snRNA after cleavage.
The start position of this sRNA suggests that its biogenesis is linked to the mgU2-61
domain. As there is no evidence that the mgU2-61 domain is transcribed separately
from the full length scaRNA, it seems likely that this domain is cleaved from the
mature scaRNA2. The C box 30mer sRNA could be either a cleavage product of the
mature scaRNA2 or of the mgU2-61 domain directly. As they both share the same
5’ cleavage site, the most plausible explanation is that the C box 30mer sRNA is
produced directly from the mgU2-61 domain. If this domain is targeted for cleavage
in the presence of Poly(I:C), interaction of the C box 30mer region with proteins
or with the U2 snRNA may result in protection and prevent the full degradation of
this sRNA. Whether this sRNA still interacts with U2 snRNA and performs some
function requires further investigation. In the NGS data the C box 30mer sRNA is
present at higher levels after Poly(I:C) treatment than the D box 30mer, but this
could be an artifact resulting from sequencing bias. Its presence at lower levels in
the NGS data does, however, fit with its production after a second processing event
of the mgU2-61 domain.
The band at the top of the membrane (Figure 5.4) in each lane of both of the
scaRNA2 probed northerns is the full length 420 nucleotide scaRNA2, which did not
run into the gel very far and is therefore difficult to size correctly. The intermediate-
sized band visible on the membranes for both scaRNA2-derived sRNAs ran more
slowly than the 100 nucleotide band of the ladder, although the mgU2-61 domain has
previously been shown to be 82 nucleotides. This is probably the result of differences
in the purity of the samples, as the ladder was pure ssRNA, which the samples were
processed from cells and were not as pure. Interestingly, the intermediate band
appears to be increased in the Poly(I:C)-treated samples when compared to the
controls, despite the fact that a smaller band is also visible. This is true for both
the C box 30mer and the D box 30mer sRNA northerns, suggesting that both
sRNAs are derived from this intermediate RNA; giving us more confidence that this
intermediate band is the mgU2-61 domain. The discrepancy with the expected size
and the visible size requires further investigation. The C box 30mer band appears
to be stronger in intensity than the intermediate band, while the D box 30mer band
appears weaker. This mirrors the NGS data, where the C box 30mer sequence had
more reads than the D box 30mer. An accurate comparison of the levels of sRNAs
by northern blot can only be achieved by comparing the band intensity of each to
the same set of size standards at set concentration. Given more time, this would be
done to further characterize these scaRNA2-derived 30mers. Both of these scaRNA2-
derived sRNAs fall between the 30 and 35 nucleotide size markers, although on the
C box 30mer-probed membrane there is a wider band visible, as would be expected
if this sRNA varied by one nucleotide in length. In order for the mgU2-61 domain
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to be stable after a cleavage event from the full length scaRNA2, it is possible that
it undergoes some sort of 5’ modification. This could explain why the C box 30mer,
which has the same 5’ end as this domain, is at higher concentration than the D
box 30mer, which has a different and probably less stable 5’ end.
The difference in levels of the intermediate band between the Poly(I:C)-treated
and control samples could be investigated by mutating the scaRNA2 gene in a similar
manner to the hY5 gene in Chapter 3, introducing a mutation that prevents 30mer
production. The levels of the intermediate band could then be compared between
control and Poly(I:C)-treated cells expressing this mutant construct, to determine
whether its biogenesis is altered during apoptosis. As the levels of this scaRNA
are much lower in humans than the levels of hY5, this might be more effectively
investigated in a human cell line, where we have confidence that all of the cleavage
machinery is present.
5.3.1.2 SNORD7
SNORD7, otherwise known as mgU6-47 or Z30, methylates the A47 nucelotide in the
U6 snRNA (Zhou et al., 2002). The human SNORD7 is located in the nucleolus and
is 105 nucleotides in length (Zhou et al., 2002). It is a C/D box snoRNA containing
one C and one D box, with the 3’ and 5’ ends forming a stem (Zhou et al., 2002), it
may also contain a C’ and a D’ box (?). The upper band on the membrane resolved
just above the 100 nucleotide band in the ssRNA ladder, which is the expected
size for the full length SNORD7 RNA. Three 30mer sequences were identified that
mapped to the SNORD7 gene. As they are all derived from the same region of the
gene and vary in length by only a few nucleotides, they are likely to represent one
sRNA. The band pattern on the northern blot for the SNORD7-derived sequence
confirms the NGS data, as a diffuse band is visible, probably representing an sRNA
sequence with several nucleotides variation in length. The sRNA is derived from the
5’ end of SNORD7, but could occur as the result of a novel transcription event or
of processing of the mature SNORD7 RNA. This sRNA contains the C box region
of the SNORD7 RNA, so is unlikely to be able to interact with the U6 snRNA
in a similar manner to the full length SNORD7 RNA. Perhaps this snoRNA, like
HBII-180C (Scott et al., 2012), contains an alternative box complementary to a
different RNA. It may interact with the target RNA to regulate RNA splicing or
gene expression.
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5.3.2 mRNAs
5.3.2.1 ZMYM2
The ZMYM2 protein (also known as ZNF198) can interact directly with chromatin
and with the LSD1-coREST-HDAC1 ternary complex via its MYM-type zinc finger
domains (Gocke and Yu, 2008). The ZMYM2 protein recruits this complex to an
as yet uncharacterized group of genes, one of which is E cadherin, resulting in
transcriptional repression (Gocke and Yu, 2008). It also prevents transcriptional
repression of RE1-silencing transcription factor (REST) -responsive genes (Andres
et al., 1999; Gocke and Yu, 2008) Alterations in expression of the ZMYM2 protein,
therefore, could have a dramatic effect on the overall expression levels of the cell. The
ZMYM2 mRNA is 10199 nucleotides long, which explains why no mRNA band can
be seen on the membrane (Figure 5.8). According to the NGS data, the ZMYM2-
derived sRNA of interest was considerably higher in the control sample than the
Poly(I:C)-treated sample. This is not as clear when examined by northern blot
analysis. A clear band of the correct size is visible, but it is only slightly more
intense in the control samples than the Poly(I:C)-treated samples, if at all. This
30mer is somewhat unusual as it is produced from a middle exon, but does not share
a terminus with this exon. Its production may be linked to the splicing of the full
length ZMYM2 mRNA. The relationship between biogenesis of this 30mer and the
ZMYM2 mRNA cannot be separated, as this 30mer is not differentially expressed
between the two experimental conditions tested here. The exon encoding the 30mer
is present in the majority of the protein-coding isoforms of this mRNA. The 30mer
looks to be present at low levels according to the northern data. miRNAs, even when
expressed at relatively low levels compared to mRNAs, can have dramatic effects
on gene expression. Although this 30mer is unlikely to act in a similar manner
to miRNAs due to a difference in size, its production could alter ZMYM2 mRNA
isoform ratios: this could have dramatic effects on the full length mRNA levels and
therefore on the chromatin modification status of the cell.
It would be interesting to investigate the biogenesis of this 30mer further, and
to determine whether its production has any effect on the levels of the full length
RNA. Validation of this 30mer shows that not all 30mers are apoptosis-dependent,
even though very few are derived from mRNAs. Does this 30mer represent an
exception to the rule or are there many other 30mers present in cells at low levels
that are not up-regulated after Poly(I:C) treatment? This question warrants further
investigation.
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5.3.3 tRNAs
At the point of analysis of this dataset, tRNA cleavage was already being investigated
by a number of other groups. Therefore, cleavage of other ncRNAs became the focus
of this part of the project. As tRNA halves made up such a large part of the dataset,
however, it was important to validate a number of them. The most differentially
expressed tRNAs between the two conditions in the NGS data were validated, as well
as two tRNAs known to play a role in blocking translation initiation, which were
also differentially expressed between the two conditions. A tRNA that has been
shown to be cleaved during cellular stress, but does not play a role in translation
initiation was also analyzed here. tRNAs are very abundant in the cell and, as the
majority of the sRNAs derived from these tRNAs were present at similar levels to
the full length tRNAs, we can conclude that they two must be abundant.
Both Leu-tRNAAAG and Gln-tRNATTG 5’ halves, which were up-regulated after
poly(I:C) treatment in the NGS data, were validated by northern blot analysis. As
the tRNA code is degenerate, the majority of tRNAs are present with a number
of isoacceptor sequences. The human genome contains not only many tRNA genes
with different isoacceptor sequences, but also many copies of the same tRNA gene
with the same isoacceptor sequence. The sequence similarity between tRNA genes of
different types means that northern blot data should be interpreted with caution, as
it is possible that a probe designed to detect one tRNA may also bind less stringently
to a different tRNA sequence. This appears to be the case for the Leu-tRNAAAG
probe as, although only one sRNA band is visible on this gel, two full length tRNA
bands are visible. This suggests that this probe hybridized to either two different
isoacceptors of Leu-tRNA, or to a Leu-tRNA and a different tRNA with a similar
sequence but different length. Using the University of California, Santa Cruz blat
search (UCSC Genome Bioinformatics and International Human Genome Project),
the most abundant NGS read was mapped to four different Leu-tRNA genes, all
predicted to be 82 nucleotides in size, so hybridization of the probe to any or all
of these would not explain the size difference seen on the membrane. What is also
interesting is that the tRNA half detected is clearly larger than the predominant read
in the NGS data, as it resolved notably more slowly than the 30 and 35 nucleotide
size markers. It is hard to determine whether a 30mer is present at lower levels on
this membrane, but this larger sized tRNA half is definitely more abundant. As this
tRNA is 82 nucleotides in size, a tRNA half derived from it might be expected to
be around 40 nucleotides. This 40mer sequence is Poly(I:C)-induced.
The northern blot membrane for Gln-tRNATTG, containing DLD-1 samples, showed
that this tRNA is cleaved to give a 5’ tRNA half after Poly(I:C) treatment. As no
30mer bands are visible in the Hygromycin-treated samples, we can make no con-
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clusions about whether this tRNA is cleaved under general apoptosis conditions,
or whether cleavage is Poly(I:C)-specific. The Y5-probed image for this membrane
shows that ydRNAs in the Hygromycin-treated samples were at much lower levels
than in the Poly(I:C)-treated samples, so it is possible that a Gln-tRNATTG 30mer
was present after Hygromycin treatment, but was below the limit of detection.
Although Ala-tRNAAGC was not the most significantly differentially expressed
tRNA between the two conditions, it was chosen for validation as it is one of the
tRNA halves shown by Ivanov et al. to inhibit translation initiation of certain
proteins (Emara et al., 2010; Ivanov et al., 2011a). As this tRNA half was detected
at such high levels in the presence of Poly(I:C), it is possible that it has a similar
function under these conditions. The northern blot validation confirms that a tRNA
half of 30-35 nucleotides is derived from this tRNA and is dramatically up-regulated
after Poly(I:C) treatment. A 5’ Cys-tRNAGCA 30mer was present at low levels in
the control sample and slightly higher levels in the presence of Poly(I:C), according
to the NGS data. This tRNA half was also shown to inhibit translation by Ivanov
(Ivanov et al., 2011a). Northern blot results did not confirm this data, as there
was a striking difference in expression between the two conditions on the northern
membrane probed for this tRNA half, with levels in the Poly(I:C)-treated sample on
the membrane much higher than in the NGS data. As there were so many 30mers
up-regulated in the Poly(I:C) dataset compared to the control, this would have
resulted in a dramatic difference between the overall numbers of 30mers present in
the two conditions. It is therefore possible that the 30mers which remain at the same
level under both conditions may be lost from the Poly(I:C) dataset. Alternatively,
unfavorable sequences may be lost from the Poly(I:C) dataset as a result of the
inherent sequence bias of the Truseq method. This may explain the discrepancy
between the NGS data and the northern blot results for the Cys-tRNAGCA tRNA
half.
5.3.4 Virus-dependent or Apoptosis-dependent?
As seen in Chapter 3, the flow cytometry experiment, although it only contained
one replicate of each condition, provides strong evidence that Poly(I:C) treatment
induces apoptosis in a large proportion of the cells. This experiment was conducted
in DLD-1 cells rather than MCF7 cells, and DLD1 cells appear to show a slower phe-
notypic response to Poly(I:C) than MCF7 cells. This indicates that the proportion
of MCF7 cells undergoing apoptosis after the same treatment is likely to be even
higher. In RNA derived from the same samples as those analysed by flow cytom-
etry, Poly(I:C) treatment, like many other stress treatments, induces the cleavage
of a number of tRNAs to produce tRNA halves. Another apoptosis inducer, Hy-
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gromycin, did not produce detectable cleavage products of Gln-tRNATTG. This fits
with data by Thompson et al., who found that oxidative stress induced by hydrogen
peroxide treatment induced His-tRNAGTG cleavage, but a number of other apoptosis
inducers did not (Thompson et al., 2008). Met-tRNA, however, is cleaved after Hy-
gromycin treatment. Our NGS data, along with the corresponding northern blots,
suggest that apoptosis-induced tRNA cleavage patterns are tRNA isotype specific.
PBS treatment, which has been shown by Fu et al. to considerably increase tRNA
half levels for a number of different tRNAs (Fu et al., 2009), also did not produce
any detectable Gln-tRNATTG halves in these experiments.
Most cancer cell lines have obtained mutations during the process of transforma-
tion, on top of the mutations accrued that are characteristic of the cancers from
which these cells originate. MCF7 cells have increased proliferation rates as a result
of an inactivation of caspase 3, an effector caspase that is key in apoptosis. For
this reason the DLD1 cell line was utilized for the flow cytometry analysis. Any
conclusions made on apoptosis-induced cleavage of RNA in MCF7 cells should be
interpreted with caution. The cleavage of tRNAs during apoptosis requires further
investigation, and should be conducted in the DLD-1 cell line using an inducer such
as Staursporine, which has been used to induce apoptosis in NIH/3T3 cells in this
project.
In 1999 Rutjes et al. found that Y RNAs are cleaved in an apoptosis-dependent
manner (Rutjes et al., 1999b), and the data presented here confirms these findings.
The other sRNAs, however, have not been examined for apoptosis dependence. Nu-
merous experiments using Hygromycin were conducted to determine whether these
sRNAs are produced after Poly(I:C) treatment specifically, or under more general
apoptosis conditions. These sRNAs were undetectable in Hygromycin-treated cells
to date (data not shown). The full investigation of all 30mers during apoptosis was
hindered by the fact that Hygromycin is a less potent inducer of apoptosis than
Poly(I:C), unless used at very high concentrations. Given more time, validation
experiments would be repeated in a number of cell lines with another apoptosis
inducer.
No Poly(I:C)-induced sRNAs derived from mRNAs could be validated, suggesting
that sRNAs of this size class may be solely of ncRNA origin. Interestingly, the
only mRNA-derived 30mer that could be validated appeared to be unaltered in
the presence of Poly(I:C), possibly even decreasing in concentration in response to
this dsRNA mimic. Do the sRNA sequences identified in this dataset represent a
ncRNA-derived class of 30mers that are entirely up-regulated in the presence of viral
nucleic acid? It seems likely that this is the case, with a small number of 30mers,
such as the ZMYM2-derived sRNA, acting as the exception that proves the rule.
The high overall read levels for each of the scaRNA- and YRNA- derived 30mers
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can be explained by very high levels of one particular sequence in each class present
in the Poly(I:C)-treated sample. Surprisingly, very few bona fide microRNA se-
quences were increased in the Poly(I:C)-treated sample over the control, despite
the fact that microRNAs are known to be involved in cellular response to viral
infection (Pedersen et al., 2007). One such miRNA, miR-1246, was up-regulated
in the Poly(I:C)-treated sample in our dataset and Dr. Nicolas further identified
it in Argonaute 2 immunoprecipitates, indicating that it is a functional miRNA.
This miRNA has recently been identified as p53-regulated and pro-apoptotic (Zhang
et al., 2011b). This finding matches with our data and gives us greater confidence
that our NGS data is accurate. A number of other miRNA sequences were detected
in the Poly(I:C)-treated sample, but these sequences actually mapped to Y RNAs.
Our lab has shown that these sequences are not miRNAs (Nicolas et al., 2012).
The Poly(I:C)-treated and control NGS data were based upon a standard Illumina
sequencing method, utilizing the provided illumina 5’ and 3’ adapters. As a result,
an inherent bias was introduced into the data as certain sRNAs, once ligated to the
3’ adapter, form preferred secondary structures and are more likely to be ligated to
the 5’ adapter than less favored sequences. This can be seen by the fact that the
predominant human Y5-derived 30mer sequence investigated in Chapter 3 can be
detected by northern blot after only an hour, while it is only present at around 800
copies per million in the Poly(I:C) NGS dataset; this is the result of a preference
by the RNA ligase enzyme for other sequences over this one. With such a dramatic
difference in overall levels of 30mers between the control and test conditions, it
is therefore more likely that the sequencing bias will affect interpretation of the
differential expression of individual sRNA sequences. In the Dalmay lab, many
efforts have been made to reduce this sequencing bias through the use of specially
designed ‘HD’ adapters that increase the ability of the RNA ligase to act upon all
sequences equally (Sorefan et al., 2012). These ‘HD’ adapters were utilized in the
new NGS sample libraries prepared from MCF7 and SW1353 samples.
Wild type MCF7 cells do undergo apoptosis, but not as efficiently as those trans-
fected with caspase 3. It is therefore somewhat puzzling that these cells show such
a dramatic response to Poly(I:C). A particularly interesting follow-up experiment
would be to transfect wild type MCF7 cells with a caspase 3 construct, and deter-
mine whether this has any effect on 30mer production in the presence of Poly(I:C).
The flow cytometry experiments, combined with northern blot analysis of the corre-
sponding total RNA samples, showed many of the cells were undergoing apoptosis
in response to Poly(I:C) treatment. Although the levels of cleavage of Met-tRNA
and hY5 RNA correlated with the levels of apoptosis, their apoptosis-dependence
had not yet been proved.
Work by Xue et al. showed that, although MCF7 cells take longer to undergo
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apoptosis when caspase 3 is absent, they are still reproductively dead and are com-
mitted to the apoptotic process (Xue et al., 2003b). Perhaps the cleavage of numer-
ous classes of ncRNAs is an early event in apoptosis and these sRNAs accumulate
to higher levels in MCF7 cells as a result of the delay in the apoptotic process.
Poly(I:C) was initially used in this project as a viral mimic. Further work needs
to be done to determine if any or all of the sRNAs detected here are apoptosis or
virus dependent. Alongside experiments in a number of other cell lines using a range
of apoptosis inducers, experiments should be conducted to infect cells with viruses
under physiological conditions. This would allow us to determine whether 30mer
biogenesis is a true physiological response to viral infection.
5.3.5 Why are 30mers produced?
ANG cleaves tRNAs during stress to produce tRNA halves. 5’ halves from Ala and
Cys inhibit cap-dependent translation initiation (Emara et al., 2010) by binding
to the eIF4F complex, but IRES-dependent translation initiation appears to be
unaffected. This mode of translation regulation is likely to be vital for the cell’s
survival. In our NGS dataset only the 5’ Ala-tRNA half is dramatically up-regulated
although both Ala-tRNA and Cys-tRNA show up-regulation by northern blot. So
are all 30mers produced solely to create 5’ Ala- and Cys-tRNA halves, even though
these are not the most abundant halves? A run of terminal G residues is thought to
be essential for the function of these tRNA halves in blocking translation (Ivanov
et al., 2011a). It might, therefore, be expected that a more specific mechanism for
their production would have evolved, if only these two tRNA halves were required
during apoptosis. In support of this hypothesis, other functions for tRNA fragments
have recently been identified; shorter fragments have microRNA-like functions, while
the 30-35 nucleotide-sized fragments have been found to act as small guide RNAs.
These fragments interact with the long version of the tRNaseZ enzyme (tRNaseZL).
Intriguingly, the tRNA halves identified with this function, like those involved in
inhibiting translation, are mainly derived from the 5’ end of the full length tRNA.
Perhaps, like Ala-tRNA and Cys-tRNA halves, the 5’ monophosphate is necessary
for this function (Ivanov et al., 2011a). It seems likely that yet more functions
will be identified for these tRNA halves, suggesting that these cleavage products
are not simply generated to directly block the translation stage of gene expression.
rRNAs fragments were also isolated from tRNaseZL complexes; we found many
rRNA fragments in our dataset and perhaps these should be investigated further.
Full length tRNAs relocate to the nucleus to halt gene expression during cellular
stress conditions. It is possible that tRNA cleavage is another method of blocking
gene expression, as it is possible that the number of receptors available to transport
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tRNAs into the nucleus limits the rate of tRNA relocation and cleavage may remove
tRNAs more rapidly. The levels of Met-tRNA cleavage appeared to be lower than
for the other tRNAs tested. A number of different versions of Met-tRNA genes are
known to be encoded in the human genome to counter-act any mutations that may
occur in the initiation region of mRNAs. This variety in the Met-tRNA sequence
may explain why such a small proportion of full length Met-tRNA molecules are
targeted. It is also possible that other versions of Met-tRNA are targeted by the
cleavage machinery, but are not detected by the Met-tRNA specific probe used here.
As well as their relocation to the nucleus, tRNAs have also been found to interact
with cytochrome C during apoptosis and prevent caspase 9 activation (Mei et al.,
2010). tRNA cleavage may provide a mechanism to allow tRNAs to dissociate from
cytochrome C and enable apoptosis to progress. tRNA halves, as a whole, could be
produced to either block apoptosis or allow it to progress. Further experiments could
be conducted to transfect cells with varying concentrations of synthetic versions of
different 5’ tRNA halves and to determine the effect on apoptosis, as induced by a
chemical such as STS. It is probable that transfecting in these tRNA halves at the
point when the cell would naturally produce them is vital to see their physiological
effect on this process, so experiments should be set up in parallel where tRNA
halves are added at various time points before and after apoptosis induction. The
aim would be to determine if any noticeable effect is seen on the progression of
apoptosis and the overall survival of the cells.
Peng et al investigated the response of mouse lung cancer cells to viral infection,
and the effect on sRNA expression (Peng et al., 2011). This group identified similar
cleavage products to those seen in our data, as they found a 30mer produced from
mouse Y RNAs. They also identified a cleavage product derived from the SNORD76
gene (Peng et al., 2011). A similar 30mer was identified in our NGS data, but was
less differentially expressed than those sRNAs validated here. This snord76 30mer
is particularly interesting as it is encoded within the GAS5, lncRNA. GAS5 is up-
regulated during apoptosis (Mourtada-Maarabouni et al., 2009). The production
of this sRNA may affect the levels of the lncRNA. The overlap between 30mers
detected in mouse lung cancer cells infected with severe acute respiratory syndrome
coronavirus or influenza virus and our NGS data, which is derived from human
breast cancer cells treated with a viral mimic, provides strong evidence that this
class of small RNAs is a bona fide cellular response to viral infection. This overlap
should be further investigated using the new NGS data to identify 30mers conserved
across different organisms and cellular stress responses. Perhaps moving the focus
away from tRNAs will enable more rapid progress in determining a function for this
class of sRNAs, as a whole, in the near future.
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6 SUMMARY
The first part of this project involved further characterization of the requirements
for hY5 RNA cleavage during apoptosis. Through mutagenesis, a double-stranded
stem region close to the cleavage site was identified as a requirement for cleavage.
Deletion or alteration of this region to remove the stem structure resulted in an ab-
sence of detectable cleavage products. But, when the nucleotides within this region
were substituted for nucleotides that maintain the secondary structure, cleavage still
occurred. This indicates that the protein complex that cleaves this RNA recognises
the secondary structure of this region rather than a particular nucleotide sequence.
The effect of the mutations on the secondary structure was predicted using the
RNAfold and Mfold prediction programs. As neither of these programs take into
account tertiary structure, it is possible that as yet unknown tertiary interactions
may occur that are not taken into account when interpreting the results discussed
here.
Mutation of the Ro60-binding site within the hY5 RNA also abrogated cleavage,
confirming studies previously conducted by Dr. Hall (Hall, 2013). Surprisingly, the
Ro60 protein does not appear to be necessary for exogenous hY5 stability, as the full
length RNA containing the mutated Ro60-binding site was as abundant as the wild
type. Further investigation is necessary to determine whether the difference in the
requirement of the Ro60 protein for stability results from the expression from the
genome compared to a plasmid, or from the expression in mouse cells as opposed to
human cells.
High-throughput mutagenesis experiments allowed analysis of a larger region of
the hY5 molecule, with no reliance upon secondary structure predictions. Data on
the full length mutants expressed in NIH/3T3 cells, along with any plasmid bias
that might have been introduced during cloning and precipitation of the mutant
plasmids, is still in preparation. Preliminary analysis of the sRNA libraries pre-
pared from NIH/3T3 cells transfected with mutant pool 1 plasmids highlighted an
interesting pattern. In these samples, transfected with plasmids where the mutation
site was only a few nucleotides away from the wild type cleavage site, the cleavage
position appeared to be shifted. The most abundant mutant sequence reads were 2
nucleotides longer than the wild type sequence read.
A more in depth analysis of the most abundant pool 1 sequence reads involved
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grouping them by read start site. From the results of this analysis another pattern
emerged. The nucleotide preferences at each of the mutated positions within the
32 nucleotide reads were very different to the preferences in both the 31 and 30
nucleotide reads. Using RNAfold to predict the secondary structures of the full
length RNAs that the most abundant reads were derived from, showed the reason
for this. For the abundant 30 nucleotide reads, the secondary structure was similar to
the wild type structure and was cleaved in the same position (i.e. between the second
and third nucleotide within the internal loop). For the abundant 31 nucleotide
reads, the secondary structure again was similar to the wild type, although a slight
shift was seen in the position of the nucleotides within the internal loop, so that
cleavage occurred at the same position within the loop, but led to a sequencing read
1 nucleotide longer than the wild type sequence. For those mutants with nucleotide
preferences at the mutation site that were very different to the wild type sequence,
the position of the nucleotides within the RNA molecule was shifted even more,
so that the nucleotides were moved two positions along the internal loop. This
predicted difference in secondary structure offers a convincing explanation for the
difference in the start sites of these groups of mutant sequence reads. The secondary
structure suggests that, as long as a double-stranded stem of five base pairs within
the RNA is conserved, the cleavage machinery is able to bind and to cut the RNA.
These mutations indicate that, when cleavage occurs, the cleavage position is most
commonly between the second and third nucleotides within the stem.
The most abundant sRNA reads detected in the samples transfected with mutant
pools 2 and 3 were all 30-31 nucleotides in length and were similar in sequence to
the wild type RNA. For these mutants the position of the stem was also similar to
the wild type RNA, as was the overall secondary structure. The caveat with these
interpretations is that only a single secondary structure prediction algorithm was
used to predict the structure of each of the mutants and chemical and enzymatic
investigations have previously suggested that these predictions are not entirely ac-
curate. As a clear pattern was seen that explains the cleavage position shift in the
mutant pool 1 mutants, it seems likely that a similar pattern would occur in the
physiological structure of these mutants, even if the secondary structure was not
exactly as displayed here.
Along with examining the different cleavage patterns of these mutants, they were
also useful for investigating the role of Ro60 in cleavage. Data by Dr. Hall showed
that, when the wild type hY5 plasmid was expressed in mouse cells, mRo60 was
necessary for cleavage: however, in the same experiment it was clear that mRo60
was not required for stability of hY5 (Hall, 2013). It is possible that the role of
Ro60 in cleavage is independent of its binding to Y RNAs. Interpretation of the
secondary structures of the most abundant mutants from each mutant pool shows
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much variation in the region where Ro60 binds, especially in those mutants where
the mutation site is close to the Ro60-binding site. Again inaccuracies in secondary
structure prediction could explain this variation, but an alternative hypothesis is
that all of these mutations open up the structure in such a way that a small internal
loop is formed, which still allows Ro60 to bind. Only a detailed examination of sec-
ondary structure and Ro60-binding for each of the mutants can determine whether
this is the case.
Although only in the preliminary stages of analysis, the high-throughput method
of RNA processing analysis used here shows promise. The production and identifi-
cation of mutants that are cleaved is rapid and has the benefit of being independent
of secondary structure prediction, even though these predictions may be necessary
for interpretation of the data. Combination of the full length and plasmid bias data
with the sRNA library data may enable identification of full length mutants pro-
duced at high levels which are not targeted by the cleavage machinery, providing
further information on the requirements for cleavage.
This high-throughput method could be implemented to look at the processing of
many other small ncRNAs or, indeed, the RNAs targeted by particular enzyme com-
plexes. The expression of PCR products within mammalian cells could increase the
consistency between replicates and therefore increase the number of different mu-
tants that could be investigated at once, making this method more powerful. In the
final chapter a more general consequence of apoptosis treatment was investigated, as
a number of 30mer RNAs generated under apoptosis conditions were validated. The
majority of these 30mers appeared to be up-regulated during apoptosis, suggesting
a general function during the apoptotic process. In this chapter 30-35 nucleotide sR-
NAs derived from snoRNAs, tRNAs and mRNAs during Poly(I:C) treatment were
validated, although their production as a more general consequence of apoptosis has
not yet been confirmed due to problems with variation in the sensitivity of each
cell line to different apoptosis inducers. Analysis of the newest NGS data, which
comprises of three replicate samples for each condition and two different human
cell lines, should provide many more 30mers to validate and provide more clues
as to whether the majority of these 30mers are likely to be functional or simply a
by-product of the apoptotic process.
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7 APPENDICES
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APPENDIX I
Component Amount
Bacto-tryptone 10 g
NaCl 5 g
Yeast extract 5g
H2O Up to 1 L
Table 7.1: Bacterial LB medium
Component Amount
5 x M9 salts 40 mL
2M glucose 2.75 mL
Water agar 157.25 mL
Table 7.2: Bacterial M9 minimal medium
Component Amount
Na2HPO4 6.78 g
KH2PO4 3.0 g
NaCl 0.5 g
NH4Cl 1.0 g
Table 7.3: 5 x M9 salts
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Component Amount
Bactoagar 3 g
H2O 175.25 mL
Table 7.4: Water agar
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APPENDIX II
Component Amount
0.1 M KOAc 30 mL
0.5 M MnCl2 10 mL
1 M KCl 10 mL
1 M CaCl2 1 mL
Glycerol 15 mL
H2O Up to 100 mL
Table 7.5: TFBI
Component Amount
0.1 M Na-MOPs 2.5 mL
1 M CaCl2 1.875 mL
1 M KCl 0.25 mL
Glycerol 3.75 mL
H2O Up to 25 mL
Table 7.6: TFBII
Component Amount
Bacto-tryptone 10 g
Yeast extract 2.5g
NaCl 2.92 g
1 M MgCl2 5 mL
H2O Up to 1 L
Table 7.7: TYM broth
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APPENDIX IV
Figure 7.1: The secondary structure predictions of the deletion mutants, as predicted
by all algorithms in Mfold and RNAfold.
193
Figure 7.2: The secondary structure predictions of the substitution mutants, as pre-
dicted by all algorithms in Mfold and RNAfold.
194
Figure 7.3: The secondary structure predictions of the other mutants, as predicted
by all algorithms in Mfold and RNAfold.
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